var title_f30_43_31408="Intraop bladder exstrophy";
var content_f30_43_31408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraoperative picture of a male infant during a complete primary bladder exstrophy repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31408=[""].join("\n");
var outline_f30_43_31408=null;
var title_f30_43_31409="Dx resp distress on ventilator";
var content_f30_43_31409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Approach to the ventilated patient in respiratory distress",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 552px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31409=[""].join("\n");
var outline_f30_43_31409=null;
var title_f30_43_31410="Granuloma annulare on hand";
var content_f30_43_31410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Localized granuloma annulare",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 65 year-old presented with a 14-month history of annular lesions of granuloma annulare on the backs of each hand and left dorsum foot. The periphery of the lesion on the right hand demonstrates papules in some foci and a rope-like rim in other areas. The central area of clearing is hypopigmented.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31410=[""].join("\n");
var outline_f30_43_31410=null;
var title_f30_43_31411="Carglumic acid: Drug information";
var content_f30_43_31411=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carglumic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/54/34660?source=see_link\">",
"    see \"Carglumic acid: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/49/38675?source=see_link\">",
"    see \"Carglumic acid: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10107689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbaglu&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10109473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Metabolic Alkalosis Agent;",
"     </li>",
"     <li>",
"      Urea Cycle Disorder (UCD) Treatment Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10228991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute hyperammonemia:",
"     </b>",
"     Oral: 100-250 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia levels. Concomitant adjunctive ammonia-lowering therapy recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic hyperammonemia:",
"     </b>",
"     Oral: Usual dose: &lt;100 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia levels",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10228990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/49/38675?source=see_link\">",
"      see \"Carglumic acid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute hyperammonemia:",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic hyperammonemia:",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10228998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbaglu&reg;: 200 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10228962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11285248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbaglu&reg; is not available through pharmaceutical wholesalers or retail pharmacies, but only through direct shipping from the Accredo specialty pharmacy. Prescribers must contact Accredo Health Group at 888-454-8860 or refer to www.accredo.com to initiate patients on this product.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10228993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer immediately prior to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Carglumic acid tablets should not be crushed or swallowed whole. Tablets should be dispersed in water (minimum of 2.5 mL) immediately before use and administered orally or via a nasogastric tube. Tablets do not dissolve completely, and some particles may remain; container should be rinsed with water and swallowed immediately. Follow administration via a nasogastric tube by flush with additional water to clear the tube. Carglumic acid tablets should not be mixed with any other foods or liquids other than water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral syringe: Appropriate volume of dispersion should be drawn up in an oral syringe and administered immediately (discard unused dispersion). After administration, oral syringe should be refilled with a minimum of 1-2 mL of water and administered immediately.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10109474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of acute hyperammonemia and maintenance therapy of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10228970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (17%), headache (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (26%), abdominal pain (17%), diarrhea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Ear infection (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Tonsillitis (17%), nasopharyngitis (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infections (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Somnolence (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperhidrosis (9%), rash (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Anorexia (9%), dysgeusia (9%), weight loss (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pneumonia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (9%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10228966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10228967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nutritional management: With acute episodes of hyperammonemia, protein restriction and a hypercaloric diet are recommended until normalization of plasma ammonia concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10228963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10228964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were reported in some animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. However, due to the potential for irreversible fetal neurologic damage for untreated NAGS deficiency, women with this condition should remain on treatment throughout pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10228965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk is unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10228992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take immediately prior to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Carbaglu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (5): $837.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10228996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood ammonia; monitor for physical signs/symptoms of hyperammonemia (eg, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Carbaglu (AT, BE, CZ, DE, DK, EE, FR, GB, IT, NL, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10228978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     N-acetylglutamate synthase (NAGS) is a mitochondrial enzyme which produces N-acetylglutamate (NAG). NAG is a required allosteric activator of the hepatic mitochondrial enzyme, carbamoyl phosphate synthetase 1 (CPS 1), which converts ammonia into urea in the first step of the urea cycle. In NAGS-deficient patients, carglumic acid serves as a structural analogue to NAG.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10228980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~2657 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Via intestinal flora to carbon dioxide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: elimination: 5.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (60% as unchanged drug); urine (9% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9040 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-F9B63D4400-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31411=[""].join("\n");
var outline_f30_43_31411=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107689\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10109473\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228991\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228990\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682504\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682505\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228998\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228962\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11285248\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228993\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10109474\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228970\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228966\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228967\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298977\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304539\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228963\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228964\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228965\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228992\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322850\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228996\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390246\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228978\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228980\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/54/34660?source=related_link\">",
"      Carglumic acid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/49/38675?source=related_link\">",
"      Carglumic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_43_31412="Treatment of spinal cord ischemia after thoracic aortic repair";
var content_f30_43_31412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Algorithm for the treatment of spinal cord ischemia after thoracic aortic repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 770px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McGarvey ML, Cheung AT, Szeto W, et al. Management of Neurologic Complications of Thoracic Aortic Surgery. J Clin Neurophysiol 2007; 24:336. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31412=[""].join("\n");
var outline_f30_43_31412=null;
var title_f30_43_31413="Armodafinil: Drug information";
var content_f30_43_31413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Armodafinil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/31/17909?source=see_link\">",
"    see \"Armodafinil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5263022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nuvigil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5263025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5263062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Narcolepsy: Oral: 150-250 mg once daily in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Obstructive sleep apnea/hypopnea syndrome (OSAHS): Oral: 150-250 mg once daily in the morning;  doses &gt;150 mg have not been shown to have an increased benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Shift work sleep disorder (SWSD): Oral: 150 mg given once daily ~1 hour prior to work shift",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5263063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Consider lower initial dosage. Concentrations were almost doubled in clinical trials (based on modafinil).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5263064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established in severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5263065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic impairment: The manufacturer recommends a reduced dose; based on modafinil pharmacokinetics, a dose reduction of one-half the normal dose should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5263071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nuvigil&reg;: 50 mg, 150 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5263024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F5263020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10961085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231717.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM231717.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5263067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5263026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy and shift work sleep disorder (SWSD); adjunctive therapy for obstructive sleep apnea/hypopnea syndrome (OSAHS)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5263036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Headache (14% to 23%; dose-related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Palpitation (2%), heart rate increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (5%), insomnia (4% to 6%; dose related), anxiety (4%), depression (1% to 3%; dose related), fatigue (2%), agitation (1%), attention disturbance (1%), depressed mood (1%), migraine (1%), nervousness (1%), pain (1%), pyrexia (1%), tremor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (1% to 4%; dose related), contact dermatitis (1%), hyperhidrosis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (6% to 9%; dose related), xerostomia (2% to 7%; dose related), diarrhea (4%), abdominal pain (2%), dyspepsia (2%), anorexia (1%), appetite decreased (1%), constipation (1%), loose stools (1%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Polyuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: GGT increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (1%), seasonal allergy (1%), thirst (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Angioedema, hypersensitivity, liver enzymes increased, nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction), pancytopenia, systolic blood pressure increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5263031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to armodafinil, modafinil, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5263032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic effects (severe): Serious and life-threatening rashes including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported.  In modafinil clinical trials, rashes were more likely to occur in children; serious, postmarketing reactions have occurred with modafinil in adults and children as well as with armodafinil in adults. Most cases have been reported within the first 5 weeks of initiating therapy; however, rare cases have occurred after prolonged therapy. No risk factors have been identified to predict occurrence or severity of these reactions. Patients should be advised to discontinue use at first sign of rash (unless the rash is clearly not drug-related).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rare cases of multiorgan hypersensitivity reactions with modafinil and cases of angioedema and anaphylactoid reactions (armodafinil) have been reported. Signs and symptoms of multiorgan hypersensitivity reactions are diverse. Patients typically present with fever and rash associated with other organ system involvement. Patients should be advised to discontinue therapy and promptly report any signs or symptoms related to these adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use is not recommended in patients with a history of left ventricular hypertrophy or patients with mitral valve prolapse who have developed mitral valve prolapse syndrome with previous CNS stimulant use. Patients with these conditions may also experience chest pain, palpitations, dyspnea, and transient ischemic T-wave changes on ECG. Due to limited experience use caution in patients with history of myocardial infarction (MI) or angina. Increased blood pressure monitoring may be required in patients taking armodafinil. New or additional antihypertensive therapy may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction is recommended with severe dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use caution in patients with a history of psychosis, depression, or mania. Modafinil has been shown to worsen the symptoms of these diseases (eg, mania, hallucinations, suicidal thoughts). Discontinue therapy if psychiatric symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep disorders: Appropriate use: For use following complete evaluation of sleepiness and in conjunction with other standard treatments (eg, CPAP). The degree of sleepiness should be reassessed frequently; some patients may not return to a normal level of wakefulness. Patients with excessive sleepiness should be advised to avoid driving or any other potentially dangerous activity. Use &gt;12 weeks has not been studied; patient should be reevaluated to determine effectiveness if use exceeds 12 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use reduced doses in elderly patients; concentrations of armodafinil are significantly higher in patients &gt;65 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential: Use with caution in patients with a history of drug abuse; potential for drug dependency exists.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5263043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5263042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Armodafinil may decrease the serum concentration of Contraceptives (Estrogens).  Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Armodafinil may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5263046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid or limit ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Delays absorption, but minimal effects on bioavailability. Food may affect the onset and time course of armodafinil.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5263027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5263028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies, including visceral and skeletal abnormalities and decreased fetal weight. Efficacy of steroidal contraceptives may be decreased; alternate means of contraception should be considered during therapy and for 1 month after armodafinil is discontinued. A pregnancy registry has been established for patients exposed to armodafinil; healthcare providers are encouraged to register pregnant patients or pregnant women may register themselves by calling 1-866-404-4106.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5263030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5263066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with or without meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nuvigil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $169.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $508.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $508.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5263069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of hypersensitivity, rash, psychiatric symptoms, levels of sleepiness, blood pressure, and drug abuse",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5263049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism of action of armodafinil is unknown. It is the R-enantiomer of modafinil. Armodafinil binds to the dopamine transporter and inhibits dopamine reuptake, which may result in increased extracellular dopamine levels in the brain. However, it does not appear to be a dopamine receptor agonist and also does not appear to bind to or inhibit the most common receptors or enzymes that are relevant for sleep/wake regulation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5263051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 42 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~60% (based on modafinil; primarily albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, multiple pathways, including amine hydrolysis and CYP3A4/5; metabolites include R-modafinil acid and modafinil sulfone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 15 hours; Steady state: ~7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2 hours (fasted)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (based on modafinil: 80% predominantly as metabolites; &lt;10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hirshkowitz M, Black JE, Wesnes K, et al, &ldquo;Adjunct Armodafinil Improves Wakefulness and Memory in Obstructive Sleep Apnea/Hypopnea Syndrome,&rdquo;",
"      <i>",
"       Respir Med",
"      </i>",
"      , 2007, 101(3):616-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/43/31413/abstract-text/16908126/pubmed\" id=\"16908126\" target=\"_blank\">",
"        16908126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roth T, White D, Schmidt-Nowara W, et al, &ldquo;Effects of Armodafinil in the Treatment of Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome: A 12-week, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study in nCPAP-AdherentAdults,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2006, 28(5): 689-706.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/43/31413/abstract-text/16861091/pubmed\" id=\"16861091\" target=\"_blank\">",
"        16861091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9260 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31413=[""].join("\n");
var outline_f30_43_31413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263022\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263025\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263062\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263063\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263064\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263065\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263071\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263024\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263020\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961085\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263067\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263026\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263036\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263031\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263032\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263043\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263042\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263046\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263027\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263028\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263030\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263066\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324147\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263069\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263049\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5263051\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9260\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9260|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/31/17909?source=related_link\">",
"      Armodafinil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_43_31414="Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus";
var content_f30_43_31414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31414/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31414/contributors\">",
"     Lynne L Levitsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31414/contributors\">",
"     Madhusmita Misra, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31414/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31414/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31414/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31414/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/43/31414/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus, one of the most common chronic diseases in childhood, is caused by insulin deficiency resulting from the destruction of insulin-producing pancreatic beta cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children and adolescents with type 1 diabetes are at increased risk for developing other autoimmune diseases, most commonly autoimmune thyroiditis and celiac disease. These associated autoimmune diseases are presented here. The diagnosis, management, and complications of type 1 diabetes mellitus in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HLA GENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, associated endocrinopathies are more common in patients with type 1 diabetes mellitus expressing HLA-DR3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/1\">",
"     1",
"    </a>",
"    ]. These individuals have a longer period of dormancy before developing diabetes, presumably because of a slower pace",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    later onset of beta cell destruction and are more likely to have positive anti-islet cell antibodies, compared to patients expressing HLA-DR4, who are younger at diagnosis, have positive anti-insulin antibodies, and are less likely to develop other autoimmune endocrinopathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE THYROIDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 20 percent of patients with type 1 diabetes have positive anti-thyroid antibodies (anti-thyroid peroxidase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-thyroglobulin), and 2 to 5 percent of patients with type 1 diabetes develop autoimmune hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. The prevalence of autoimmune thyroiditis is higher in girls with diabetes compared to boys, and it increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in an observational study that looked for evidence of autoimmune thyroiditis in 659 children with type 1 diabetes with a median age at initial screening of 10.9 years (range 0.1 to 24 years) and a duration of diabetes of 1.2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/4\">",
"     4",
"    </a>",
"    ]. Antibodies to thyroid peroxidase (anti-TPO) and thyroglobulin (anti-TG) were present in 15.4 and 14.4 percent of patients. Girls were more likely than boys to have anti-TPO (19.9 versus 11.6 percent) and anti-TG (18.6 versus 11 percent) antibodies.",
"   </p>",
"   <p>",
"    Children with beta cell autoantibodies (glutamic acid decarboxylase: antiGAD) appear to have a higher risk of developing anti-thyroid antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Specific HLA subtypes (for example HLA-DQB1*0302) have also been associated with greater risk of developing autoimmune thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with circulating antibodies may be euthyroid, or they may be hypothyroid and require thyroid hormone replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. Rarely, they may be hyperthyroid with a reported prevalence of 1 to 2 percent in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/12\">",
"     12",
"    </a>",
"    ]. In the above study, 9.4 percent of patients required L-thyroxine therapy, and 6.1 percent with positive antibodies remained euthyroid after a median diabetes duration of 3.9 years (0.2 to 12.4 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subclinical hypothyroidism in patients with type 1 diabetes mellitus can be associated with an increased risk of symptomatic hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/13\">",
"     13",
"    </a>",
"    ] and reduced linear growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/14\">",
"     14",
"    </a>",
"    ]. Subclinical hypothyroidism is defined biochemically as a normal serum free thyroxine (T4) concentration in the presence of an elevated serum thyrotropin (TSH) concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thyroid screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high prevalence of thyroiditis and its potential clinical impact, all children with type 1 diabetes should be screened regularly for thyroid disease by measuring thyrotropin (TSH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyrotropin, also known as thyroid stimulating hormone (TSH), is the most useful screening test. In general, TSH should be tested several weeks after the diagnosis of type 1 diabetes, when metabolic control has been established. This is because at least 20 percent of patients will have transient abnormalities of thyroid function when type 1 diabetes is first diagnosed, which resolve as the diabetes is treated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. However, thyroid laboratory studies should be performed more promptly (within a few days of resolution of initial diabetes symptoms) in newly diagnosed children with clinical suspicion of thyroid disease because of thyroid enlargement or symptoms of hypo- or hyperthyroidism. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the TSH level is abnormal, free T4 is measured.",
"     </li>",
"     <li>",
"      If the TSH level is normal, patients should have a repeat measurement every one to two years. Additional thyroid function testing should be obtained whenever thyroid dysfunction is suspected or thyromegaly is detected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with elevated TSH levels should be treated with thyroid hormone replacement therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link&amp;anchor=H21#H21\">",
"       \"Acquired hypothyroidism in childhood and adolescence\", section on 'Treatment and prognosis'",
"      </a>",
"      .) The ADA suggests that antibodies to thyroid peroxidase (TPO) and thyroglobulin should be measured at diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/15\">",
"       15",
"      </a>",
"      ]. An alternative strategy is to measure these antibodies only if abnormalities of thyroid function are detected.",
"     </li>",
"     <li>",
"      If Graves&rsquo; disease is suspected, then the thyrotropin receptor antibody should be measured. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7641?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the initial antibody screening is positive, the patient should be monitored closely, by screening with TSH annually and if any symptoms of hyper- or hypothyroidism develop. Repeat antibody testing is not needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CELIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 5 percent of patients with type 1 diabetes will develop celiac disease (gluten-sensitive enteropathy) diagnosed by a positive small bowel biopsy sample, and 7 to 10 percent have anti-endomysial antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] or tissue transglutaminase antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/6\">",
"     6",
"    </a>",
"    ]. These prevalence rates appear to be the same in the United States, Europe, Canada, and Asia. Risk factors for celiac disease include female gender, younger age of onset of diabetes, longer duration of diabetes, and the presence of thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/6,21-23\">",
"     6,21-23",
"    </a>",
"    ]. The genetic susceptibility to celiac disease and type 1 diabetes has been attributed to specific shared alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only a minority of children with type 1 diabetes and celiac disease present with gastrointestinal symptoms of food intolerance, food avoidance, gastrointestinal discomfort, and diarrhea. More common initial findings include unpredictable blood glucose measurements, recurrent episodes of hypoglycemia, poor glycemic control, and growth failure because of erratic intestinal absorption of nutrients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. In addition, bone mineralization can be reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Celiac screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the prevalence of celiac disease and its potential clinical impact on patients with type 1 diabetes, all children with type 1 diabetes should be screened for celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/15,30\">",
"     15,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with type 1 diabetes should be screened for celiac disease by measuring antibodies to tissue transglutaminase (tTG) or performing an endomysial autoantibody assay (EMA) soon after the diagnosis of type 1 diabetes. Because these tests are IgA antibodies, a quantitative serum IgA level should also be obtained during the screening process to ensure that levels are not falsely low due to IgA deficiency.",
"     </li>",
"     <li>",
"      If the screening test is positive, the patient should be referred to a gastroenterologist for confirmatory small bowel biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the small bowel biopsy confirms celiac disease, the patient should be placed on a gluten-free diet. Nutritional counseling should be provided by a registered dietitian who has experience in caring for patients with both diabetes and celiac disease. Because gluten-free dietary substitutes are often high in carbohydrate content, identifying gluten-free products with acceptable carbohydrate content is essential for successful management of these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=see_link\">",
"       \"Management of celiac disease in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Implementation of a gluten free diet is associated with a decrease in gastrointestinal symptoms and episodes of severe hypoglycemia and an increase in insulin requirement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/31\">",
"       31",
"      </a>",
"      ]. Interestingly, the development of celiac disease in children with type 1 diabetes mellitus is reported to have minimal impact on quality of life in these children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some asymptomatic children and their families will reject a gluten-free diet. In this case, monitoring for symptoms and for adequate bone mineralization is particularly important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the screening test is negative, patients should be rescreened for celiac disease every other year. Additional testing should be obtained if the child demonstrates poor growth or weight loss, or develops symptoms suggestive of celiac disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other autoimmune disorders associated with type 1 diabetes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Addison's disease &mdash; Less than 1 percent of children with type 1 diabetes have autoimmune adrenalitis. In one report, about 2 percent of children with type 1 disease had circulating antibodies to steroid 21-hydroxylase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31414/abstract/33\">",
"       33",
"      </a>",
"      ]. This condition is associated with decreased insulin requirement and increased frequency of hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathogenesis of autoimmune adrenal insufficiency\", section on 'Humoral immunity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyglandular autoimmune syndrome type 2 &mdash; Autoimmune adrenal insufficiency is present with other autoimmune endocrine disorders in polyglandular autoimmune syndromes types 1 and 2 (",
"      <a class=\"graphic graphic_table graphicRef67520 \" href=\"mobipreview.htm?9/25/9629\">",
"       table 1",
"      </a>",
"      ). Although type 1 diabetes can be seen in either syndrome, it is more commonly seen as a component of polyglandular autoimmune syndrome type 2. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Autoimmune adrenalitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune thyroiditis and celiac disease are autoimmune disorders commonly seen in patients with type 1 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroiditis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 2 to 5 percent of patients with type 1 diabetes are hypothyroid. In addition, 20 percent of patients with type 1 diabetes have circulating antibodies to thyroid peroxidase (anti-TPO) and thyroglobulin (anti-TG). Subclinical hypothyroidism has been associated with an increased risk for hypoglycemia and reduced linear growth. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Autoimmune thyroiditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all children and adolescents with type 1 diabetes, we suggest screening for autoimmune thyroiditis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically measure thyroid stimulating hormone (TSH) and antithyroid antibodies. This testing should be performed after metabolic control has been established, usually several weeks after the diagnosis of type 1 diabetes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thyroid screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If TSH is normal, it is repeated every 1 to 2 years or obtained whenever thyroid disease is suspected. If it is high, a free T4 level is measured and thyroid hormone replacement therapy initiated. If antibody screening is positive, there is no need to repeat the antibody testing. TSH is sufficient for screening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Celiac",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 5 percent of patients with type 1 diabetes have celiac disease. These patients do not usually present with gastrointestinal symptoms but more commonly are asymptomatic or have episodes of hypoglycemia or poor growth. Decreased bone mineral accrual is a major concern for children with untreated celiac disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Celiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children and adolescents with type 1 diabetes, we suggest screening for celiac disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Screening can be done by either measuring antibodies to tissue transglutaminase (tTG) or performing an endomysial autoantibody assay (EMA) soon after the diagnosis of type 1 diabetes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Celiac screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the screening test is negative, patients are rescreened every other year, or whenever the patient exhibits symptoms suggestive of celiac disease. A positive result requires referral to a gastroenterologist for a small bowel biopsy.",
"     </li>",
"     <li>",
"      If the child has celiac disease, nutritional counseling should be provided by a registered dietitian who has experience in caring for patients with both diabetes and celiac disease.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/1\">",
"      Levin L, Ban Y, Concepcion E, et al. Analysis of HLA genes in families with autoimmune diabetes and thyroiditis. Hum Immunol 2004; 65:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/2\">",
"      Kordonouri O, Klinghammer A, Lang EB, et al. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. Diabetes Care 2002; 25:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/3\">",
"      Sumn&iacute;k Z, Drev&iacute;nek P, Snajderov&aacute; M, et al. HLA-DQ polymorphisms modify the risk of thyroid autoimmunity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/4\">",
"      Kordonouri O, Hartmann R, Deiss D, et al. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch Dis Child 2005; 90:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/5\">",
"      Rold&aacute;n MB, Alonso M, Barrio R. Thyroid autoimmunity in children and adolescents with Type 1 diabetes mellitus. Diabetes Nutr Metab 1999; 12:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/6\">",
"      Warncke K, Fr&ouml;hlich-Reiterer EE, Thon A, et al. Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28,671 patients from the German/Austrian DPV-Wiss database. Diabetes Care 2010; 33:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/7\">",
"      Karavanaki K, Kakleas K, Paschali E, et al. Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM). Horm Res 2009; 71:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/8\">",
"      Bonifacio E, Mayr A, Knopff A, Ziegler AG. Endocrine autoimmunity in families with type 1 diabetes: frequent appearance of thyroid autoimmunity during late childhood and adolescence. Diabetologia 2009; 52:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/9\">",
"      Kordonouri O, Charpentier N, Hartmann R. GADA positivity at onset of type 1 diabetes is a risk factor for the development of autoimmune thyroiditis. Pediatr Diabetes 2011; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/10\">",
"      Katahira M, Maeda H, Tosaki T, Segawa S. The human leukocyte antigen class II gene has different contributions to autoimmune type 1 diabetes with or without autoimmune thyroid disease in the Japanese population. Diabetes Res Clin Pract 2009; 85:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/11\">",
"      Kordonouri O, Deiss D, Danne T, et al. Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with Type 1 diabetes. Diabet Med 2002; 19:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/12\">",
"      Leong KS, Wallymahmed M, Wilding J, MacFarlane I. Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. Postgrad Med J 1999; 75:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/13\">",
"      Mohn A, Di Michele S, Di Luzio R, et al. The effect of subclinical hypothyroidism on metabolic control in children and adolescents with Type 1 diabetes mellitus. Diabet Med 2002; 19:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/14\">",
"      Chase HP, Garg SK, Cockerham RS, et al. Thyroid hormone replacement and growth of children with subclinical hypothyroidism and diabetes. Diabet Med 1990; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/15\">",
"      American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/16\">",
"      Joseph J, Saroha V, Payne H, et al. Thyroid function at diagnosis of type I diabetes. Arch Dis Child 2011; 96:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/17\">",
"      Gilani BB, MacGillivray MH, Voorhess ML, et al. Thyroid hormone abnormalities at diagnosis of insulin-dependent diabetes mellitus in children. J Pediatr 1984; 105:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/18\">",
"      Aktay AN, Lee PC, Kumar V, et al. The prevalence and clinical characteristics of celiac disease in juvenile diabetes in Wisconsin. J Pediatr Gastroenterol Nutr 2001; 33:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/19\">",
"      Crone J, Rami B, Huber WD, et al. Prevalence of celiac disease and follow-up of EMA in children and adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2003; 37:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/20\">",
"      Al-Ashwal AA, Shabib SM, Sakati NA, Attia NA. Prevalence and characteristics of celiac disease in type I diabetes mellitus in Saudi Arabia. Saudi Med J 2003; 24:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/21\">",
"      Cerutti F, Bruno G, Chiarelli F, et al. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care 2004; 27:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/22\">",
"      Fr&ouml;hlich-Reiterer EE, Hofer S, Kaspers S, et al. Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus--data from a German/Austrian multicentre survey. Pediatr Diabetes 2008; 9:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/23\">",
"      Fr&ouml;hlich-Reiterer EE, Kaspers S, Hofer S, et al. Anthropometry, metabolic control, and follow-up in children and adolescents with type 1 diabetes mellitus and biopsy-proven celiac disease. J Pediatr 2011; 158:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/24\">",
"      Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/25\">",
"      Verkasalo M, Kuitunen P, Leisti S, Perheentupa J. Growth failure from symptomless celiac disease. A study of 14 patients. Helv Paediatr Acta 1978; 33:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/26\">",
"      Ashkenazi, A. Occult celiac disease: a common cause of short stature. Growth, Genetics and Hormones 1989; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/27\">",
"      Freemark M, Levitsky LL. Screening for celiac disease in children with type 1 diabetes: two views of the controversy. Diabetes Care 2003; 26:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/28\">",
"      Iafusco D, Rea F, Prisco F. Hypoglycemia and reduction of the insulin requirement as a sign of celiac disease in children with IDDM. Diabetes Care 1998; 21:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/29\">",
"      Mohn A, Cerruto M, Iafusco D, et al. Celiac disease in children and adolescents with type I diabetes: importance of hypoglycemia. J Pediatr Gastroenterol Nutr 2001; 32:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/30\">",
"      Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/31\">",
"      Abid N, McGlone O, Cardwell C, et al. Clinical and metabolic effects of gluten free diet in children with type 1 diabetes and coeliac disease. Pediatr Diabetes 2011; 12:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/32\">",
"      Sud S, Marcon M, Assor E, et al. Quality of life in children with diabetes and celiac disease: minimal impact of the 'double diagnosis'. Pediatr Diabetes 2012; 13:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31414/abstract/33\">",
"      Peterson P, Salmi H, Hy&ouml;ty H, et al. Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. Clin Immunol Immunopathol 1997; 82:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5823 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31414=[""].join("\n");
var outline_f30_43_31414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HLA GENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AUTOIMMUNE THYROIDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thyroid screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CELIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Celiac screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Celiac",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/25/9629\" title=\"table 1\">",
"      Polyglandular autoimmune syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=related_link\">",
"      Management of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/42/9896?source=related_link\">",
"      Pathogenesis of autoimmune adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_43_31415="Curved Gram negative bacilli";
var content_f30_43_31415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Curved Gram negative bacilli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Gram stain of Campylobacter jejuni in stool. Note the curved and S-shaped forms. B) Helicobacter pylori organisms present in the mucous layer on the gastric mucosal surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     A) Reproduced with permission from: McClatchey KD M.D., D.D.S. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"     <br>",
"      B) Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31415=[""].join("\n");
var outline_f30_43_31415=null;
var title_f30_43_31416="Inferior skull anatomy";
var content_f30_43_31416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Inferior skull anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 418px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGiAlwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKo3+pwWcixHdLcsNy28Qy7DOM46Ae5IFAF6iuWHilciQvp7QiYRyJFcF3VS23dnaAcdSPTPJrO0rx1HqMhgSXTodRYb00+4lKPtPK5fkZIweF4z3oA7qisfS9egu7o2N1E9jqSjm2mIywAySjDh19x+IFbFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU2R0ijZ5GVEUFmZjgAepNc7e+KoBp0t3YWt5dW/CxXESLskJB5TcwLgY6gEHtmgDnPih4+tfDFtGstxPEZpjbxJbKrTTsAN5XPCqucFuueBXjPjvxXq8ul6fb2l1PHZ3E0v2lvNYzXOCCiu3XhWGAf6VmeLmu/EWvW3iRUa7sJYIobeOPJ8jZ99SMZHz7s+5NGqNbaDr+k6frisbbULQSy7c5ilViFbPUfKwBq0rEt3J9Yv7y08IXs9uUijiaCGIHLb5DJkMR35xn61l2ey5vtA1WdVMl5aRrJuUfLJF8rY7/AMII7ipfiVqNre6dp+j6OT9mSdZWkH8QXBJOOgA4+pqWGH7Bosi6jpKT6fcyG7tXCsQshzuXgjGDz6HcfSlzJSsPlbVzvNR8YwL4c05dSmlMVpM10rq22YJFksoYcjJKoDx9412Xgv4ladcaQL65uWg0xAPOS6kMktoTyMv/ABoegz82Tjmvmy3uNS1jU9RElpJBAYo0trSJMkRhgxJJ+4CQvzHrkYDV1Gk21v4eszf6taR3DxDbZ2ZyQ0p4XZGeWPP3myeRjbit1QSXPN2X4v8Arv8AmZuo78sT6DT4mWkyLJa+G/F1zA43RzRaRIUkU9GU9wRzTv8AhZEX/Qp+M/8AwTSVV0fxFqvhXwxpC+KNLna2W3jR7uGbz5EbaOJEwDn3Bau802/tdTso7uwnS4tpBlZEOQannpfy/j/wB8s+/wCBxv8AwsmL/oU/Gf8A4JpKT/hZMX/QpeM//BNJ/jXeUUuel/L+P/ADln3/AAOD/wCFkxf9Cl40/wDBM/8AjR/wsqL/AKFHxp/4Jn/xrvKKfPS/l/H/AIAcs+/4HBf8LKj/AOhR8af+Cd/8aP8AhZUf/QoeNf8AwTv/AI13tFHPS/l/H/gByz7/AIHA/wDCy4/+hQ8a/wDgnf8AxqzpvxAjvtQtrT/hF/Ftv58ix+dcaU6Rpk4yzZ4A7mu1opOdPpH8f+APll3/AAPMfGGtvoniXxlfWV873eneGDfQ2kl1I0IlXzjuMO7b0SPOADj68vv/ABPq+n63No17qdrDGb+GFtUe3CLBG9u8u3BO0EvHtUsf48HJxn0ZraBpGdoYi7rtZigyw9D7U54Y3Dh40YPwwKg7vr61iWeUat4r1O0ub42Wq2U8SvbBrlJo0adDbu5Nus0oh3FlUkZAK7jycETp43ntHn1uWTdocX9ny3ryRyKywTwH94IyxEZEjRlgB93dnJGa9PeCF1IeKNg2MgqDnHSlMcbb9yKd/DZHX60AeTv408Txana216thYXC29tdPBcvHCsgldi6ZdgTsXCZQH5xk5BC1v/EZLy41/wAMwW0haAG6uJLUKWFw0cQKLwRz1xnOCQcZAruXijdlZ0VmQ5UkZ2n2pxVSwYqCy9DjpQB5JF431iXTd1pq2k3jS2tpdSTJ5cP2d5XYPAu99m8qp2K5BGDuJ4qay8d3k2p6AzXyNp96LeMKkUHntJJK8ZMsXm7ghwu14d68Oxyo49SMERR0MSFHOWXaMMff1pfKj3o3lpuQYU7RlR7elAHnXw/8aXeveJ/srXEVxYXVg19CGMYnhxIihXRCdmQ/3WJYFecHIHpFMSGKNiyRorEkkhQCSetPoAKKKKACiiigAoorN19dXaxA8Py2EV5vGWvo3ePbznhGU56d6aV3YTdjSori/J+In/P94S/8A7j/AOO1Vj1fxfpvi3w9p2uyaDPZ6pLNExs7eZJEKQvICC0hHVQOlbewvtJP/gEe0tumd9RRRWBoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFQ3VzBaRGS5lSJPVjiuQ1PxLCNGm1rUtSOk6EGKQsgHnXHXBBOcZwcKBk4zkZxQBH4yvoZtauLPUlEmjaXpx1S6tz0uWLMI0bsVHluSDwSVzwK+ZLTxJ4j8UeM1v7/ULhRJOZRCJSkccYPQL6AHH/669HvdSvtWk1XWLBry+svsyx3VpdhTM0BJK4IAG7lvlIyc9eleR2mr6VqVy8ejm5kjDbktxGYzyQSHc9Bnrj0xVqy1ZLu9EbOnTX2g+JtZudAvlFtc38jLbzruiYFVYsp5KncWHocCrl3p93rV4bnW3R7p1CYQcImckfieSfYVHLe2djsubuYSOiELGByuSST9Cc/hXPXniA3d0ztcLEiScx7MA45xz/MVwVK0pvTY7adKMVd7l7x/pi6ToNtHZIsc19crDtVgGwBnljwBgV0ljfahJ4Hs7OWTydNWdz9tbmSTJA2RKegA/jYdT8q8Vwvi/VJNb8NxRr8t7aSrcRNvxjAO7n+X0qV9ex4a03SUkRp7SMvJuOcuxLM35sRW1OqqcLxV5ef52/r0M503Kdm7I9F06Cws45Bpu+KZly06uWLnqSc9fr196l0rwzbJ4l0y8Z5bq5kdrmS4nYv5RQZCjPCjLDoO3tXm+nas9uFKL5eWA5b7wx1+mOK9K8Oa1DcxKksixBjkODnYwHX3BBxiso4iTn+8d7lyoJR9xF8+L7rRL670vWi9xBdOUcM2dwbOCAeh5HIq/wDs9a3Nb+KtY0R5JZbWYuY9xyFkjOCfqVYZ9dtch8RZdUjkht7DSnvZbqRY4JYmUhiQcAZ5U9fpiqvwt8MXl5r0WnLqjWkUscv2m8tm2qygrviik/iOSFMnTrtyMk+lTp+0Tey6s4ZS5XbqfQt38S9Chvbm2to9T1D7PIYpJbGxkniDjqu9RgkZ5xUX/CztJ/6BXiT/AMFM3+FZ/hHWLfwr4jh8GST2zaeYd2nyogjKkctG+OCepDcE85yTk+l0OVFOyi/v/wCACU+/4f8ABOE/4WdpP/QK8Sf+Cmb/AAo/4WdpX/QJ8Sf+Cmb/AAru6KXNS/lf3/8AAC0+/wCH/BOE/wCFn6V/0CfEn/gpm/wpP+Fn6V/0CfEv/gpm/wAK7yijmpfyv7/+AFp9/wAP+CcH/wALP0r/AKBHiX/wUzf4Uq/E7SSwB0rxIoP8R0mbA/Su7oo5qX8r+/8A4AWn3/D/AIJ53481jWovENnZaHc6lG8ul3F1FBZ20UhknV4hGJDIh2p85B5Xr1FVb7xzqYlltGghaKWK8t1vLZHVYrqCJ2cBn+/ho3XgYBHU4Nd/M2mxXc19M9qlxZwssszMoMERwx3H+FTtB59M1VPhbQjfy3x0ix+2Sly83kruJdSr8/7QJB9c81iaHH6f45vlutFtkhS9tpmtrK5nCOpinkgD5Zz8pOSuVUHAOSQeKz7bx3rVj4N0zWdWSG4uG0O/1Ro4XCpN5EcbqHymQSWYfKQB6HjHeHw74dj1W2nOmacuojDwsY1En7sBQy9/lG0ZHQYHpUg8L6ELeWBdIshBKsyPGIQFZZQBKMejBQCO+KAOU1PxzqenahJpM+nwSao17HbRNbiSWMK8DzZKgbmIEbLgYzweOQNu78S3ln8PrnxBd6YYL23tnlezlcr8ykjGcZAOMjIzgjIzxWvfaHpV+LgXun2tx9oZHl8yMNuZPuMc917HqKq6joGmap4Su9Ctljt9MuIXtyLUKAoJIbA6ZznPvnNAHO3XjDWrfVE0dNN0+fVX1JbFW+0vHBta0luQxOxjkeUQRjnIPGcCve/EO606wm1S906BtOY38cKQzN5oe18wNvyuAG8puf4eAc5OOt07S9BtrkWen2djFPZSi88qJFDRSOjxiQ47lN659Milm0jQrCS/1Waw0+B5InN1ctEo3R4y+446EDn1wM9KAOb1vxRr2kXWnabNZWVxqd8k06NarNLGscQj3AqF3ZLSgA9MAnH8NRp421YapBDd6G1itxAr21vcCTfcSm284xiYKYlcOGj2sQTtZhkYB6JPCnhyTT0tk0fTjaFxMirAuA23AYHHB28ZHbjpToPDPhyV0vINI0t98IjSRLdCrR+XsGMDGPLwv+7x04oAreB/EE+u2t0L5I4b22dVlgEM0LxFlDYZJVB7nDDKt1HpXG61471qfwmLm0gtbSbVdL/tGwkSRmaBPNgQrJlcb9twpBAxkMMcZPpOk6Rp+jwyRaXZW9pHI29xCgXc2AMn1OAB9ABWVJpvhaxvmsWs9KgvNTyxgEaK84VtxOOpAY59MnPU0AR6tqF/4f0TSIYo4rm+ubmKzJnndlVnz8xbG5gMegJ9qwLbx7ewxpcaxb2FtZt/aMBkR5G2y2cjIzkbc7GKMQoBYcdScD0C6tLe68r7TCkvlSCWPeM7XHRh7iszUdM0K106WXULSxjsohPJIZkXYolJaYnPHzFmLeuTQBxzfEW907TdUu9Z0rammXMCXATMUjxTKNrRxsclgxA2E5I6c/LTNa8UaqzWiFxayyjRZ2S2nSWJVuNRWN1DhctmP5S2dpB4A6ntLTw1oWmsJrXS7K3MbifesYXDhSu8n1Cswz1wTSW2jaApjtrazsMxxwukSKvyxpKZIiB2VZAWXsCOKAOATx9qGl6AZwg1Oa0a5ubyMo5dYBdzRoS4+VBtjYDOSdh44JrpvGH/ACP3gL/r6u//AEkkrXu/CXh68CC60XT5goYDfApwGYu3buxLfUk1keMP+R+8Bf8AX1d/+kklbUPifpL8mZ1NvmvzM3XfG+paefFscOnyynTNQgtre4WIGJUeC2c+YdwJOZn6Dptq7eeP4rTXprCSzEsCi4WO4t5HcGSGNnZHPlhFbCMMB2YEcgdujuPD2l3EOqRTW26PU5luLseYw8yRUjRT14+WKMYGB8vuc5Gp+GfDFg0mpX8MkSNM55upjEslwTG5WMNtUuZTkgDJYnrzWJoc94m8fasvg/V7rStH+yajBos2rA3Nwh8iLy2Mb4UMGYsrfJ0+Q5PIz6bXM+IfC3hy60qT+2YvJ0+3sJLSaT7ZJbqLXb8yyMrrlAAT8xOOTxya6agAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqtqF/a6dbNcX08cEK9Wc4Fcjq/juFIyulQPNIejyDC/lWc60KfxMuFOU9kdnPNHBGZJnVEHVmOBXF+I/H1rZq0Wlobm4PAcj5F9/euaddV1qRpdXupBHgtsUYVVHsK5/Q76y1zV5I7CCRtJswGmuCuFdvTPc+w6d6wVeUtUrI19lGOjepqR38t20l7r14qjp5kzhEQHsM8D8K8z1vV59e8O6ZpXki/m0rfbiENtCsp25YZ7gfr7131h4v09NHur2CGGbU5JXjt1mUMLdB3x29c+9c9YaXeeKNH1DXdYe1tjGdsd1ZkRzuRgby68HkEAHNdVGLiryMKkk3ZHUeJtY0zwt8PIdPtpQs7Kks5C/NkDJJ9WPQD2x6V45cQR6PZW7KPIvplaeaMLwrO27afoDz71CNPlsPGUj6rqtzqaQxrLbrdOGCk5B3Y6lfp3rG8U6qzyzKZC8zkHjjg56n1NYYiTb5EbUI2XOzHurg3IbazBZDkknkj61CjTMfLkkhMgB3bifkGc/L69hTdPiaWUSSEAZ2gL93I4x9a2o9P2uHO1ZMYZSOHBB79vWsJNR0N0rmA73Mtr86sFb5evT1xVizt5JbeBt2xiu7CgA46ZPc4x0rpotJW7hkMIHlpnDAZyegI9a7fTfB0J02ARxEK8akMw5wQeD/hRKdloO2up5tDp8h2sSSG4B9j/AErd0GSSO+gIXcAdrKOqnPU11+q6DHFAY0HkqRk44OFGTkngDGc57VyNxbboTcKuYXOFY/K02fbsmOmeWHoOCqdP215Sdord/ou7fb9AlP2ei1b6f10N7UdSj1K8tXm3rpy7o2l83YJ+xRW/hQjILfxcqOMmt7xPdags0F3oo0/S7JWVYlklCIibQoj/AEHTriuFsbtkc2s5WS2fCOkgDAjPpj6D2r1fwf4C8I23jVLy4sWuXESJFbPGzRCVgSzgEkHIKj0GDXfSxSqL2cVZR/rXzOOrQcHzt3b/AK+48s8QtcDU7K6uNWeUuSXuAjCKPC5C+ZjHO79K9M+GXxSvrKVbHWJnvbRTt3sdzqvQbT3+ldV4o1Lw5eS38WpXVvZ2enyCMQSRq3mfICQE6becZrxGaHTbrXJ7XSwRpkkm4YyHA/ijXPc5BJ/hBHcgVUqTqe9eyW77L+unUmMlH3bXb2Poqz8U+I/Fl9dzeB00iPQrY+SL3UopG+1Sg/N5QRh8i9Nx6nOOhxe8r4kf8/fhD/wFuf8A45XBeFbxLDVbTS4bsWtxPF+4ijOBuUfdwP8AZBx9K9Q0/XmU+TefM4/jxjP9KX16CdlFJdLq4fVpdXdmZ5XxI/5+/CH/AIC3P/xyjyviR/z9+EP/AAFuf/jldfbXkFycRSAsOqng1YrVYjmV0l9yM3Stu2cR5XxJ/wCfvwf/AOAtz/8AHKltI/iCLuE3d14UNtvHmiK2uA5TPO3MmM46ZrsqKftn2X3C9n5v7zyzxz4Z1jU7f4jNY3Gowi90vyra2gSEpeP9mddpLozckhflK9fxrQ+xa3/wmpl8rUvO/tPzPtPnt9k+weTjZs3bc7uMbd275unNX7rxhPp/ijVbS9sZZNLtprOEXUWzEJnwo3gtuI3svQcA5pr/ABEsIbKW9n0+/SzNpNfWsv7s/a4omUMUG/g/OpAbbkHPYgYmhzemaVrWk+HPDNzeQ+ItSuhoksmpwf2hM0z3Zjt8IGL/ACHcrgbcY+Y9SSWRaXq0el6eLhfEuoQtBdtMsd1PHKl65iMW0ySB/KUCRVJOB1bk5HT33xEsNOhmXUrSaxvo71bH7Nczwpl2hEwYyF9gXZ6tnIwASRnpPDmsW2v6La6nZBxBcKSA+MgglSMgkHBB5BIPUEjmgDgodI8Sfbvtt7JqEmoQ6hpqho7lxCYvKhW5Kx7tm0ky549+wrNttF1Sx0KDSo9O1ZQdRvGuZjPPMVzLI0JjUTKNrKwO7O1T94biSPYaRmCqWYgKBkk8AUAcH8MrLWYZTd+IIp1vJ9E0tJ5JvvPcIkvmg/7QZufrXIrbavrem62dPj1aeYy6/a3Ms87tDNH51xHBDGrMRkEIBtA2hWHG7n0n/hOvCX/Q06D/AODCH/4qmReNfB0SlYvE3h9FLFiFv4QMkkk/e6kkk+5rT2NT+V/cTzx7nHadZeIm8baVJLa39rardSQXaxvJ5TWv2SUIxcylcmQRkBEXYeCc8tgaf4f8SWnhnw9p0Y1myt7TSEtZAomuJIb5VVXZAJ0wvA2H5oxtbhQfm9zikSWNJInV43AZWU5DA9CDTqzKOU8aQXs9rop8q+uLBLndqMNm5SZ4/JkC/cYEgSGMlVPbuAQcTwToGqReKYtT1tb8TR6VHCrSXbsM+fcEJIA5WR1jePJO75uc55r0aigDy7Wf7RvvHeq22n/2q95b3WnPbvHcOttbx5Bn3LuCcxhwQQS2cDnphNpfim+0/XY5rC/j+3aNMstoxdo1u96bURnlcuQC43gKGHboF9rWNFkd1RQ743MBy2OmT3p9AHkU2meJNR8Q6gGtb63hu4dRtp4hJIISrAiA+Y0pBJwCCiqEzt45ylvpGt/2bZ29hFrttbfZdIgkV7qVZFK34+1ANv3AeVuyQfu8DjFevVm6/rVjoNiLzVJJY7cuI8xQSTHJzj5UUnsecU0nJ2W4m0tWea6ppHiSIRW8RvhokF9fAp++nkCsYzA3yTRyMg/fAfMcEr8uACuzfx3EOv8AwvjvpZ5rtDOs0s6qsjuLJ9zMFJAYnJIBIz0Jq/8A8LO8Lf8AP3f/APgqu/8A41WLd+JtM8S/EDwWujNdzfZri6eYyWU8KoDayAEl0A68V1UqFSLblFpWfTyZlOpFpJPqvzK4sb7UvHviB7CwlN1Za9buupvKgjghFjatJABu3/PuIIC7TvyTleMyw8JeI2S6ZtKltDcxWT3ECtaxwtcR3aSO0axsSQE3ENIS5xj0Fe00VyGx4pqvg3xFqz+IFOmfZZtS0vVLWYq1vHbTSyEfZ2BUmV+hO6T7uTgLkitPUfC+qXWvQ3cWmana2Iit/sUVs9p5lgyOxcEs/wAu4kEtGW3KSpHAB9YooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBCQBkkAVyXiHxalqWg04JJMBzIx+VfetjWH320oMhRMduM//AFq4BtKW9uWRVkW33jzcdNmcnJ9K8+viJN8kDpo0o25pGdLb3ur3DXWoyS3EiEhA33UHqB6n19Pxro9M0NLeJZ7tSWP+rjA6D3qWbxN4dspxDHeRPInQKRgmrcWsW92PMV0KZCoQeDWMYdZGspv7KNCwtogH8xVxjkkdq4jxFqqPrVn4e0KCGO4lBO3bhEQHliB154HvXW3+pQQW0vllS+w555rxzSZtUvfHerX2mTWQuLRI7VftEpQjADswIB6lz+Qrrp0lKXK9jncnFcxQvvhbrVjrN8Ej07UY2YutsLlY2cNk7WUt154wRkYrjvHXifUNCsbXw1LYatpkYyI7RwCH56LIDyor0+TRIbXWYLzUPISdWaSS7im4kJ5+bgZ5PHfiuK+I3iDTtUBCILtYXRopWBBTDDGOM5Nd17I57HE2T3U/mXF437+YBSv3iiDoM/j+Nc7HCb/Uz5TNgfdUt3rpPF97s+0LAW2k8ED73oD+P8uazfDUSrKo+9K55Hr3/L3rznLebO9R2ijbtra20q0+0XUhMksiRxrjdhj22n1/Sr+n20l3c4QLIpPG3oB/WpDFvdTtG5eGxz83t/KvSPA+gJFai4njXaUB/TkVg31NbWKUukLovgm9uZFjkkiTKkr+QxXoBsy1krRwhMxpgeny8VkeLrQS6DaWIlWKC7u4YZJGxhVLDOSfXp+Nd7eIIY2hRMEthRj+EDAFdEUnG5zyk1I8y1vQodT8pb4yeVG+94gPkkwOAw7gHBx0JAzmuZ8Q6XL9mmaI4jCsQw6nFenXcDmcqeH5GKwtSt90DIOVH6GsKkm0o30RrBJNvueF3LCxvTAmfMjAbcx4I7YPpXY3HiPVruysbvSbmSHyIPLunjTe0YXkNjqRzg4yRgcGsHxfaPHdPMF3DO3B6Uvhm6KWOo2kKyfbbyE28IJwihvvyFuyhc5xzkgDk5rbCKc6qUN2TiOVU7y6DNMsJPHt6Hsl/tG4K7pbiMssUSg/NIwbapJPQE4JBzgA51zpcmi69cXFlcaVqCRWwQ6fbXBknjiDZLA4wWySTnqTxV7T/EXhew8BXfhzTJ4/t8kgabf+6NztOGUsPurgYVRwBgepPbeGNK1rUNIt/sGoaBp+lNEDDawRYfp0bHJPuTzzXr1pJx9nH4fz8/8AI82mmnzvcxNG/s0arp3iKKN5p413wSCUiMkjG4p03YOM16Ra6paaoAXURnJPJ6V4xp9rqGkajfaTqPlMLa4Z4jCCkYDktgA84ByK7HTLtAfLVxk8tzzmvBqJxk49EerFKUVLqzvMTR+WYJRJGOVx2rdXWrjTVX7fFLLFjOVXLj/GuI0668vyl35Zc8A9vSuw0sjUbNlLbrlBlM9G9qdObTstyJxXXY6XTr+21KziurGZZoJFDKy+h9QeQfY1ZryvTo59N1++fS28l8C4EJztdTjeMdOp/wA5r0HQ9Yg1a3LRho5kOJInGGU/4V2UcQqmnU56lJwKN54R0281qXUbh7pmlkgmltxMRDI8JBiZlHXaQD1wSBnNVW8BaI1vcwMt01vNBLapE07FbeKRg0ixg/dBKqe+MADA4rq6K6DIwL7wnpt5d3F232iK9luUu1uIZSrxSrEIgVPYFMqQcggnIrX0+1FlZx24mnm2Z/eTyF3Yk5ySfr+HQcVYooAKr6l/yDrr/rk/8jViq+pf8g66/wCuT/yNOO6E9jzbw4dO0X4L6RrD6NYXk0WnwMVlVU3lto+Z9rEdc5was2XiTw+Zb21v9AtPt1pK6SJp0AvIyiJG7yK4RSQomQEbQdxwAat+DNHg1/4NaFpl2zLBcafAHK4JwAp78dq2tX8KW17LbS2FzPpMsMEtpuskjAMMhUuu1lIByikEDIOexIO1ecvay16sinFci9Cu3jXTPJ1E6bDdXkWnwNI8sEJMWRCJgm7sShUg4xyBnPFQN8Q9Hg060ur5bq2821W9mR4Tm2hOR5kmcYXIbBHUKTjAOGt8PNLbVra8aWXy7a3a1giWKJGSIwmHyzKEEjIFJIVmI3YP8K4jk+HdrIbSVtSuWvILRLBriS2t5DJChYoNrxlQy7mwwAzuOQeMYGhoT+NNP+2SWtqs0kkN9FYzPJDLHEsjyKm1ZNhVm+cHaD9SBzTB4+0MWct3LJdRWq2/2uKV7ZwLiDcqmSPjLLl09/mU4wQTZfwpatBLEZ58SaqmrE8f6xXVwvT7uVHvWWnw7sRYJZyahfS21vafYLJH8v8A0WDfG5RSFBP+piGWycIO+SQDfuvENlaaANYulu4bTKrtktpFlyzhFHlkb8liOMZ5rOuPG2nQaVNfyW98I7eZ4LiMxAPA6gMQ+TjoVIwTnIxmtfxBpMWt6Y1lcSPHGZYpdyYzmORZAOfUoBXO6n4As73UZr5b66huJJ5piRHFIB5scSMArowBxCuGxkZYdGIoA0tO8Xabqeota6aLq7VVRnuIoGMSF4hMgJ6glGUjjHzAZzxWbL49s5T5VhE/2yK9s7a4t7gbWjS4l2K/BI/hfjrleQKg/wCFa6c8+nvPe3TrY2otISscUcoTyDAR5yoJNpBLbd2N3PQAB2m/DqzspfMa/uZWH2EKBDDEqi0lkkjAVEUcmQ57+mOlAG/qviK003VbbTniuri8njMwjt4TIUjDBS5x2yw4GT144qhN430tZp4kFwGje4hSWWF0hkmgVmeMPg8gI5yAQQrYyQRT/GHhC18UtbC+uJEhhIYIsMLEEMDuR2QvG3GNykHHTnBrI07wLJK162sX8zxNfX11a28WzZEbjzU3527i3lyuMEkAsevGADTtvG+ly3NvbsLjzJHgikkSFzDFJMivGpcgZ3B1A46kZxmrGgeL9J12++y6fLIzvC1xAzptW4iVgrSIe6gsnXH3lI4INVYPBNlDE0a3NyQbqzu+dv3rZY1QdOhEQz9TTvCPgyz8LSgadO5tI4TBDA0EIMaZBAMioHbG0AZY8ddx5oA6miiigAooooAKKKKACiiigAooooAKKKKACiivOrLX7qa2sNZ1HWNRtYbzUjapaW9nHJbxf6SIEilYoXVmJCltwwxOAAMUAei0V5y/xC1D7Pbyf2JEn268ntbPZNNcMwhaQSO6RQll/wBWuAN2dxzt28vvPiHcWx0920hlDi1F7bsJvOtWml8v5j5ewYyGAZlZh/CvBIB6HRXmNp4+1eG1jjvNOt5ry61LUbe2aAzyjyra5kjO9I4WYEAIowCDyxK/dPQeH/FOpazrcdkNDFnDHZW93dtc3JSaBpVkxGIvL+Yho8HLLwc9RggHXUVxeteNH07xPDp0VpHdWv2uCyuJYjKWgkm27dx8vywfnQ7d+drA8ZAObH8RrmO0W7vtIhSC4sLq9tFhui7MYJooij5QBdzTIQRnADZoA9GorlfBuoareaz4mt9ZMCvaXUUcUcDl0jVreNyASqk5LE8jvXJ2HxD1GC3NqmnXOr30Kz3UwjhlZnj+13EUcaeXGyhsQsMuVHC88kqAerUV5/d+OtSt77VrX+wybm2L/Z7U+f508azJGZlAiKyJtfzCIy7AYXBY4FWf4k3Bigj07SxqN79mkuZorVLmQHbK8YjXEJZXJRsiQIFPGT1AB6VRXO+HtevtY1rVoP7Nit9OsJjbfaGuSZZJNkb48rZgDEhyd+cjoc5HRUAFFFFABUVwwWIknA7mpa4b4oeKYPD2jSySN8+DtRerH0FY158sdN2XTjzM5X4n+PrfR/8ARYSXnIOFXrj0rxPxF4y1/wARu5+1tptmQY1jikx8pHfHWub8S6y93dNd3pMjyNuRBySfT8OM1gma4mdTPKFXBxCowoH9fxrmhT5UdV1c1LSebcGS8fcMKQBwccZzXpPgDVXnXyTM0tyG3EMSCq+ory7S5hHA0bndKuc4HT8P89K6jwqskWo/aIuenzBshaJpPQcT2zUNYWCxdpmY4ABGeWJ6CuA13wh4mgvP7btYfs32kqTD9qQSoQu3cVOAcjAxnIIH0qxrmvraal4cd4JrkPqCFoIgGZxgngeo616RDJdXl4b+8s08hztSKeP5ogPU9Ock104amoR5urOatNyfKeS6j44l0n5Xsbiw1Xy/LSS8kA7HO3zBx6kq1cFHO+s34P2kTxRN51zcZ4dgeAp7getew/FzV9D1TR5fDv2WGWV1ZgVORAVXIYeh57e4ry27S1t/D1o9ohRpVTKHncdgzn2zmtK0mo2XUmlFOV30Od1S9S81URAkW0Zz0xz0JP5Guh8NKshMvKjyywyM5zwP55rkogpv0yUUuC7DGB6V16yiG3Uh9oC9W4yB/kVwVlb3UdlN9WdVpEK319GsY3LC+Gcfxnsa9ptrdLLRdpOG4wM9K8o+GscDzxylt2WOfqBzk9vxr168iO0xykgMu4Lj7w9fpWUYy5dEVOS5jE8QJ9rsrGNmIH9oW7LzjOHHFd1rTl79icExnA7YrhvFYlh0S1+yw+dqH223a3iDY3sJFP5YzXTz38WqSyLFHNBMoDSRTIUIz7ng9CMiumKlGmc7acyldY8ze743HjHpWXchVhdnIKngAdq1njjkCgHKg9Qe1c74qu4NOspru6kEcCAsx7/QepzgAetYqEpSUUtWa3UVd7HnvjHyFRo9hdpCEVFHzOxPAB6DPP6ntXKaLdraX8lkZjElzE1tLIgwB3AAPRQcEZ6nJPJwOmv7e6Vkv75PKuZQQkDHP2eI8bR/tnGWPX+HgZB4vUofO1KILnEjjHUnOen611VJqgvZU9+r/ReS/F+SRnCPtfent0X6+v5HVad4zHga6ltDBFZ7z87NGFExJ4ZXK4YH07fpXR6Xrekatcwayqwx6hjyhJp7K9wzHGCyR8MP94ce1aS+G/8AhILrT/DhkK2k0Qmv7jjeEzhYkOPlLYOT1C9MZzW+lta6fezeHfCMNr4f0mxws95HEGmnYYzgngADuck54rqhNyjdo5ZRUZWR5V4tv9ai8V3V7faZd2Njc+WIPPXbuIX+I54Jyf5Vny69c2V5LsO9DwMnr9P/AK9dV8UPFbX2n3nhrTk1C8aACZru9jIkl2kOPLTA+X5TyRz29a8yklaSVY0zJ5nKKFyT3GMdeK48TC0lLudWHndOJ1tl49eBg0kbbweQOQK9D8HeP7aeRSZPL2jc+8hAij+Ik8Ac9TxXg0xihXddSL1wFR+CR/tc57cLu9ytZV1rLu6QwoqWxbIyPlB57c884ydx6ciqWDUVes+Xy6/d0+f4g63NpT1/L+vQ+lF8WX+r+IZp/CsUF1G0Zja5uy0dovIJx/HIeCPlAGeckVYbU/GltepexnwvHOnBZRc4Yeh55FfP/h/xfeacscCOojJLPySSW65Pr0r2LwrrTalZLu+ZXU8Zyc1DrQg7U4Jeur+//Kw/ZSkryk/loem2dz8S7y2jntpPBLxOMggXX+NT4+KXr4J/K6rI+FOstDrN5os7naR5kSnjBHXH1H8q9VrupYrnjflX3HHUo8srXZwGPin6+Cfyuv8AGkx8VPXwR+V1/jXoFFa+2/ur7iPZ+bOAT/haW9fMPgnZnnaLrOKkvv8AhYP2G43/APCKbPLbOPtGcYru6r6l/wAg66/65P8AyNNVtfhX3A6fmzgfDumTav8AA3SLS0IW9GmwTWjHotxGFkib8HVTWTZ3eo3sqeIb+LWdJ0/WZ5POWC3c3NvFDGEt42CqzKrP50nQcuoPXB3fB2rrofwc8O3xhaeT7HaQRQqdvmSyskUa57Au6jPbOav6t4i1rQ4LaTVtMs2We8gtkFjNJOzb924bSinIwuD0O4524qK/8WXq/wAx0/gXoco1x4vuLH7Rd3WqW1/BaaS3lQxKFMsspW4JXYQSF6jkL1x0NN1e78TWl09iLjUV0eG+uYjeMJDIB5UDQgukbMUy8/zYxlFUnseyk8e6MlmtyftjIqSy3AW2ZmtUikaORpQPuhXR1PUna2AQCat3Pi7TLXXo9JuvPhuJg3ks6fJMVjMhC4OT8qsc4wdp5rIsx/Bv9u3mtzTaxqV60NvaWmIRbCCGeV4cyuVZN4+bnbkbTwRXcVzOm+NNN1K1uJrSG/byraK8VGtyjzQyEhHQHHBKt1xjGTgYNaXhzXbHxDp323TXLRCR4XDDBR1OGU9vxBIPUGgDUooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxJPDehSaobp9PtTeeYt0wxwZAQVlKdC4KghyM5A54rbrxvSPDWrX0N/c6VplhZXUV9ruLq6UE3vm3M6ojrtyY/usd2R8iYBHQA9A1Kz8OLY6bY3NvA9tc3rLaCME7bhhJIWVl5Un95yCOpHeob7w/4ShSG6urOyVIpYLZXyceb5oESnB5bzHGCect7muR0fwXrlpe+fbwx26f2nDexpPJGdu21liZmWJVQEsycKOg68YGdb/DzV5LO8F3ptmwdNLdrV2gEc0ltdebKoWONUVWTci5HRsHGTQB6M/h/wAO3P21nsYlC3Rmlcho9kxGWdDxgnecsvXc2STmtOw03TdLm/0OCC3lljSHC8FkjztHvjc35muHs/BEk3iCK41HTLFtMF/Pc/ZZAkioj2sMaALjHDIw47AVi2Xw/wBbSPRP7TMt08GmadbN5U8KtbzwKN/zvEzhS3zbo2BJzkdDQB3PiCx8N2us2d5qOnibVLqdDCIoXkd5IxkSbV4yoUfOegAGegrRTw/okkKwiwtZIYoZrPYVDKI5WVpYyDxhiikg+grL8Y+GP7f1zQ7lobdksluf30iKzQu6AI6A9wwB/AVyEfgDUJ9LW0k0zT7KELpUFxbwSgrd/Z7yOWWU4UfwKwXPzHcc44yAekaPpel6O88OmQxQSzESyqGJdyAFDNk5PAAyfSqV14Z8OXCxxz2FofJZ1AztP7xt7IcHJDMclTwfSuQTwZqMHjfT720sLK1sLLUBJEbRYYUW1FsYgm1UDlskA5bbgDHHAyY/hjcReDFsY9M01NRXwmNODqqDGoCMgSbsdQxJD9eSaAPQW8O+G7iXUZ5NPh3s7LPJIrLtYssjFScbcttYsuMsAc5HEk/hbw60VraSafar5YkEKglXIc7pBkHcwY8tknJ5Oa5z/hC5brxY13qlnZ3WnHUrm6McwWQFXtoY1O0jruRq55/A/iWTTvDlvcw28lxp9lpUf2hJIgySQMrTb3KGRjkHbtYLyeh6gHrdlYWtiZ/scCQ+fJ5smwY3PtC5/JVH4Vx7eMvEP8PgLWSfe4tx/wCz13NFXCSjvG/3/oTJN7Oxwn/CZeI/+hA1f/wKt/8A4qj/AITLxH/0IGsf+BVv/wDF13dFX7WH8i/H/Mnkl/N+Rwb+NPECIWfwFq6qOpN1b8f+P14B8W9fk1vUxcavb3NhBAQyws0L47Z4k5Of619KeOtSWz0mbJAAUk5OO1fG3jC6Ou6yQjAJuLFj35wv1+lcsq9OVT+GrLzf+Z0QpSUb82/p/kY0dmL28aQ30UsnbMbgIp7DZv8A8inSWUiytmSCWNMkASqh474faT9KvLp6NCxxuXjB459B9ajuongZSjSKWOSVyvH4Gn7WjLeL+T/zX6lclRbSX3f8Eh0+GaIMJLSbZvzmJCy4PuM56Hmur0HUrSYRxK5Qn5CrAYIzWv8ADPwppWsWeoxXx33cbBxvALBCOxPPXOfqK27z4dvDCTpuo3MKtkYDsR1PYMPyrOf1eT1k18v+D+hUXVitk/n/AMAz/tw07XtD1OYr5NrK6uWGQjEDBP4Aj8q7bxnLqOtme8h8Q2dvGVC28UkbszE9flX29c59K870u2km1q10PUr5rSWYyLNLdRxTooUZyAyZwcjGW/GtCHwjNpUhszb6be2TzBUnvZJ1V2PTiOc7e/8ADj9K7KNGKjpNfj/kctWo3K/K/wADN8SXlmbeHStGiilvJyDJg+ZKz7dvnSAD5FUE7V45PTArlfE0iwxxW0afu4VCYC5xjjFeiavbT+CNVs7yPwlp1jFMpiN7ZXTC1uUPLKd6ja+eQXwfl4yDg+c+LrWa+1KX7KoXzzvaLzY3IzzxsZv5Uq2Eq3T0ae2q/wAyqVaFmuvozlYHdb15EGCIyeee4A4/pXW2Vq0yozky8Ag4x+lc1NpuoabqcM5tJvKCkbiCm3rz82M161oFvZy6Npt1BGAGhBlBbdhwNre3XP51wYqjUpJSlFpPrY66FSE20mdZ4H06APb5iTJwrlk5I9/WvRb+3iaGK2i8xYxkBg5BC4+6D6Y7VyfgqIGaLjjBOe47V6RvtI4imC7Abd+OAe9Y0XO1k7Iqry3u0ctqdmyafbXFogWZb23Vck42rIp2/TFb+qWCXOoBsNvQkhlYrweSDjqOOlZXiKINpdrLI8jW63kW5E4LfMD/AIV1N15dvbRz/L5k5LdfWtE20ZS0ZyeoQLZ213PLePb2zM0ju2PkXHzfMfugAE+1cVb2d14lmj1m4WVLCDnSoWADSEdLmQHuf4c9AcjBOa6zxlaQ65qGm2V1c50yGQy3FqF+W4IxsDnPKggkr34qxcSRuyqHGD+VdEa0aUFy6yf4L/N/kQ4Ob97ZfieNeNLefR9ON1qc8rbhnDfwEucLkD0I71xdpKJoF1KBhstZAGdvu59M16B+0PqIttJ0vTV+V7iVpicZ4Qccfj+ledWAt18Es4DhxOAzE/7OeffBrlqK65u50QdtDu73xFcWd9BqGmXMrPcIjblUKrbAFZRkdgAefXNb13qepC882e0vrODUJgq3NgrXBCn+4yjhmOF56ZzXB6RcWcXhme11JZ3ZwJVS3fEsLk4VyT8sYJIHzYzuHDVs6BoviAaH5niW5k0LwuvySfaZGWW5PPymNcM2eOCUGQPlNepQpt01Kp7q/F+i/pHBVlabUdTqH8S6FpVrc/2Topk1IbjcyGYOwJHWaflc4yMDJyMYrwm91PbGUgUY5GQOGAI9eWGeRu4/2RXsHjTwZaX3gu4vNEuNcghSEvHbXEaQQuAM4CBQQDj1/nXilpHHeyJhCUIUBQOSd3QD6Uq1dU1+6VvPr/wPl95VGnzP39fLp/wSoY5Z3Mj7nwo3ZbOcDgD+VTzWxEiRBVQtxgZB57/zr1jwz8PHmtFnv3+zyvhlijUMV9N2a5PXLKOx1y7g+0tczRMFZ1AVOmcADOMZwea8xzdzvSVtDi7ixbzxghMDA4zwB3/Oup+G2vy6VrMcE7t5LuBtz8ob1B/rSzWySRGQMOpBQcg88GsLU7Z0Kz28bBlOcgbRn/IpJqWjBq2qPo/xRJcaDqmk+IbYOUR1EhB+8Og/OverC6jvbK3uoSDHMgkXnPBGa+boPGema38J4UvmdruJPLPGMkdOfXivUPgTry6x4Mjh37mtTtGeu05x+oataD5ZOLMaqvHmPSKKKK6zmCq+pf8AIOuv+uT/AMjViggEEEZB7U07MDyfwjrfhG/+FOiaPq/iPSrZxZQbl+3xRywSptZWAJ4ZXVSMjqORWk2qeF7hrZtT+IdhfNb3MNzGJL20QK0e7sgH3t3P0GMd+1/sLSf+gXYf+A6f4Uf2FpP/AEC7D/wHT/Cuic6M5OVnr6f5GUYziktDmW8A2Fxa3AtNUvYob9bpbloTGRcQ3E8k7JkqcAGZwrLg4Y8k4IcPh7YrrSX8d5coiXkt6sAjixvkgkhIL7N5AWU7QWwOB0AA7RVCqFUAKBgAcAUtcxqcXdfD3T7iwhtmu7kCGys7JCQjAi2kMiMylSGyTyCMEelbfhfQY/D9ncwRXMtybi5e5eSVUU7mxnARQAOOwrZooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAornrrxhpFrquradPLKl1plqLyZfLJ3R4ydn94jKggc5ZfWptP8AFOi31no9wuo20J1eCO5soZ5VjlmR1DLtQnJOCOBQBt0Vzt94y0W11ltLF3FcXkdvPczRwSI5gWEKWDjdlSd4xkdj0rQh13SZtSGnR6lZHUiob7H56ecAVDcpnP3SD06HNAGlRWTpOv2Go+GNP1/zRaafe2sV2jXTLGUSRQyhjnAPzAdTz61Xl8YeHo59MiOsWDf2k8kdo6TqySsmAyhgcZBIGPU460Ab1FZsOv6PP9q8jVtPk+ysEuNlyh8li20B8H5SSCMHvxUltrGmXVqbm21GzmtxIsRljnVkDtt2rkHGTvXA77h6igC9RWZD4g0aea7ih1fT5JbRWa4RLlC0IU4YuM/KAeuelJb6/pl2tm9je293BdyPHFNbyrJGSqlm+YHHAU9KANSisTQvE+la7qV/Z6RdRXn2JInkmgkSSI+ZvwAyk8jYcg46itugApCQBk0tc9471RtI8N3NxGpeThQo64yN36ZqZS5VcaV3Y8k+PmvtdeRodgx826bMpBwViHU9O+K4bUfA91omm6dd3EQha9tfPkSQcoA2FU56HaVz7k16P8NdBTxR4qu9evl821t2AjzggvgEL9AME/UV7RPawXBQ3EEUpjO5C6Btp9RmuajSbheXU3nU5ZJR6HzDo3w71rWD59vp8kVko3CW6bykGO4zliOpyB+NcT4stm095Lea1jBDYV4Jd/HY8gHFfXfji8+x+HrgjOZRsyDjA7/pXx/8Rr2SXWNkRVeD8x7r9KJJRkoocG5K7GaPqJijiazu3t5g48uaPGV9mU9QR1B9q9D07xhJHaFdWjRwh/4+rXJjP1X7yH8x714lDdN9oVoWAY4BOcDitq2vbqPAjdkIwDzx9M0pLoUmdzrmk6f4q8R6ZO97JZLIHia6jKsGbblBtPUHa341rQ+Ehp2owPb2XibVorWTehkYLCcAgSAZGev0rzi5i+2QlIwIJ/v+UXIR29R/dPA5FGp+MPF1vo7W0Ov3y+RxJBMq7wuOSJP4h9eea6aM1blOerB35jvfin45jNvaafZYCWivlXYN5sjcFSpOGUdycjr7Z8nsoo9Xt2M6KDaxBnmLhEPGOCfu844PGScbaqaVYW+vXv2i6u9UmZmBKRweZI59Cxwtev8AhPwW8+y61S3TTNJtF3JbyMDk4+/I3Qn9B9eaqeIdL3d12fX+u6+8VOkp+91OH0XwtLrOr2kFvdXNhptmxeeaOQRzNlQQAgOVz03Hjngmuw8QamPtSRW5ZY4x8+8ZLY9c98etdt4o0nTrZbO/S2YXdvuWG42ELGD144yOeM8DOfWvIL+6hj1CSXUp4o4Gc7meQBQevPc/hXDVaqSTgml2/rc66fuJ8z17npeja4bSFTb88gdOwxXUweJTLHlhhm7A9BXlVj418KlEQaqgkz1+zuB+e2us0jUNN1dAdIvLe47sI3BYY9VPI7dqyaqRWzLvTkzvfEN4174VsUhf5hqVsSF7LvUH8KteKtWjxEZJVjjijC8+oFcdPdtBb2JeORyl7DlQM8bxyfQD1qteyyaoxmuHwikhV6fjUVJNxsOEUpXJl1ZrjdJHGQj9WP3j/hVyHUfs8ZyuO+4da51Nf0GxhYvfxSspK7If3hLd1AGcnt7d8VzeoeLzqs0UVrcW+l6Y24vM0gEzAZ2gOfkQuQQMFiNrHPGD1YbB1qq5to73f9XfyMq2Ipw03fZf1oaXxoFr4i0bS47K4Ua1bSblgCF3eIj5jgcjHBycKcHmvOYZjZ+EI5bC4jmhkuHkCJ98OuF+Y9VHGAF7E/Ma7jwxqhuIJbXwysMGqRzLNMZFLBwJBuDtyzZG7nJ9iK6nxb4I0zVnlntillfTY3SKvDsfVe5PqOa6PrEKUVGmte73+S2X4vzMfZSk7zfyX+fX8Ct4C1DTR4V0drVIfOt7p3mVFA/eBPlYjucFuT9a39V8Sad4ynsJLaT/AEnSWaUwHjEvRW/rmvC7vTde8CT3jz288thIDG81oFdVYD5WweVI96i8NeKk065m1ZbiCPdEQ4uImTceuBgkEnitIT5tZO77mc4Wfu7HpNlF421uzYTajaWNlJLKD5mZHKhzk4I9sdelcr8NdJtraD+1r+VAsQYKz/KoJY/Nz3Ixj61asfEmpat4UeO9+y6PpkufNcB3nKMfup2BbJGcd+lYd/4g82722IaCG3QJbxkjbCMAZ93wOvbPHNZYiaa5UaUYO9ztfFvit0tvsuk3Pkzv8sjH76D6fwk+/PsK5HTdFnuyAVceYcnAz/nrWemoWtmgnug0hwdqJktIf/11D/wk2oXcnlxXH2K2HSGElSo926npXI03sdC03PRLDwkwQP5DFiOjN1PqayNd8NTeRcYXKAfhXZfBW30q51IW2sWMd59tGwSTu0hVhkrgse4Hb2r1jW/hjpt0qNpFxPpcqdVUmWFxxwyMfbqpBqo0r6pkyq2dmj5Q0O2aO6vtJk3Bzi6jwDxnIP4c/pXs/wCzlfNpfiXUtEugym4TzIsjgkYOM/TP5V1njf4eafpPhJdQ0i3Emq6YTcSTso33Mf8Ay0VsDpt5A7bfrngPGN1H4Z1Pwz4k0/8AeyiUNsDAF4xg4/75Yg06kfZ1FIIS9pBxPpqimQSpPDHLEwaORQysO4PINPruOMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5G48FWt/4qutW1MCRfPt7i2VGKkNGmMP6ru2tjplFJ6VzGm/DS7srTTIJ3gv0TTLCxuEa/ubdI3tlxvVY+JVJ5CsFwcnPOBs654r1Ox16/igFgbKxu7C3aF42M0/2l1T5WDgKV3ZA2nOCOOtcx/wAJ3qmj+HnktnF/LZG4urxLiLewhN7PHH+9aZNuRGygKshG0cYwCAbEvgTV5LR7E3Fh9mhsdTtIJtz+ZKbtgyvINuAQQd2Cdx54zgWF8Ha0/ibTb27vo5rWxvVuo2N1MMRi3aLyhAP3YILE7+WIPaqMvivxDp41AB7e/kufEMml2aC2ANsgRpBvLTIr8KFA3J8zDk5C13fhW91DUNCguNYtUtb/AHSRyxI6sPkkZQ3ys4GQobbubbnaSSDQByuq+HtQ0/4P6ToFvGl7qFhBptuVjzskaGSEMemdvyE5x07U6HwlqqawmsGSzW8nv5rq4t45XVIkkt44P3b7MllEStyq7iT93rXfUUAeVWXwzuItDTTJ1tJTBBb2aXMt7cz+dDHPFIQYZMpECsX3V3DJ6gcVtXnhl7j4lWtzAjRaPHBHeXUYjxHLdRl0gwe5Cu7N6GKH8e7ooA8b0bwvq2pLDpJQ29rpOkf2dFeTQSx/aJEnhdS6uq7twh+fYWX5j8x3YG3q/gLUtcF7Je3lvZT6hNcSTLasziASWBtFKMQu5hwxJC+nbJ9JooA5nwxpGpWmt6nqWqrYRNd29tAkNmzMqeV5meWUcHeMDHHTnGThf8Ip4/8A+ikj/wAEMH/xVeh0VcKjhtb5pP8AMmUVLc88/wCEV8f/APRSR/4IYP8A4quH8ajxfZk2kvjddRmLCKOEaPCnmO2AFHPckCvctRuBaWNxcH/lmhYfXHFeN+CraTX/AIn/AGq8UzQ2MTXeT0WRjtTj1+8R9KmpiJyaikv/AAGP+RUKcUnJ3+9/5m7o3gTxppOnRWlh4+htYUGfLTQoSATyeS2T9avf8It4+/6KOn/ghg/+Kr0Kitfby7L/AMBj/kZ+zXn97/zPEPiFqni/S7ZbPXYtK1OIDKXFkxgkx3Z43+UnjorCvnzXw93L5nBkfJKyfuWz3xu+XHoFY17/APGK9lOoM0T42Shf+A9D/I18930T6hqrtEWVFJDPGcEj/Irl9tTnJucPmnb8NV91jpjTnGPuy+/+v8xuh6a4lj8+KaMsc4ZSN309fqK9C0zwqLiDc0fD8AAj0/8A1/lWd4d0F/LHlz3EEjANvt227h6ED5e3cGuxtofEViiMpsdSjPO11+zy/RWUFPxKiolTpzf7uf36fjqvxRopyj8Ufu1/4P4GRJ4TSQBHQr8xYFTnb1/rXP6/4Pu7wLp0UbS3NzKkdmckyKx+8SP7oAJPsK7keJLe1G3WLW+0xl+808ZkhB9BJHkH8QKuRajGNRuNX0TT5NZvrez8qzltp4ykUjk7ySW4IUDH1NTGhVg7zWnfp9+wTqwkrRev9dDL1DWfCvwh0K10qKNb/V1TErRqGIYjn8ff8K891j4z6rdwKYNOtkCTLMFmk3ghTnBXA68d65mS2v8AVvEM934jaS2vPN2yq6DMZ7Ag1zmpIILuZSAWBODjr7VpaPNZ7mfvct1se92/jW78T/DTV9ZMK20aD7PsPO1/4sHuORjjPJr5z1+VpNQTecgRqPmzycck59TXrljq1hafDrT/AAhpt1BdalOXvdQkhO+KMscqm7oWA2g4zggivMfEGnqdTZZXkOMAlecHv+FK6hOw0nKNypZXBixI7RhQRwQCaZeapJ9tjurOWSGWHAjki+Ug9c5FUtQtUtXRVkMhYbvoKjjUkEKCVPbP61pCKvcicnax9KeCvGNt4j8Cs+v3Qh1Gxng86YfelQspVwByScEEAHofWuC8a+Kf7a1RNPV28jedloDhcDkvLjPQA5Bzj+53qh4Beeyh1KSJmSWDSbmVQDg7ljZgwPt1Fctb/wDEo0b7ac/bLpQkQP8ACvBz/Ju/8Hqa1wcabk5OO3XsvJd/UjEOaSinv0Lt1KNR1k6fZ+YlsmFkC5zgYGD+gA6bj6AYmm1RZJpIoIke1jHlKo6M3A4POV4AHPQZ7mqtpZHTdH8okx314DnK8ogyD1PHdenUt/dFaGh6I1ri8lBIQ8A8KTwR9RWuNrvVP4nv5dl8uvn6E4amt1sv6bOy+GVzPYa9aXEe4s48hyGyWG4qOOwAAz7CvU/iL4103w1qC2LMTNbxJcSSu2AobIXAA+ZzzgD05rznwLbyNr9vhSFZi64OGOOM/wCf60n7Rnh27kurDxTC8U1g0cenzoJF3wzDeVyvXDL0PsenFcFNKTbOmb5bI7Lwx8U9C8TalFaXcUttLKAmZ4wFdhx1BPXrg9M1w37QXgSPw/f2OvWNuiWk8gEoT7pY8hse+CD+FcL4b0uSWMSwhxImOdx4PUYIr2K/8cabr3w8vfDHi6+htr5EIguHGQT1CsQPlbIBwf8A9QleV49BS0VpHhk+v3N/IPMk2qvCqnAWn2N20JGfmIbgHof61lQIUQD+MnrngH1NdJoOnGVgXQs+fvc4B+tZztc1hexpWlhLcZnn3McZzwNo+n1qwlliUB0TPTfnr/nNddpWkCOzAMWHIwDuyOv51FPppeWQIhk2AkjjP14+tYKepq46F3wDqEunalbAJl42DqVJO7ac5I7V9e2Vwt3ZwXEf3JUVx+IzXxpFbCVJIAxWQyIN6NyvzYGD+dfU3wvvBdeDbJN25rfMBJ6nHT9CK2w8veaMa8fdTOqkjWWNo5AGRgVYHuD1r5h+KGiTWV3p1pcvK8NmZIkiQ4GOCn5rj0r6griPiZoUGpaa80sQZTGY3PcHqjD8cj8R6VtXjzQ06GVGXLLUq/A3XBrPgK1jckzWDG1fPXC/d/Qj8q9Br5n+Fp1pPFF34f0/xJPpDTL5u5LK3lEjLxyCvHGeleu/8It4z/6KHcf+Ci1/wroowhKCaqL/AMm/+RMqrlGT91/h/md3RXCr4W8Zbhu+IdyVzyBpFqD/AOg1P/wjPin/AKH2/wD/AAW2n/xFaeyj/Ovx/wAjPnf8r/D/ADOzorjP+EZ8U/8AQ+3/AP4LbT/4ij/hGfFP/Q+3/wD4LbT/AOIo9lH+dfj/AJBzv+V/h/mdnRXGf8Iz4p/6H2//APBbaf8AxFH/AAjPin/ofb//AMFtp/8AEUeyj/Ovx/yDnf8AK/w/zOl1XUk02JHkt7ycMcYtoGlI9yB0FVtB8RaZrmix6rZXAFm6eaGmHlkJkgMQ2CFO0kHoRyMisXxdo2vajoen6Vaz2t9AxC6pJczm1kuowPuAxxsFDnhsAfLkD72Rl674ev8AVPE+gK9rFZ29xAU1eG23SwNBbyrJAgkKpzvYjbtGVeQchc1izQ7mLVdPlvprKK/tHvIRmWBZlMkY/wBpc5H40yLWtLlsGvotSsnslJU3CzqYwR1G7OMivKE8Nanq15NoKwmK2t7LVrU6k8E6CR7iVNpYSRqGzhs7GcMATkZGenfwjqV9qAv72LTLaR7+zuHtIJWkiCQKw3BjGuXO4D7oACKM8UAdfb61pVy5S31OxmcQi5Kx3CMfKP8Ay04P3f8Aa6VUm8WaBFbWly2sWLWt1cfZYZo5g8bS7S23cuQOFJ5I/UVyT+B9XhsoxplzYWt6lxrE6zbSwH2uWR4uCuDgMgYHgbeNwAqtB4F1lLuW/eLT5JxqNvfLbXGoTXCvsgeJg0rx5BO8EYTA24wOtAHfHXdMjhjlub2C1WSeS2j+0uIi8iOyMq7sZ5U4x1HNT6nqmn6VGkmqX1rZRu21GuJljDH0BYjJriNK8I6vpGpy3kUWk6h573yPFczOgijmvpbhWU+W2SVkUOuAMoMMcVr+O9E1bWjaJp0sJsxFPHc273UlqXLhQj+ZGrNhcOCg2htwyflwQDpJL60jl8qS6gWXBbY0gBwBknH05+lY0vjLQIruzibVbMxXcE08d0J08jETxIwL5xuzMmB9a5G3+HFx/YuoQ3X9mvqM1hYW0c5UvkwRqHRiVB8tyCDjqrHjtWtqfhjUtZ1FL69tNJtXGl6jZGKKZpR5lx9mCPuMa54hcE4yAVAzzgA7miqei2sllo1hazsrTQW8cTspJBZVAJBP0q5QAUUUUAFFFFABRRRQAUUUUAFFFFABRXD32v6kPHl5paTNDp9rBbTEpYNMDvMm7e4bCDCDHHrULfEQw6ZHeXWjTL9qtYb2yhinR3nikljjAbOAjgyoSMlefvcHAB00XhzS4/ENzrbWsUmpThB50iKzRhV24Q4yuR155qe40LSLkxG40qwlMW/yzJbo2zecvjI43Ekn171zV145ey1qysL3TVUzTQ20/kztM9tLLwgfbHsA5X7zgkNkA96i/EG8lhSS30EMs9ndX9vvvQu6K2dEl3/IdpzIm0DdnPJXFAHZz6Ppk7XbT6dZyNeKq3JeBW88L90PkfMB2z0qxZ2tvY2sdtZQRW9tGMJFEgRFHoAOBXGWvxDt73XYrKy065mtWmht3nCsWR5I1kB2hSuwB1DMXBBzwQM1c8JeMX1+6s45dNNpHfWJv7VvOEhaMMqsHAA2nLqRgnIPY8UAdbRXE33j1LLVdatbiySJdNgmnCS3Gye4WKMOWSMrhkPQMGJyOQKT/hM5zqEFhc2P2O7eezbariZWgufNCHPy7WzDICOcYGCwNAHb0V59a/EfzLS2uJ9IeJb62iuLBFuFZpjJPHAqvwAh8yaPnLcEk4IxTtU+IbaaXhu9Migube4ktruSe72WsLLHFKB5+zGXSdCu4IDhslccgHV+INe03w9ZJd6xc/Z7d5BEr+Wz5YgkDCgnoprA/wCFoeD/APoL/wDktN/8RV6HxbBLfWlqLaTNxq02khtwwGjglmL/AEIiI/GubT4l3DaGNWbQStqdHXXubwbhabSzZG3/AFgHIXoQeWU8VpF00veTb9bfoyGpX0f4f8E6LRvHnhrWtTi0/TdTE15KGKRGGRCwUZPLKBwK6euM8U/8lI8D/wDb9/6JFdnVVYxXK49V+rXl2CDbun0OY+IN0sGixwtLsNzMsQAPLZ9P5/hWR8NtPSy1vxEwJ3SNCFUkYVQpAxUfxanW1XRp5WIjSZ+M9Ttrc0dY4Najmj2+XfW/DAdSuCP0JrhcrVbHRb92dNRRWD4w1ldI0qQoy/aZFKxg9vVj9K3k0ldmaV3ZHgvxZvhLcy7GwDJjJOcZzXn2gWW64yy5K8Hb2roPF0n9o3HlCQlXPO3BJHQ1NomiRpnfudXGdpkPI6CvOcna/c71FaHTaXbhIlCrkjtW9DE5QqT+77YNUdPSOBUiUy4xnnLH6Z9Op5rdtYeFXBA6YJ9qyemxSK6w4+VVB9ST2rNufCOj3dyJ1sxb3S/MlxauYJA3ruXGT9a6hYdgJA7YGe9PSMoF3nnFaUq06WsHb0JnCM9JK55H8SfBU9no13rr6pLfLaQ/OLuMGZkyOsq7S2M5G4HFeK6haW96Va3nPmMPlR2zvzznoG/8dr6R+N2rnTvh/PYRHN3qji2jUHJKdXP/AHzx/wACFfNWp2z/ANnF9hLLHtJ/2a9COI54p1Ypv7n+Gn3pnJ7LlbUHb8fzLvgDS7qPxBLJOgMccJHyMG3ZIHA6+p6UzxFDu1C5VgyoXyAT26Gs3wvqEkN9Z2bIk1tPKEKSKGYDkYUn7o78Yyav6888t4UC5ZiBgLwD2/lUV1DmUoX+f+f/AAEXRcrNSMVtOe5uFIxINwwc4wD3+laGm+GWkMilGBiYbyTnj/6/t2zXofgTwutzNGbmLZHjljjB9q7vw94aSe+v7KKJf9HuTMVClV8tvuMCeuACuB0IrnlVlZ8u6NVCKfvHFeEvDUp0/WbhLRpn+wyW6xs20YkGxiT6BGJx7cc15hqATVWklyUWM7IQV+bGT970Lck+hOOgFfXbwWHhnTUhmVhLqJ8pFU8hB95j7ZIFfP2reGF0nUNQikKrbLI0iM3Qqc8j0rSnWlGmqb9X/Xl+pE6cZTc/kcTFpbu0T/vpoyo+d3Odo/h56Y/GuqjtWRIbdAWUkFixyf8A9fbPsKveG9DklNvBcq8ZiZ2ZZchgrZIyPXp9K3tO0xW1CEx7Gj8vekqkMr4PUEfhWdWrrYunT0Os8KaPlrGGEKl0zkK4xxnP9a+cdJsnm1OaOfLTJK+/cedwOOT9c19LSaqmiaBe61kKLCM3Cq3G9h0X8TgV4hpkn/CTeOry/t7RbNb5/tBh3AhCRzjjucn8aVCbVGUvMVWKdVI19Tt5fD/w/m1S0JhmluFtLdwd3LA72+uAcGvKYXO0h8so4P8Aia+jfijYwyfCa1t7WeL7ZbXqSeSZFWR02lCVXqxG4E46V8/SaXf7zm1uDk/3a6aVOTgmk9TOUo8zTewunI00vzZweOPfpXrXhDTgIUMiggYPzDOR/KuO8M6U0S7p02EryGYD+Zr1jw2bGC2QTXVoh463Ean8eawq06j2i/uNYTh1aNKO3ZRkRBWJxyevvThYTPKzyRiJQPmOcbhWgt/phkDNqOn8DPNzH1/Oq+sanp88c0IubF0QAqwu4zvOOmM9B71hTo1N3F/caTqx2ujk9Unt49ThEc65MgUljnI79PTFe0/AHU1uLHU7NXDLG4kGGzgng/TtXhepTxCKY23kbpAGIWRMgj6Guw/Z/wBettL8U3japewWNtPA4ZriZEVmBXHJb2NdVClPmT5X9xhWnFxauj6fqrqlot/YT2znAkUgH0PY/gcGsr/hNPC3/Qy6J/4Hxf8AxVH/AAmnhb/oZdE/8D4v/iq7fZT7M4+ePc8JYyaH400q/kIjljuArZ4ypPI/Q19Kg5AI6V87/E+80e5vorjTtW02dhO0gMV1GwX5s5617FaeNfDH2SHzfEmiiTYu4G/iznHP8VceFo1IylHldvQ6a9SMoxlc6auL+Jst55fhuzsdRu9P+3avHbTTWrKsnlmKViASCOqjt2rVXxp4WZgq+JdELHgAX8XP/j1c1431vStS1XwZDp2p2N3KuuxOUguEkYL5MwzgHpkj869KhTkpptd+nkcdSScdGM/4R24/4Sf+xv8AhL/F277H9r837VBjG/Ztx5P45qu15Z+FtSu57vxJ4tvp7C1uLoWV8oEV0sSHdtIhXdjORg84yMgGuv1XQbu48QR6vp2pLZzi1+ysr24lVl37s/eGDmsD/hWdk9/dTTXsjRzi8VsQRiVhcgh98uNzlQ2Fz0AAOcZqHXm1Z/kilTijZTxto5S2aRryISpG7mSzmUW4diqeblRsywIG7HHPTmnx+MtJmS9a0/tC6FnO9vMYbCdlEiO6OofZtO1o2yQcDj+8ucdvh3byalDqFxdW9xfeVFDNNPp8MpYRk7GTcD5bYIBIyDgHGeat3ngaC40q2sxdnFvqdzqa+dCssbPPLNIVeNuGCmY7T1BVTWJZe0PxRba1rP2bTwJbJ9Phv47jkFt8kibSpAII8vvzkkEDFNn8aaPFdz22+5aWJ5Yci1lCNNGhdolfbhn2qxABOcHFR+EfB9v4aljeC6ln8uySyAdFXKrLJJu44zmUjA44rO0vwbcSareXGr3bGzGqT39taxquCXjMYZm6/ddjt45wcnpQBasviDos+j2eoTfbbeOe0S8lV7SX/RomH35Dt+VM5w54IViCQpIvL4y0RtUfTxcz+elyLNm+yTeUs56RmXZs3dON3ceornW+GFo6WDTXcNzc2tjHpolutPhnzBGT5eA4IVxub5hwd3KnAA09e8KySeE/EOn6dIXvNSne6gkZgn2edmUpID/0zZVceu2gCxqHjzw/Y201xLdTyQQLO8zwWssoiSFykrttU4UMrDPQ4OM4OL3/AAk+l/21/ZfmzfaPO+z7/IfyvO2b/L8zG3dt5xn268VxfjDwLePo39k+GN8SXWjvos8zyIVEZBCs4YFiQXckrknJHBIYdMPCEX9tG7+3T/Yvt39pfYtq7ftGzZndjdt/i2/3u+PloAzp/iJYnSdHubKJ7qfUG07csSSNFCt3LEilpCgAO2QsAwUnAyBuFdJrevWWjSW0V39pee53+TDb28kzybRlsBAcYHriuWsPhxDYadYWFrqtytpB/ZrSxmJD50lk0RRs9V3CFAwHoCMc51vFWi6lqWvaDd6ZdLaCzM/mzFA5UOgUYU9f6e/SgBtp40s7m6vTBFLc2EVraXUM9tG8rSrOJCDtAyoAjzk+vOKZb+P9Fn1GCCN5/sstg1/9sMEgijRXZWEjbcRlSjZ3EYxg8kVny/DSwWC3itbyVY7dLRI0njWZHFukqDzFPD584t2wyqw6U61+HFnBYCxN9NJZy2V1p93GY1Xz4Z5HcgbcbCC5GRxjsKAOm0TXrLWZJ4rT7Qk8Co7w3Nu8MgR87H2uAdp2tg+qkdQRWrXOeD/C8PhpLlYXtW84IuYLGG2JCbsF/LA3MdxyenoBk56OgAooooAKKKKACiiigAooooAKKKKAKkVhaW+o3eoJGEurmOOOaQsfmWPdt4zgY3t09ea47w5YeDdSBs9Jtr2SGSKOWIzJdrEYYpFdBA8mF8sNsIWM7cY4xXcygtE4CqxKkBW6H2PtXj/iDw7q9j4R12K0s7mx0hdJnhOmSag16jynb5YhDAlEUBxjI4YDZxwAd9feHdAudYhv54Znuri7jlHlXE3lPcRLlXdFbZuCxAbmH8KrnoKsQ+G9DjjjjitlC2ttcWQHnOdkU7I8qn5u5RDk8jHBGTXIJ4P1FtTgvbewtNOtv7Ua6+wxOuIk/s6e33fKAu5nkTgfwgHOcgZx+HWpQ6EtnpsdpZFtK02G4jh2KtzNBMzyq2UZTuUkbmVgdxBBGRQB39p4X0aK6ivbKKaJgIz+4vJkjl2KFRnRX2yEKqjLAnCj0FQPbeH/AAvaWl8kRjSxiGmW4iMkzAPIgESqCSzFwg5yR6gZqp4c8PXVn4Q1XTomuLC4vGnaJ5JI2aFnTG4CJFRPmy21R1yc5Jrlx4AubyONZ9F0qztFl0xZLFCskcpt5WaWYjaByj7Rn5iBhscCgDrNb8K6Vq1je3EjXFvdX1tNDHJczyutu00ZQssLvsVsHBAAPJGeTVnT/Cei2KW8ZjkmuVkinEs91LJI7xDCnLuThdxwudo3Hjmsr4leGrjWbOwXS7OOWe0WVYQxhMSFkCgPFKjKydiRhgPu9SKwNN8P3174z1mT+zbWKa3120uX1QYVgkdhah44hjcQx3L1xhn7jBAOq0fRPC2s6FYS2FsJLAWIt4MyyKyQMyuBydwO5EYMfmBXgip5/CXh+fTDFKLg2bGR5W/tGcefvAD+a4kzKCFUYckYGOlcIPhvqkfh6xs9Pjs7G5/slbe8aLaouJVuIZCjnawYMiSpllYDecggkHV0bwKxvdNfUdNSSyju7m4mt71oJQC8MaKQkcaxrkqThR1JYnLHAB1ieFdDh1yDUUt2S+SdrqJRcyCNZTEYmdYt2zOxiCQvfPXmszUNL8Jaf4Sna7tmj0aHS30h0ZpQ32RQUaMAnceAfm+8eoPeuX0bwLrdvY6PBe21nPfRwaVnUnlBlsjbLH50anaSQxR8YOCZG3YHWvqXgHWJdK1G3k0+xv5Lq0mgtjLKv+hSG7uJt65B++ssWcc5iAPqADofiJLqMPjfwU+jW1vdXoN7siuJjEhHlLnLBSRx7Vaa/wDiGR8uheHgffUZD/7TqXxT/wAlI8D/APb9/wCiRXZ11yqKMIJxT08+78zFRblLXr+iPEviofGFz4fim1zS9Fgt7eYMHt72RmyQR08ul8Hav4u1Lw3aPpen6JLDat8ksl7Krgj1Hl9Oor0/xvpi6v4V1K0YAs0LMnsw5H8q8g+DOsC1u7rT5NyorEY/X+tefXrJSTVNfj/mdVOm3G3M/wAP8juINf8AHcyuU0jw38gJZTqEoIA68eXXmfjfX9evrwy6jbacmVwFhvJMYx0yY+Px4r1rWZoWb5Lfzc/dG3OfoBXF3uki7lmW705Ap6o2I+PTJIpRxarKypp/f/mP2Ps3dzt93+R4nBcPNqSxuTHcZAaFuHIIByOzA5zleo54rtLO7SFI0ClpGAxgZH+cV0OseA9I1LTWtmsY7fbzHLFcpuiPqo3dPUdD7HBHENp+s+Gb+KLWgL62ZtttcPJ5fm9wolOVD4/gk67cK3Izs8HDExvQ92S+y/0f6PbuSsU6TtU1Xdfqv8jvtJ+RDPJkbevsB7117RBJW2jOSSMVy3hu/wBP1ISw20rpcw/660uE8ueLH99D9eoyPeuu0xcwW/mcgL0/pXiyhKnLlmrM9BTjNc0XdEUyMrr19sDmgkDAyGGcc1m+MdX/ALM017mUKu1hEAcdT2FcTeavq174KudZ02zeawt8b7mWdYI8ZwdjH77Z+UBQcsQOvFbU6bnsZymorUtfF3TI9T03SbhCRdpO0aADJClTnA/7557V4j4jtrpbO5Lny9OWTyo0A+aQjhmJ7DJwPxr2HXdTvrTwrZ3GphpdWEAb7MnDCRz8qc9wMA/QmvPfHkNwypYxI3nrErykA7RwOMVu5XfKiIR0uzzrwzbJPrizOP3doDOzKM9Og/76KitnS43v9YmuXQyhM4VQf3h/hQHHc4H41vaN4eWw8MzSlXF9Mv7z5TgHkBAQOoyScdSa7r4b+CGtRbXRjY3DDLE/8swf0z0HtzTlU7AoW3Oo8FaXczR2Q1iGC3SFN8qQNuTcO2SOwwPrmuf1T4h+H/D3xNh+0mctHC9vcvCu5EDFWG4j3X0OM1L8UPGseiQQ+HfDZSbWrgguU+YW65xlsfxeg/Osbwl8NVW2a41mRSJCXlllJIbJ5ZifeoT5WnJfIbXMrJmH4v8AGkviTxjod7ai7uLSyvknnS1G1BCGAEaFsbm2hie2Wq34g8aaJqkujW8KXG03kb3PnRMgSFG3BHJGPmO3oexr0gaHpmnalFYw2k8rIvzzxW+IY+gVN/TfjHH0zXMeJtLg2mzKmLyXJwMEMBwSCOCOhqnNRs2iVFyukzTu4La4vUni2/OGRwp6qRzj8/1rOj0NtC0PSool8z7EBC+3PzKM5YfgQcfWvObXVrzw5rAuLdvNsA3zptH3PUL2YD86998OXmmeLNJ+06VMkyfLvQDaUOO4PODWM4NRutUaRkrq55/48hkuvh7rtvbopc24kCjrhHV2P5A15r4EtbuKOS50zyVut8catcA7UViAWx3x6e9fQOo6CYZNsqboUyGGOHQjBB9iDivM9J0x9Iv76BUGy1meHce6g5X6ZVlqKNXlparqXOHNU07G78bd8HhrQ0gSCKe4kkjuLhYlLAiMEKpIO0H5jx6da8Nghv5LkJ58x46Bu1fRV3Z2/jTw62mXUhiaXa8LkfclQ8fnyPo1eRavpz+DvFEdnd7XLxbn3kqAu7Ax75r0Y1J8q5XocbhFN8y1J9A0uWeWLeN0YGSWGfzFejaZpOnjL3cFlFBGNzvJCgCjHqR/OsPQ72GWNotJsJry76OvEccWSfvueFHBwOp9Oa7DQfBrX88Vxr0iXzbwVg2lbaM56hD989eX7HG0UOnU3qycV26v5dPV2+Y+eG0En+X9ehV0+wj17zE8L6HprWqgmTVb61VYFA6+WuMyHgjj5cgZODXO32k6dpPnFLeO6uJAS9xNAuWP+ymNsY9AozzjJr3nUIvI0pra1jbYQEeUd/8A63FeQ+J9HkuppjCqNI5JLkgY+p/pUVsXNQVKk2k/PV+r/wArLyHSoxcueer/AK6f0zyvWblS8ohSNQBjKIB/StL4W3cEXiixk1O2iu7YTDzIZo1kVlPB4Ye9Xm8I3D7o94dzydqk8/Wtnw94HnsryKYyysF7eWB+ZzWca0o7yf3mk4ReyPpgeDvC5AI8OaKQf+nGL/4ms3WNF8HaZE3meH9DM5GUiFlFk/X5eB71zsHiHWnto4hOyoqbPljCn8+tSWoitre81rU23rapuO/JLH0HrVzx7+GDbZhHDLeS0PPfH+m2MWt22l2en6bFKI13tHaxrl2I7Ae9e3W3grw0ltEsnh3RmdUAYmxiJJx/u18+fD+e48U/EIXzAuslzkAnPAOT+QFfU1PDVKl5Nyf3lV4xVkkjBHg3wwCCPDmigjkEWMX/AMTXM+N9E0rTdV8GTadpljaStrsSF4LdI2K+TMcZA6ZA/KvRK4j4omeFPDF5DY316lnrMc8yWVu08ioIZgW2qCcZIH416NCcnNJvv+Rx1IpRvYd4l1vVIfGdtpFhK8MD2X2hmjsWuW3eZt5ww2rjvTG8fpFbTXk+muunvb3lxZyrMGacW2dwZcfJuAJXk8DnaeKh/wCEx0z+1f7S/wCEZ8WfbfJ+z+Z/Y9x/q927GMY685xmq2i/8I5qmqT2ieGvEludQiuIZGvbS6it0SUFpQu47It5HJXbk471DoVErtFKpF6XLOp/EKXTUtZL3RzGsixyzQC4MtxDFI+1XKxoyAdTlnUcEAk1YHjW8m1JLWz0VZFnvbnT7eSS7Cb5oCxYsAp2oVRiCMnIxtwc1rap4O0TU5/NvLWUsYo4XWO6ljWRIySgdVYB9pJI3A4zVuDw9pkE8E0VttkgupryM+Yx2zShhI3XvvbjoM8AcViWchB8T7e6axNnpV1MksFtPcBQzPF53RVCqQ5Xq2Sox03HitbRvGL6jrUNo+nGC1uLi+tYJ/ODM0lrM0b5THCnaxByTxggcE3IfBmhwfZvsttcW32eFLdfs95NFvjQkqsm1x5gGTjfnqfU1dtfD2l2k1vLb22yS3muLiI+Yx2yTuzynk87mdjg8DPGKAMrVfF32HVbmFbAy2NlcW1reXPnBWjknKBNqY+YDzELHIwDwGIIqmPH9u9sGS1Ec6QTSXKXEwjW2kSYQCN2wTl5N4XAOdhwDkZ3r3w1pV7qyalcW7tdK0bnbPIqO0Z3Rs8YYI5U8gsCQQMdBUM3hHQ5n1Z3sFEmqyRTXbpI6M7xYMbBgQUKkBgVxhvm6kmgDkJ/iSUW3vbi2mtLa0a9S/txGxZzDCsi7PMVG5DLjKr19Oa6vwh4kk1/7Yk9hJaS2xTJ+do5AwJG1nRCSMEEY445IINEPgvQI0dWsDOsjSvJ9pnkn8wyxiOTdvY7tyKAc5rR0fRrTR0kWza7YPtB+03k1wQB0AMjMQOegxQBo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXO+M/FVv4Vj0qW8gllhvr0WjOhAEC+VJK0rZ/hVYmJ74oA6KiuU0zxvZX11raLa3vkaZcrbebDA9wZycgsqRhm2hlYZx2z0NTXPjnw9b20VxLfSeTJCbnclrM/lxKxVnkAQ+WFIIYvjaQc4oA6WiuZvfGFlD4l0vRbWOa5nu717OWRY5BFAy20s5/ebdjN+7AKBsjdnsRVDSviHpt3dRJcpJb281nY3UVyqSSxH7Vu2qzBNqDKgBmIzu7UAdrRXO6t4u02z0W5vraVbqSO1u7mGEZXzvs2RIuccYbAz78ZqxD4l09r+1sZjcwXdztEe+1lETuY/M2LMVEbHbk4DZ4PcGgDaorF0nxPpOsaLLq2lXD3VhHH5vmxwv8AOu3d8oIG7g9s88dQRWH4d+IVhqOmWV1qcUmny3ccc6RCG4kEUUhxG8rmJRHuO4An5TtO1mwaAOi8Q2epX1kkej6r/ZdwJAzTfZ1n3Lg/LtbgckHPtWB/wj3jD/oeP/KRD/jWlL4y0SM3e65n2WrmKSUWcxjaQSiIxo4TbI/mME2IS27jGQa4670/SbPT4r668WeO4bR1dzK5uAIlU4Yy/uf3QGDy+3gE9BmuilOys2l8k/0M5xu7r87G9YeEtX/4SXS9W1vxKdS/s8SiKEWKQjMi7ScqfpXaV514j8HS6d4e1S9t/FXiozW1rLMm7UcjcqEjPy9Miuv8Izy3PhTRZ7iRpJpbKF3djksxjUkk+uadb3oqd79NreYqejcbfqarKGUqwyCMEV81C3fQPHl3HkqI5nyoGAyhiV/H/GvpavEfjBpSReKIbonatyu7OOAQMfzFefX0SfmdVLdowdT8cSTFoftIjhjIUDJXJ56nv9KxG8ZwErGdoBGee5968c1aaddQkHmBHDnPP3uf/rVDYWCz3K+fcYGSzEyYGPX6V6EdNEcElzPU9wh8SrLEdkoPUYyO1aFtqK3ds9vdiOa2lXa8TgMrDryD16CvJtOsIDJJ5eoRYBBKuQQff6112jQSxONswm46A5q1JmbikdDdaWLa3jaW3uNS0mD/AFL28hF/pvXBhk6vGM/cOSOOoBrp9K8RX2kadb6hcXEHiLw7KQseo25WO5hycASxnAfGVHG1hySM8VhWFzc4lhjuFtAsBnubskFbWEcFyO7Hoo7t9DTfCNhpHiPRdWtrm12aPqcRKWpfJEY2hZS/Uu2wOWJJyaxxVeMo/vI3/r8H6b9Uzqw9Nr4Ha/8AX9X+R0/iv/hG/Evhi6vL+/8As+lJKyXDygocp2wcEHke/OPavLNP8YadPNY2GhQ3V5pulr5Vve6nMWEKDAUQxngEgAA43dKy/i7rGmxHSvCmhoE0nT0D+TG2VeQ54b1x1/GuW8M3kliqXbp517M2LeBF3AHoqqvcnoK81PlTt1O5R5tz26O1RLQ6vrZSKQtughlYfIf77++O1ZazQ3VveT2MsUDOCpu5l3O7Ej/UxZ3SHng8J0y1cLDp2q+MtUS0lu7jbExW8dMCFOeY1Izvb1bgZGAD1r2HRfDej6fEJpYRczrkCWQb2Jxg5Y89gMe1ZNxg7S1ZoryV46HIeE59Aitphpv9qXGlwymaRbqMG5hB+/Iyr99C4c7kzt/iA6l/j/4xaLpPhoW/hST7VeOuN6RsqRZzySwzmrnjy9ntTa6jo8EEV5ZXUV6pbAE8kZ4R+hKkcYBB96wvBMXgfX4PEPiCOO8sfEEGl31w+k7g9tbgo6maL5QdoVgAD0LADO3jeko1NTGbcFY5H4TaJd6ldz3s0jGeX95Lcs2TuPQL9Dz+lfRmmeH1sI1lu5Jp8qrFZHLKCP4sHufyrzP4XxeVpERVPLjQKhbcMMcDP05zXr3nvPZlJAc78DnJIx/jXLOs1exuqa0uMv7ZpNNN4pGN7AjtkVxep4lt5FKpIrHBx6EV2V2zp4Vv497MzE4CEAgFexPf3rzyK5aeYwqhKNGWLgfKDwAPrz/OsJy2aNILe55Xrumm21SSGVfMjflWJAJAPHf2qn4a1K/8IeJkudGkBBUv5TcrIgOXQ47dMema6rxnZB7+BwgSBAFBK9yeVH0xmqfw9sF1TxxfWU9jDf2v9lXk8weYwlQvllSsnRDvVBuPABNdtCTm+TuYVkormPVV+I2lapZxvpen6lqd6+xJLO2tWYwyN0R3I2L9ScVxv9geIb7xpLdpdrYvcFo9UhhRZ4bNlUmKHPAeRQPmYHClgBnmrngP+y/E73ltNaD+zLbY1jp/nhi8bIoPmooUSsWUN5rBuGUZ4rrrsrb6ELbQ7eS0ktD5RtpshgDk5Ock59cmt6sFQUo8upjTk6jTvocPqSaxouphVgFxCYzIs0OSrBepC9Qw64GeAT61sXOv2uu2igXcVlqHkNbNK6eYk0LkBo3GQSrYBypDAgEEUiSW8nkaLcPObqUGa3n7Bxlt0bZOGUjpXIXdpfpqmqPHp2+3FvPLOIITmyuPKco6qP4JGAdMfxFl/h5mhK/w6MuqrfFqjrdGv/D+k69fxXmraZZ28CeR9jsIrm4SJiq7hlYyoO4E4yWGcMSQTXcWPxB8E2lukf8Aa5Z17mxuuD/36rwj4V+MIrbwrNoXnanbQXkscdu8aGf7NNGGdhIFC5RgN2AM43ddua+gfCE1zZ+HtDk1TVIru6lgk8yeKQskp3llbOOu0gc/jXXUnS5bzTv/AIl/kcsYzbtF6en/AASj4j+JHhu8EVvZaoUg4MhNldKcfTyq5C68X+FzIQ+sRxp1A+y3AOP+/damvazqWnXd7qT3U01rLqUun3MLEBLdQivC64AOWDANnOc54xXkGteLL7U9TmSKeQEkjJzk04UcPN80k/8AwJf/ACJM6tSCsmvu/wCCeip418IQEsup72B+75EqjH/fBq3D8TfCyDHmgAf7Epz/AOOCvMtMsriaYPNcSccFmc8muis4grDypiB35PWupUcN/J+K/wAjklWq/wA39fed7Y/FTwVGyi4vVhUH73kzHP8A45XK/Fn4l6JqekDTvDN6JUuH3y4jdAo+jAZJ9q09NmuLa4UQzSN6ncaxfiXHdar4j01maQtIix8tnJ/pWOJWHhC6g/k0v/bTfC+0lPf7/wDhzR+Cni7wf4bjkuNa1PyLgLtiU2krYz15RCPb8a9YPxn8BA4Outn/AK8rj/43XWeFNLGjeH7Oz/jRAX/3jya1iAeoBrOmqEI2UX96/wDkTabqSd7r7v8Agnnkfxo8AyTLFHrxeVmCqi2VwWJPYDy+tavj/Vb620bSZdFmu0e8v4If9GSLzmjfJIUTDYCePvYxXWeTFu3eWm7Oc7RWT4uj0v8A4R69utdtEurCyja8dCm4jy1LZUeuAcU5ckmlTT++/wCiJXMtZP8Ar7zi9G8Ya2YDprRRTavbfbprg6gyxlYoJI9iExAoXKTREsvyr6HpVy38d3t3dRzW9hAmmfarG1bzHbzibqKNlOMYG0ygEZOcHp3oDV/Dt3pdrb/8K91uawjzLCn9jKUG/ksOf4s8+uec1ffxPp7vI7eB/EpaSaO4cnSx80kYARj83Vdq4PbAq/q9TsL2se5p+EfF0niHUjZCzWGazt2OpDfn7PciVoxEOPmz5crZ4+XYcYcVWvPGF5ba7fRPaWo0uz1aDSpHMreaxlt4ZRIBjACmYAjJyATxjB6TRdHg0mTUZYWZ57+7e7nkYAFmICqOOyoqKPZeec1TsvCelW3iDUtaa1in1G9uBcedLGpaEiCOHahxkDbH9fnbscVgaHHr8R9QWC7caZFcBoLa6sZPnt0nSa4WIffBYD51IbaM/wB0cZ6Dwvqmv3fi3XLLVksEtbRLfakEjMUd0yQCVG4ZzyfatS18JeH7Tf8AZdFsId4UNsgVchWDqOB0DAEDtitAaZYjVG1IWkAv2jEJuAg3lAchSe4GT+ZoA5aTxZff2y8cVnbHTxqR0kFpG87zfK3iQjGNueMddvzZ/hrO8La9qenfBV/FerN9vvzpB1llMpw5+ziTb0+QEjoAQM8Zrtf7E0v+1/7V/s60/tL/AJ+vKXzPu7c7sZzt+XPpx0qvq3h+yv8Awhe+HI1+yadcWL6eqwADyYmjMeEHQYB4+lAHIa14k14a3Z6TGtnDfxapAhaORjDJFLbzsFbjOVMeSB1wp+XPFe++JF5b6Ol7DYw3E9rE82oW0SyNsRZ5ISwfhVVjDIVzknaeOCa7uy8P6RZRxpZ6baQLHN9pQRxBcS7Su/67SRn046VXu/CXh68CC60XT5goYDfApwGYu3buxLfUk0AYMnjLUYH1G8uNNtE0Ow1IWE1wLljKF3KplKbMBV3gn5jwGPaqN54+1NtOW90/TbTyn0281eMzysC9tC4EeAB1kRlb/Zz3rsdY0Cz1LQ9T0vb9mt9SDrcmEAFw4w/4suRnrzVmfSdPnBE1lA4+ztaYZAf3LY3R/wC6cDj2oA5JfGt3LqcDRWUP9lyal/ZnLt5+4QGUvgDGONoXqeuecVkal471pvC5u7e2sYLq802HVbJkkMipG8salJMrgttkGGHB54GMnqJPBOnyeLINdkb95BIJookgiQK4iMQJcLvYbSeCT27BQNODwzocEF7DDpFhHDertuUW3ULMvPysMcjk8dOT6mgDn18W6kmqPHcWVn9kt9Sh0mfy5WMnnSRxvvUFcbAZVGDyRls9jlp4512eCGWDT9MUXWn3moQh5pDsS1kjRlbC8l/NXGMbefvcZ7aDw5o0F9Bew6VZJeQIEjnEK71AGBhsZ6EjPXBI71KmiaYiRqlhbBY4ZbdAIx8schUyIPZiqkjvgUAcvpfjl7/WrTSUsQl/cSpMIy/SyaESfaOnTcfKx/f9qPFPiTVtH8S3wto7WbTLPQ5dRkikYq7OjN0IB64A/E10VnoNpaa5LqkQ/fG0iso0wAsMSFm2rgdy3P8Auj0qzeaTp97dwXV5ZW89zCrJHJJGGZVb7ygnseMj2oA4nxP4p1B5RZ6aiQTxXOksHMhxItxMVZG44GEx757VWn+IWq/aTptnpCXWqwfaTMsSyPHL5MgQBNoJG4kZJyEPHzV10fg7w5FZzWseiaeltMYzJGsChXMZyhPHJUnj0qafwvoU9lbWc2kWD21tuMMZgXbHu5bbxxu7+vfNAGnayme1hmaN4jIgcxv95cjODjuKlpsUaRRpHEipGgCqqjAUDoAPSnUAFFFFABRRRQAVj+INCh1u40h7pgYrC6e4aJk3LMGt5oCh9sTE/hjvWxRQBw1/8PLWQOlhPFb23mWzR2ctv51uUhiaIRyJuHmLhtwGRhlU845rwfDSCHw9f6UmokR3WlXWl7lt1UIs8kj7goOPl8zAUYHHaun8ZRzHw3fzWt7c2c1vDJOkluVBJVGIByCMZ/lXHW3ijUNDttMsJ3k1G/1e0t5tOkuW5lmZlWZDtAAVAySeu0v/AHaAN2Hwc8Ou2d2mo/6Ba6nNqsdqYAW82WGaN1Mm77uZmYfLkcjJGMZdh8OGs7K108avu05bDT7C5jNtiSZbTO0h92E3Z+YYPHQg80sfirXrvVoLa1TTIobvUbzTYTJHI7RtBvPmthhuBEbDYMckHd2qinxB1W40w6hBaWSQ2ukWOqXETb2eUzyTI0UZBGD+5+UkHJIGOcgA0ZPh68i3ED6ufsZt9Qt7eIWwDRi8be5Zt3zFT04HHXnkui+HkaeJrTVnvopWtrsXaNJaBrj/AFJi8rzi2RHzkKAMHuaz9Q+IN/aX188VtDd6X9nv5LWYRGIGS1BLLkyFnGVYE7EAPQtU0vi7VIb6O0v0hMi3Ni+6zBUGKdZDsIbduIMZ5GM5HAoA63QNDXR/B2m6As5lSysI7ETFcFwkYTdjPGcZxmufb4fgWMdlFqbJaS6da6ZfIYATcRwbtpQ5/dswdgThuMYwRmtbwTqmpa1pFpql+1gLfULaO7t4bcNuiVxnazEkPgEfMAvOeK4/XPGesHRNTl220MM66zaW5t9wnge0MyrMWzgg+V0AG1ivJzgAGvefD8XOp6pdm6sVW8WRTb/2eDFLukR83Cb9srDZtDAIwBJyTzWbq3wpXUtEbTZ9WEySWlxak3Vp56wea7Nvtwz/ALoru2jJY7VUZBGasw+M9Q/t/TrO2jiutOuLkac85hKmKf7OZTlzJlzlcELHjB+/kYOTovjfxRJ4a8KolrBqes6hoqarI6Q4Eo2R/JtDqFYs53OMhcj5DngA9B8bf8iZr/8A2D7j/wBFtXG+FfDPiSfwto0kPji/giezhZIlsbYhAUGFBKZOOnNdb4qla48A6xM8ZjaTTJnKEglSYicZHBxUvgn/AJEzQP8AsH2//ota6YTcKOlt+yfTzMpRUp69jh/FmgfEHT9NF1oHi+71GSJt01o9nbJJInfy22Y3ex6/Xg8n4ijvNd8FtrVt4tvNUFrJ5c1pdWFtHLbP0ZJF8slWB4/lkV79XmfxZ8JWr6df+ItNuBpuqpEFuHAPlXiZACTKOuOMMPmHvgCh1lUg4SST6PlX46fiChyyUldrtd/hqfN1/ptzPAt+kdpMJRvG6CDOc4OcR1nWekz3EvFlaBd43GW3jAPrgiPP8q774di2vtNvLC5kRZIn82NSQzbG4PThhn+IcfQ8V0DaLbCQCGZMhuVBz9M+laxqzStNJP0X+RjOKu3F6erODh8NwOvlbQTkHATGfxrp7bSodIs/tBi3OSFVE+9I5OFUe5OBW0F061k2TXEayKhlKlhnaOrfQetc9qHjO10xLnWHgmKIv2fR5GXETzMcPKM8sVGQCPlGDzkjEyVouS2JheUrGL40vPKvbXwtE3ntJP8AatZkRsB3Cj90p6hI1IUe7setT2OoG60HVJprs2PhezO/ULm3XD3b54hix0QcDjrntXLeBPDl/wCKdSvSk7LErCK4uw24seWZVHXczMfYAd+K911vwp4csfCNvYeIpIbTRoAuIC+0uV6Z7mvLrzs0j0qUNGz5w8N+G9Y8V/bdeit7e0tnZjGJWba3J+Ve+BgDNbmh6Rf3E/2Ka1e0vJ98f2nzRgQgAMqY5UHu3Ug7cAFs9PqfjGPVNQj0rwva/Z9MQhFeMYA4/QV02h+HkhnlvZ3kEJiWHzC/CL3Az2HX3zXPKrK99jpjTSVtyh4fvPI0tjodq8kAnS2TaBliTjd+ePwNdhbxtaaU8t1NsKvulbcNob0JPp/OodMsrPQ9Jih0tCsXWKJhukdvcn8P/rViazb6gmoxWt+6TwvbfaHj52JNv+RcdwBknPU8+grBRTZo5NFLxVdfbbM3ADQ26jcinIbPXODzmvIdSjFvAJtLeaC+mJ8zYxVtr/I4JH95SwI7g12XjjxG9ii2qzefdzqWkkUfKgBwAB1ycf4VymgWb6zr+n2LySO6uLi4IAO0L0H1JwK3gnHUiVmrH0F4I0yO20hvlYxr8xBIYn8q6+2lVJI4iP3jK0nA6D/9dQ6FYyW2ih5kX5+FC9hjoatNiGNSzbfl4HfH/wBeuRpuRrzKxneLL+DTPCd7c3cgjhBChiOpPGM/WvKvDmqnUIWYKBOpxlHVlA6g8HGa9Q8bXf2LwdeJEzC4MT7NhO7djoPevCvD1iJIYH1WBbrnMhdMSA4671w/4bq6aUKLhapdNdVZ/hp+ZlKU1K8LP+u//AOn8Zrm3jb78ofewHoe5A7ZI5rzjxBqs+lLJ9iYR/2pbNp1y4/54uysy57ZMYB9ia9QbQi9k8tjqV/AlxhCJmWdQoH3drjcMZP8Qrz/AMYeF5ZNPlikkjWMHKModGz/AHiDuH/jwrpp0IcydOa+ej/HT8TKdWXK1KL/AD/4P4HpWi6LZHwnpVzK7W88TZW+tCPMgyCSQRwR1yvQgnvzXSHxA6gaZ4ueJfNylprECbIJyRxnP+qfjO08HnBxivPfh/4qsItCTTL5pBZxxlZbiKIyKHBzz5e7HcHNdpYa9o93qX9lxXFpqOmXS7Y1UBwBxmN1PI9QSB+lbxVaEeWtBuHft6Pb5bfmYy9nJ81OVpfn8jJOj61pU09m1zp8dtuLQNzuiBPIwRz37jritHV9ItNX0eKWO8mWR4mhE0EnPlv8roezISOVIIyOmRVR9OvdLSWWyE93pFtLte0Rg91bJ0HlM2fMTHGw/MOMHrWvoL2N1pdvFpjtdWMm8eYSqqG3bsFQByM9MAjvXPVoOnH2lN3XR/59n/Suawqqb5Jq3l/kctL4I8VpNpl3pepadeQR3Nk5W6sYoZ1S3ACsJlG5jt3KQeoZvXnqPEkDaDe3cmlpKdOv5STbs4AtbojI2k/wv+h+tbsTS20gtwyvIgDbTxkev5Zqj42sX1jwtqVtGVEs6AHZyA6kbWHpzjNYyqe10kXGHs9jhPEE5v8A/hL7IqXimsYNWiwcgPG3lSEe+2T/AMdry7RSgnZ5si4VsOMHj+nPtXQfD3WoEn0+y1yXyp9PuGt28wH95bzBo3U/7u/P/Aa0fDelwR6hd6fMiC4tJntXbBwzL9xvbcoIx/s16GGlZKLOLEQu20P06KJwQ8mcHpyc8d66rQ7NZrhVRD5X8eV5I+tS2mmJtVWjUHPB210unQbJcYVeOgrsOLqWbG0t1ZSqAEfp71DHawaj8U9C0+HZItrH9rnG3kcZGfyH51vWj21ojXN86RWsSmWV26Ko5NcR8DdUbxN8U9d10xiOKZG8pBxhOAuffAFcmId7LzOvDpq78j6IooopFhXO/Ej/AJJ34p/7BV1/6JauirnfiR/yTvxT/wBgq6/9EtWlH+JH1RM/hZk+Jru6sfhN9o0+V4rpbK3COjbWBJQcHt161Q1DWtY8PxyWkbW9pLFY3OqStqlw92JFjKDy0fcm3rknnbkcHNdRbXNhZ+CbK41cxCwjs4WlMq7lxtXGRg55xTDqvhvXp7GCQ2l9M0z+RHLBvaOWNQzZDL8jBSDzg4IxUz+Jjjsjm5vGWsSS6xJFHZ2tvb3ttp9pE9s81xLPNBbTBWXzI1GPOZclgOmSMfNStvHWv31lAtvHptteLa6rPO00DSKxs5oo1AVJsLuEpz87YI4Jr0i502xuoLmG5sraaG6YPPHJErLMQFALgj5jhVHP90elJDpWnwIqQ2FpGqo8YCQqAFcguvA6MVUkd8DPSpGedXnjzXLQm3a1s7i6uotOntmhi2rCLs3A2yB5VDlTb4B3xhi6jA7vv/GPie3spBJaabZ31rpt9qE6Tx+aJBbyKqqBHMQhdWBI3PtPHNehy6ZYSxyxy2Vq8csSwSK0SkPGudqEY5UbmwOgyfWmQaPplvbi3g06zigWJoRGkCqojY5ZMAY2k9R0NAGH4yvpl0bRbi1llgM+p2Ct5bkEo86BlJHUEEgjvXHr8StTBdxDazWl3aRXWn3TweQgSW5ihWR1EzsYwJg5LCM4RuOfl9Vkt4JURJIY3RGV0VlBClTlSPQggY9KyYLTQLfV59PgsLGK/nga4mRLUKZI2YBixAwcsBkE5OKAOQ17xZ4n07WLjSbC1sNUu7OyF9K8UaQJMGdwI/3tyPLKhPmf95jzEJUdDcXxXrI1KVpItOXTRrQ0hAA/mnJHzk5wOuMY6457V0cOj+HLyAWkOmaVNDp8xUQi3jK28uAxwuMK2Cp49RUt6ujS3Q0O8t7WSS/jluzayQBkmWNow7txtJDSRdeTnjODgA5BfGOr6ilmmlHTIXuJNXAmlieZNlncmJCArrncuCTn6elafgjxJqWsX6xaktn5dzpdrqsAt42QxCYyAxsSx3kbR8wC5yeBXUQ6bYwKiw2dtGse8IEiUBd5y+OONx5PqetPgs7a3ZWgt4YmWNYQUQKQi/dUY/hGTgdBmgCeiqtjqFrfSXkdrL5j2kxt5htI2SbVbHI54dTkcc1aoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGzRpNE8UyLJE6lWRhkMD1BHcVnTaJZy6rpl8VKnTY5I7aFQBGhcKu4DGchQVGDgBm46Yt6jfW2m2E97fTLDawIZJJG6KB/npWdZ+JtLujgSXMDGVIQl3aTWzM752gCRVJzg8jjg0AXk02xjkjkSytleOV50YRKCsj53uDjhm3Nk9Tk561kx+DdCTXhq39m2rXEdtBa26NBGUtlieVlMQ25QkzNnB/hXpjnY1O9g03Trq+vGKW1rE88rAEkIoJJwOvANSQ3EUyoY3B3oJFHfae+KAM7/hGtD+1XFz/AGLpn2m4DiaX7LHvlDghtxxk5BIOeuatNpdg0wmaxtTKChDmFdwKZ2c4/h3Nj0ycdagu9dsLTTrS+uJmSC7kgjh3IyszTSJHGNpG4fNIgORxnnFaMjrGheRlRByWY4AoAp6do+maZNPLpunWdpLcHdM9vAsZkOScsQBnknr6ms3R/B+h6Ut/5On20s1/Lcy3M00CNJMJ5XldGYKNyZcgA5+UAHPWugqPz4vJMvmp5Q537ht/OgCgPD+jDUl1EaRp41BSCLr7Mnmghdo+fGeF469OK4aXVPD81qLWX4b6vJbCRphC2hRlA7cM23OMnuepr0rzE8wJvXeRuC55I9a4g3Hj0JI5m8HbIztdt1xhT6H0NbUVF35rfN2M5trYo+IPFz3vhvUtPtPCfilHntJbeIHTsKCyFR0bgciux8IwS23hTRYLiNo5orKFHRhgqwjAII9c1y2q33xA03Sry/lXwq8VtA87Kn2jLBVLED8q6/w/fPqeg6bfSqqSXVtFOyr0BZAxA9ua0rJKmlFK1+juTDWWu5oV5b8ftZls/CbWNnG0tzcEHYo5POAB9T/KvUq8e+JN9Cby4u7wr9ngXcrMQNuOByeOT/OuCq3blW7OqklzXfQ8i0HwfpVun9kaleSrr97GbpFJ2iM45VAchuCdwP3hx2BHRtYaD4fjisoNLt73WZowWhtoQJJehLtyQiE4O5j7jNeRwWs+o+ObOf7TIb+9uj9mJfyxEOSSM+ignJHOeFPWvXdCu9P8Oy3gnXMLSKgHWW4kP8TPnJOSTyeMnGBW1R+wjGNWV3/Kv1fReS/AmC9q24Ky7/8AA/X8xp0CS5MNzrKQNvfy4raJcW0LYJG8nmQjGeflHOBzXl3xL8RQan4h03TtJP2yy0dQrTykneyDBLfiD7mvVdd+IbvZT6csMGyDGwRPgKScjI65xzk9a8Stdup+N0gtBCEmlaa5ZWBDcfN16ADNYPEur8XTp0NFRVPbqbfgvxrf+G9F1GSxVYNPknaZdi/vGcjABJ9cZwKytUvnltP7b8W3lzeXFwWW2svMJyR1YdgB09OaueObWC1v9K0WzjWO32faZWQ53c4A9+P51Q8RWZ1bVbdLSKRoYoFhSNclhg5OB3zUJ82r6ltcui6C6B8Um0edTH4cs/soxlVkcP8AXd0z+Fe+eFp5fHFnp2oWemXFjCCHVrplaN0yCfkBPJ7NwR+leL6V8OVeFZtYnisLQEGQy/K5XqVUeteqyfFPQdA0+3sNNZpreOMIr2yjaMDGBn/9VTNwdnBDip7SZr6/fwprs0dvC4+zHZJcSJiMHA3Fe7Y4HpxXIeI/E0VoZr65u1Kqpjhtiw3Fu7tjqegA4A+tcn4n8atdSO4WSJD84USbt3fkjoPasvwL8O9b8WXK6hJIbLSpG2rczKXeck5/dp/Fz3PFKFFzd0OdRRVmczqN4txcyuoYzTOERM8lj2B9c17x8FPA1vpdlJfX9zbXOozYacRyBxEey8en867fwv8ACHwp4bs1nubJb6/KkedfETMM4/h+6v4D8ay9ehsrK5M9q8UDoMiWJRGVA5w2Oo46H0ro9hzR5UzndazvY9BjuYnkjiXAUAjrjGO9cP4/8W6Zp06K1zwuASCMsR2HtXkWufEHW9ea3tfDaFFlH72Z/rjII/ya7DwD8CtR1dxqXi24lhVm3IJfmlbPU7eij0zz7CudUdOU259eYz9R+L+jX0kdqlnPMjv5ZY4UAevvVjw/qmk3V1+4mldJG4R1AC/7NemN8A/CDWzx5vldhjzFkUFfcDbiuc8RfAi4s4nuPCmryM6KCttdAfOR1G8f4U3h2tUCrLZmnpmmuEa3xlWyY2HPPb86yL3QPtLvE6h8/oareEPGU/hu5l0nxVp8kUqEEiRdrp/unPTvXRaVM2r63OkTGO1UoiHvIzZJyRzgADp1J9qFS55KK/4YJVeSLkzw7xT4L1PQtQOsaFHJmNt86JnchHG9R3GOoqaLxNa+LNI+z3tvGl/kCO7lhR3lP90k5YdP1r6E1fwho+4qbqdblc/vInKYb0yDXhXj/wCF15b38uo6HdtcSBy7QSEKWPqCMZNdEaEo605Wf3GDxCek46GtZxafiJDe6tYxlArw214/lowOCPn3469OKdc2Oh+G7HX9XutV1+H7LLErPa3iZuN4OzjZy3B596xPDWtW2tWpsdTDWuqIhSWNvlErDI/769vWtHVfCMGvab9mvru6ti2N0Qb5GdQQjlfoaUMXXjJqcmaToUpRTgjhx8UYftO9F8TrGflLnV134/79Y/DNdt4S8Q6Nq8YdNe8SWqtxJEdQUMM9QT5eOtcSfhbcWdzmeX7QEIkwvCvz059eldF4a8FCMTTPZS2azKI4drRAyt1OcxfdHrWn1iLT9/la8v8AgGapSuvdv8ybxv4KVdUiuvD1rPrFndOI3mklVpY3J+bzCEAx1OfbmsrVBeWnjk6dP9t+1yOizXLXBJZQBtl37OUAH4Y9q6LTraDSL94bu81K0jUZYwXMK+WOnzZiwBnvWH4l1BZ7y1QXmpPZzMNhuTGzTL6hfLGF9GYc54U4NdFGpKUXL2isutrfp+BnUgou3Jq/P/gm94Xex165u7dNd1lZUYtCPtIy6dj93qO+PrXcaB4HN7MsTa54hMuPmaK7VR+qGvIY9K+xXaXenXAR4W37thTa3UKNuRyO2wDFeneA/iXbQXe/UbeZWCndLBH56KPU7CWHPqtR7XEVH+7mpLytf7mk/wABunSgvejZ/wBdVoYvxKbw7pF5Jo1zr/iO6gXCTi4ulkj8zqAF2DcBxn6j3qL4NaRa6nqSJHqGsaU0rFFl0+8VCcjj+Dua808czyatqqyQq06PJLM8kQ3gBnyCcZ2nA5BxXpnw086x0SwvMKjrKGDoSOM4rGtiq1P4tH5o0p0Kcl7up7h/wrh/+h28a/8AgyX/AON0f8K3f/odvGv/AIMl/wDjddvYzi5s4J16SIG/MVPW6xNR63MPZR7HBJ8OXV1Y+NfGjAHODqS4P/jlZnjrwV9k8EeIbj/hJvE83k6dcSeVNf7kfETHaw28g9CPSvUKw/HTW6eCPELXscktqunXBljjfazJ5TbgDg4JGecGtKWIqc8depM6UeVmTremXWs/C+PT9Pz9qms7cIQQCMbDnLccAE81TvfANtP4g06e9jOs28k08+oSaiI38xjCkceUCquAEUABe2TzzXHafo3imSwtntLHxYLZo1MQHieEAJjjjZxxirH9h+MP+fLxZ/4VEP8A8RWksLFt++vvX+ZKrO3wv8f8gg8H+JmTwub2yU6hp0ekBruI2xYLE0X2pZJWBmLcS4CEKynkkkg3b/w5e+G/C8Wq6ZBEniwaq7Rl3Li5E08kaRuRn5RHNux0UqDxg161RXCdB5Zqfw/nVrtbS3S7e10vTbfT7qZlMguIbid5ZAScq5DxsW7k9eKxF025vvEt1pmleRD4hC6uLjWIXR3Uy7hbtIVO9du5AFYDGzCZUZHt1FAHj9t4M1C20meC30e6EE81t9rtLhdPkBVFly9vGEEW/c0WXlG5lXoCore+HXhvV9Gu7GTVI9qQafLa5MiMV/0p3RflwMCMr0AA6YHSvQqKAPMp/C99Zaxq99Y6KjzvrcOprPA0SPcwbI1aMEsDuDB2w2FPrk8Z1z4S1W4Wxk1Tw7FqeU11Wt5JonED3V9HNAxLEcBFOSuWXsM8V69RQB5TpvgnV7bxVbXmrS3+oXEU1rJFqEElsqokcKI6Ozp5wBZZCVQlW8w5wS1JpvgaXTtL8NG90KLVkgtpV1KweRJDJcsIxHMfMbY+wLImCeBJ8vTFer0UAeQ6v4I1W6vZZp7OWTS2vZ5m0+2a2kZt8FskcgFwpjOwxSrztbD5B7H0/wAP2r2Og6baTPcPJb20UTNcSCWUlUAJdwAGbjkgDJ5q/RQAUUUUAFFFFABRRRQAUUUUAFFFFABRXK+NvFR8OXGnQn7BAl4JSb3Ubg29tEU24RnCn523cA44VjnIANYePLa21C4tdVtHhW20+1v5rq2LXFuqzPKv+sCj5B5Wd5AyCeBtNAHZ0VymseNLLT9Vht96fZYrma3vp3BCweXatcEg98KFz6ZI6ipG8baWkbedFqENwJIoxayWriZjLu8ohcdG2MM9ipBwQcAGr4kshqOhXto1lFfLNGUNtLKYlkHcbwCVPoR0OOnWvPrzwhq99aFby0a90y3vrS6t9L1S8F5INnmCY+a4PDK64Vmb7rcjdgdbpnjXTNRnjhghv1aRZ9nmWzLukhbbLEPV1IIIHBIOCcGq0XxB0aVCsS3b3v2kWgs0jDSmTyzJgYO37isfvdiOvFAHK/8ACJ3t/e+LbC3VP7Ns4LqPSoSCqpc3kIaUZPGELNgjgCdl/hrS0/whqUHiK3uJLWz3pqC3p1QOPO8kW4j+z4256/LjO3bz14ra/wCE5sY9S1W2urS+gjsEt28427nzGmC7EC4yHLMqhepPHanzeONMhKtcMbWKM3Auxcq6SW5hiEjAqFIPysrdRkEEbs0AcNpfgDWLXSdEtbvT7G6urZdDIu2lUtaLaPAZokyM4PlyMMHB3tnHGep+INo134k8L40eLV41N1ut5guzmIAElgQP/wBeM9K2PDPiN9b1bWLVrGe0SxMIUTpskbehbJHb/OeaxdF8fi8mvTdWF0FF1cwWtvBayPK6W8rRSyE4wQCq8DoWC8kgUAYdv8Nbs6ZepeLY3Gqpolpp9peSEttkRJVlUMQWVWDhCwGSpPXpVpvCOoGcXiaPYx6eNTS8bQlkXy3RbYxbuF2b95V9p4+RTkN06qHxppF1ctBYfbL11tku91taSOnlum9DvxtBYdASCagt/Hmj3Nuj2y3c1w909kLaKHfJ5yxiUpwSv3CGznGD1oA5W38DagniY3slkEt2uYLm2jtbiGJLNEiVDDu8nzQow2BGwUhyMDJJpWngHUodHe0OnAW1vNbyWiK9p9oUpHKjbz5PlTIA6hRIu/lmJ3Ba7WD4g6FLaG6Ml1Fbm2W7heW3dPPjZlQeWCMk73RcYzlh609PHWkyRoIY76a7aaS3+yRQF5VkRFdlIHA+R1bOcEMMHmgBl/a3Vl8Kbu11FbVbyDRnilW0XbCGWEghBgYXjgYH0pPB3iHRYfCGhpLq+nI62MCsrXKAgiNcg81a8Q39tqvw51PULCQS2l3pUtxDIBjcjwllP4gisrwh4L8LT+EtEmn8NaJJNJYwO7vYRMzMY1JJJXkmumHJ7H377/oZS5ufTsU/GfxR0fS2Om6NLDq+sSoSsUM6rFEP70sudq/QZY8cDINeSfY/7f1dLnxHrNtP5R3iONwkMZ9I1J/8fOWOB0xXofxN0fwxpNqsVl4d0SK4IzlNPhzz0/h9jXF6PZ6Uyx29r4e0q91GTB2y2Uflx57sdv6d/pzXPUxFFNU4XT6vS/39F6fM3hSqW55WfkZmsyWGn6mmtWLWxi063e3s7aKMOWdjyy45XGD83O7J+p8m1LVNY1O8VPJuYoNxkkZIWy7E9OnT3r1HVfgn4mub65u7q80y0tiA3+i2SqAP9legPNef+JPDc/hSe4s726jkuI8kFokOcduR1rOcaEdW39yLhKo9FYDZrZaFPdXRaCN3UM4UsR7n0J559BTvD2gWkd5asGkmnl4h8piqqsvzbi3XlTmtnwjZaTq+nPDrenpPAjhjsXytxHIDbcbvxrufEdna6HYvfLHbW95d+VDEqrgqxISPP03D8K4XKKly0769zps7XnY8x+LOnalawaV4lS3VdKmia1ilWQlyQxwzrgbQcHHJz3xnFcJZanJHMk0cvlzJ0ZSePf2Nfa/iPQNO1PwtBoV7AstkkIh56sAAN3HfjNfPWufALVElc6BdpPA2SElJyPxFdcJw5eVnPJSvzIrade+HfF9rHF4mjuPOXgTQS7C2eBkDr09K5bxn4KubfxfpOn+GFutQTVFCWccjBnLA4K54Ax1JOMDk967Hw98EvGkNwGK6bbRA8ySyMxGO+AP8K9a0L4bW1k+m3viDWLu91CxV0txaMbdVDrtblfmxtJHUVEJRjJRvoOabV7ani3h74cy2vjG+t/Fd3a3dhpTIt0bVy4nuGUMIASBnAID46Yx617jp3iCG22u0ShoxtjVeFReMKPQV51r18qmFLQRRo0kkjJGAFDMxxgD0UAVmf2s3l5kdt2eVPHUfy616MYK1jgnVdz1jxJ4zH2fbE+GbAHfJNeS+NdSu9YibRrB2a9uObp1OfLj/ALgP95v5VR1G/kWyu71c/uYz5K9Q3TA9q7b9njws2p60t3qiGVLfF7LvAIeUn5AfcEFvwFZ1HyK0eppTXO7voel/B74X2nhixh1DUoFbU3VTHCeVtRjAHu+Op/AdMn1WiiskrGrdwooopiOJ+J3geDxdpfmQrHHq9spNvKw4b1jb2P6Hn2rxv4T6i1rqut2F150V9Eys9vIOYtjFcc+zDP0r6aryP4v+Hjpl/B4w0eGJblCIb/P/AC0jPAbrgc8HjJyPQ0tpKQPWLiZOr62d0wcldp4z2Nc5LrbyOVuHZwO2e9ZniGRry3TU7KVZLGYEhlbO09/xzXKPqqvI0OWBC7y+OPcfrXdDVaHBO99RPidpa31kNZ0lXW5tjumWLguv976j+VclqL+KvB+oW0GsW17ZTygSQmdt6TLkZKMpKvwR0PeuusLuVrpUmYeVKpDe49/Wqt1D4i1qyg8HpeWk0en3Qn0t7kYlgXacJG/9wgjhgcbRjAFYVlHdnTQlL4UdF41+KVto88Vho1qs+pCMfaJZCCkTcHAx1PqK5+08V+Ib7ZdNflztZ2SKNV2gcA9MKucDJ4+p4rl5vhT4+tr0mXw3ezvKc+ZE6SKST1LA4H416n4Q+HPipfD0mmR6I1kbo4e4u50KxnGN2EJJI7Dj+dc8YU4O7jc6OeUlvYh0WJPF2jnW3kM7s5CosJSKJl+UEL1ZuvzN0zwBgVk+KYrfTbBbq+2tO8gg54UA8lgSOvTivcfDPhfSvAz2PhZbzcl9asYRcSgs8yHL7BjJBByQOmOnWuL8deENO8RWEWmX0zQS203nl4j2Bw3Xscd6568pSqLnenTsvkb0bKL5Vr+Z5t4Q07UrfVo5Lr/SP3aSBgxCup78cbhVrUPD93a67NeaPHMygrIyqMDOTwD+Ga7OexvLB0TTWbVNPtlEYtXCpcxRnsCAFkAyTggN0Ga6vwxoOjeLtLW2tfE1/pupQFjdWsAWG5j9mSRSQBkcjj3pfV5uTqRace6/Xqvn8h+2io8slZ+f6HglzbXkuvrdXsFxJb3MmyUOpfYT3GckfhivWNN0RW04HTtfvLZwQphkK3MSDpwknI69QwrsNX+Hei21vAkOt6y9wnVzOm5vckJ1rndS8I3tmou7C6e7MQ3ETkFz9CAAeOxFW8TUS5Yyuu26+56ExpQlq1b8H961Ow8L63410+xaAaNp2u21u2zNndG2nUdclZMq30DVtxfE7Q4JUh8QQan4fndtqrqlo0SsfUSDKY981l/C/WEv5opk+VpkMcq4xhh0P6V6XLGksbRyorowwysMgj3FdNGvCpH34/dp/mvwOerTlCWj+8r6bqVjqluLjTLy2vICceZbyrIv5gkVkfEj/knfin/sFXX/AKJaqGofDbwtd3IuoNNGm3q/dudMka0dT6/uyAT9Qa53xz4d8R6V4J8QGy8VzX2nLp1x5ttqlskshTy23bZk2tuxnGQea6qUKbnHllbVbr/K/wChjOUlF3X3G74hurmz+GFrPZyyw4hs1nmizvit2kiE8gI5BWIyNntjPas3Uta0PQ7EjwxrXmXF3NBAWGoC5jiysrqzNNIUjDBH+bksQowxxXY6PJLD4U0+SCBriVbOIrErBSx2DjJ4H41Q0XxPoeqeHbS/DRW9vc21reNBKozGLnBiDAcZLcfUVzT+JmsdkcfonjPxHq1pbTWzWDmHTLi9mjjgMpu3ineIJGwcBd4QHOD14FVNQ8Warc2SC18Q2UsCT6VPJqVvGFji8+dlkhfD42gBDgnOGwxOQa9BPinQILy4gN3HHJAsxd/KYJiLJlAk27WK87gCSD15pNa8Qadp1qwiSK5drmyhlgXAwLu4WFXPHIyxb32mpGcReeKLxdR1PT21S2sLV7i7/wCJhKxZWMVvaskSb2KqX812wvGI2wMktW3HrN1pXwk8PX0MqLNJa6fFJdTgusCyeWjzPyMhQxbk445OM1uyeJtBjN4tzcLbi0je5lNzbvEuxCFaRS6gOqkqCy5AyPUUzWPFWmad4MufEEH+madEnyCFTiQ7tgA46FuM4xjnpQBxHi/x3d6LCw03W7LUJbO3+1PIwhjiuFMrKEB3Eu42MpEYGDgnGQDoz+LdVtNWFxczxNpp1a70028Vtl1jitJpxIDnLPmHGBgEN0zzXR6V4j0e+mtLGc2seoMPLEKI7Ro5Tf5SyMijdsw2wgNt5ximR+N/DEtgmoW18txZHMn2m3t5JY0AUFnZ1UhAA4yzEAZIJ4NAHA2vi7UdZmNpPeQzxQ3ui3McsMsbOFnuXDRv5RKjiIHGTw3JPFez1zl14n8OWF7JZS3MSTxSLEyxwMwWQoJUTKqRvKtuVc5bPAJp8vjHQYrOC6e/AgmV3DCJyUVG2u0g25jVWBDF8BTwcGgDoKKxk8TaQ+sjS1vAb3zTBsCNt8wJv2F8bQ2zLbc5IBOK2aACiiigAooooAKKKKACiiigAooooAKKKwPEnii08P6lo1peQzMNTnMCyoAViPABfnOCzKvGcZyeMmgC5rOnXd80LWerXWn7AyusUcTrKGx94Op5GOMEdTnPbCtPA9lpcUgsGmmgfTF02aymKeXdInmlA525U5nkztwPmHGBipNJ8d6XqMGpziG+SKyv2sdyWzzmYiJJRIojDHyysikMccVoxeKtGmuore3vfPeSNZVeCJ5I9rJvXLqCoLL8wBIJGMA5FAGBp3w7sv8AhEtH0fVppblraKcXb7s/apJ4XjmZieefNcj04HQVfj8FwteR3t9qV7e3yzW0nnzCMMVg8wxoQqgYzLIScZJY9BgBNP8AiB4fvNA03V2uZba3vrcXKJNA++OParMzgAhVXeu587Bn71X5vFOmW815HcyMr290LQLEhmeVzCk3yogLcLICeOAM9MGgDLvvAGn3unGymursRGTUJCUKhv8ATHd5B0/hMhA+nOarP8ObWS0voJtQeVb1ozMktjavEQiFFXyzEVAAORxnIHJGQd3SPE1neeCtN8S3pWws7uyhvW8xsiISIrAE45xuAzUcvjTw9BaC5udSS3Qzm12zo8cglC79hRgGDbSGAI5BBGQRQBnDwBZJbvbxajqCW7QWkWCyO4ktSphm3spJcFFJzkEgZHXKXfw+0+/jnGo3l5cTXTXD3Mx2I0rSwpCT8qgLtSNAuB/CM5Oa2YfFOiS3N1AuoRK1skskjSAom2I4lIcgKwQ8MQTtPBxVdvGehrbLM91OqtuIRrSYSbVAZn2bN2wBlJfG0ZHPNAE+gaCdKvdQvJtQub66vvL82SZY1+4u0YCKo6VnjwXDCIJLDU72zvIZr6RbmIRs227nM0qYZSMbtuDjI2L15Bvt4s0Nbi4iOoJi3jMsswRjBGoTzDmXGwEIQ2N2dpzjFXtI1S11e3eeyMxRH2MJoHhYHAP3XAPQg5x3oA57/hAdLTRdQ0q3kuIbO7tra1CgqfKSBQqAZBDDCjIYEHkEYNO0fwRa6bqKX3224nuFv21A7kjRS7Wq220KigBQqAjvnqTXW0UAcTP8OdKuNKsbC4nunhtLEWUZyuRiWKVZOVILK8KHBBU9wRxVXSk8LWF3YXLeKdMlltJJZVCy2sKEyIqEbYwo4Cg55OSecYA9ArF/4RTw7/0ANJ/8A4/8KuHJ9u/yJlzfZOWvdR8N6N8L59Dsdf064Sy0drKEm7jLyBINi5APJOB0711Pgn/kTNA/7B9v/wCi1o/4RTw7/wBADSf/AADj/wAKk13WNL8MaK93qd1b6fYwrsUt8oGBwqqOScDhQCeOBWkpRceSmnuSk0+aR4f8ZdZMuvSW6MdxcIm306VL4Q1RdBaKw0yxfWPEZzI1upCiP/bnc8Rj2PPQY5Bri9RvZ/EfiGW5tVuLGEsWFxIMTnP9wciP68twOmcV3mhC30KwWHRoRbq7xhzjIK5yxJ6lyMDJzxXmxVOhPmrO8uy/V/ovm0d0uepDlpqy7/5f5s77SZNQ03RL7UfFWqnU7m4kT/R7aPy7eEg/6uIH5iOeWY5OB0wc/LHxv8aWviHxNdS6bHi3tZyd8g6k8Ej27GvQfjZ46ls7OLw/YS7rzy9zjvGG6tj1PQe2a+fltXv9Rj02NiWLBncHqTzWk5up70v8iIQUNEe1/CqFGtJPODFgN5U8AZHUn8zVmHzfF2vXkkYW4sbZTDaq4DLLKwIyQeoUZY/QUIPsGjW2kwgrPfqVeRf+WcQHzMf5V6J4S0WLSbC2nkQW5aLZFA2MxoSCc/7Rxk//AFq5IRblzdjectLHV6ddW6aRFbbWDQoIxv5PAxTEuWjVmEmPcVm3rxyqzwll2Agt6iuZudT2t+5kyhz8rCok2ndjik1odjda3hCCdxXqP6Vyev8AiIm4t5AAkMTZ8wyADrjbjrWBf6mQrBjyxAznAPtXD+ItVllsGMYKxw4IRDgMQeAT/hmqg/euglH3dSv4kee7RLiFVt3YsHjUYAKkg8+vQ1iQy3ETKZ2xGvIbbnJ/pgVZOrKHWe7lWK3lIaTK7vKY9Tx24/Stox6VBZz3batZNbD7rLKG/wA5zXtwmpK541SDjIoXzq+iz+YoCzSqgx6Dlj9MV9F/s/6a1r4SuL10RGvZ9yqpzhFUAfTqeK+VvEus2d/NFYaJIZFkwjTdFXucDufevsD4J20dt8M9G8sNmVGkct3Ysef0rCrZz9DopLlh6nciijvRSKCiiigArM8TWCan4e1GykUss0DrgHHOOP1rTpGGQR6igD4P8PXtxF40utNido7HUWwYWPEb4yCB0B61PA37ybO8xhuJAoGwjIyAeD7g9QSD2Iv3thLbeN5NSkj+WG8cYU8YDHnp14robjQYXZrmwkieCWTcjBumeSDnoQT0rXC1WtnqjLE0+ttzB0uItchWVcRkIVU5AJ5GM87SORn+YNXJryOx8cWczndsijL54APJ/kRVa7vbPTJFZ7mFbqFtqKzZDgnlGx0UnnPRTzxyazLIXGqeIJZJ4yZZJiduMYGfu4/hxjBHt9DTzBx9lzw2vr5f10FgYt1Pe7H1NpWuedbxpE2CvBY8dqsah4gaP5VYHaOo6/jXn+h6nBBo62/zLKueSuARnjmpEuWeCWQByRng85+teI60273PVVKKVrFbxZ4jkW70y4mkz5F5EUGPmOWwQPfBP1rrhJa3+qeY6LJKx25U5A9Qa8n8Y3zf6IvlAgXUA3L95fnB4P4V3miXDxCOeOI5lVTtkbBG7Gc+45/GiEuaNn3HONnddjMYrY+ILmQNtjDH7vBPFdLqNtovinTre4njLXNvtEN5A5iuYCRwVcYI9cdPauN+JvmWmky3FpjLsp8zHvg1yvww8QNPFf2c8vlyJ8o56HPGaKTnSleLswqRjUjqipqXj/U4NTu9Omumu5LJ9sd1NEvmYz3GdrnAxn5Wyc812vg3xLLfq489ZgSFZV5CdeoPKk89QDXiPikLaeJ53lUhnf5z/e9OPpitvwrAZrtZEnmgfJEc0L7HQY6Aj8Rg8cniu11KdX+IuV91t81/lb0Zj7OcF7mq7P8Az/z+89zsCuk+JrG9gLRxSyiOcAcZzw1e2180tqmqwWq/23am/svl/wBPsYsOoB58yEcevKdAOhr33wnr2m+IdGgvNIv4L2LYqu0TZKtgcMDyp9iAaunQlTvLdPqtv+B6OzMalRSstn2Nmud+JH/JO/FP/YKuv/RLV0Vcz4l1i1e4u/D7aRf6w8ln5l3BamJdsEhdBkvImd2yQYXJ+U9MjPRTlyyUn0MpK6aLenJeyeEtNXTLi3tro2sO2S4gaZANoz8odCf++vzrlx8OJbeztbHTtXSKxjtNOtJVmtPMkcWb7kKsHULu6HKn2qhZ+G/hnPrF1pCwW0Wo2rxxPbS30iPudVZQqmTJ++o+vFPufC/w8t9ZjsJLCHBtrq5luPt0nlwC3aFZFc+Z8p/fqeemDnFayVFu/M/uX/yRC50rWX3/APAGJ4O1S91iTTbiOWDw9ENSCTSJGHb7UWyFZZWLYLsQWRCABnJrYj8D3sv2h9S1iCaeaXTH3QWRiVRZXAmAwZGOXxjOeM5weldA3irQFsI71tZ09bWSQxJIbhQGcDJQc8tj+HrS2/inQLmO4kt9Z0+WO3jWaVkuFYKjdGJB6Hp9eK5zQ4tvhdJI920+rwPLPp13p5ufsJ+0SCaSJxJNIZD5jL5WOij5jgL0ruPFOkf27oV1pvn+R5+395s37drBumR6etQy+LPD8NlDdy61p6W0zMiSNOoBK/eHX+Hv6d6jh8Y6BJLqsbaraRPpk/2e6WSVVKNhccZzglgo9TkdaAKX/CIy/wBtmf8AtBP7L/tD+1PsvkHzPP2bcebvxsz823bnPGccVh6n8M5L3wro+h/2rA8Fjo40lhdWRmjYhFQTpH5gCSDacE7sZ4xyT2H/AAkmkkRyC/tTaPavdi6E8fleWjKrNndnGWHOMDuQcCk8O+IrHX4tQm09w1vZXLWzS5G1yERyQfT58c9waAMmLwX5c80n2/Pmatb6pjyenlW0MHl/e7+Tuz23YwcZORc/DKN5nnS7sp5ZXvPNS+sTPEyT3UtwAFEikFTMyk5IYdQOMa+gfELw/q+nx3p1C0tLeeUx25muot0uMc4Vjt+8vDYI3LkAnFbF14n0K1ubm2uNZ06O5tl3TQG5TzIxuVQWXORy6Dp1ZR3FAGTD4OEV4k4vRhNYGq7RDgcW3keX97/gWfwx3rraxLjxZ4etrO3u7jW9Oit7hXaF3uEAkCEByvPO0kBv7vfFSR+JtDktru4j1exaC0YLPIs6kRluFBOe54HqeBQBr0ViTeLPD0EVvJNremolwN0Ja5Qbxu25HPQHgnsetbdABRRRQAUUUUAFFFFABRRRQAVg+JPDVt4gvbF79g9pBHPFLblT++WVNhG4EFceo5+lb1FAHBXfw8Vrq4ezvLVLOW8Fx/Z9xZma22C0gt1QoHUMV8jcpPA3kbTwaZoHw9l0e48PPFqsSrpVrb20j29s8Mt2IofKxIwlKMpxnDIxHQNwCPQKKAPPrXwDf2ejWFha65AptdLOjGVrEtvtcKEOPN4lAU/P907uU4FW7bwNJp+tPqek6kkM/wBpMkaT25lRYja29u0Zw6kt/oyMHyMZIwetdtRQBxGq+F7y1+E1v4Z0yRbu8s7G2s4pGUIJDFsG4qW4+7nG72zVix8ITR67BrF9qMc9+L5r2byrYxxvm1+zqiqXYqAMNkliTnoMAdfRQBwM/wAPPtdlLp17qhfTEgu4LRIrfZLCLg8l3LESbQSB8q/7W481JrXgq/1q7s77U9S0u5v7aOW3UPpjm3aN9hOY/O3b9yD5g4GCRt6Ed1RQBwR+H7jUftEV5YW9v9na3e3gsWRLkG38kLOnm7JUHBClA2ERd2Ac39E8HzWOgahpk+s3ii6mEqPYs8P2UAINkO95GVTsyRuI+ZsAZrrqKabTugavocZ/wgX/AFNfiz/wY/8A2NH/AAgX/U1+LP8AwY//AGNdnRWv1ip3M/ZR7HGf8IF/1Nfiz/wY/wD2NH/CBf8AU1+LP/Bj/wDY12dFH1ip3D2Uexxn/CBf9TX4s/8ABj/9jWXffD3R9Mt7nV9QutV1y8tYH+zvq12bkW5I6oCMA9OfavR6xfGbFfDGoEAk+Xj9RUVcTU5Ja9C4Uo8y0Pnfn7dPP2J6Y/DFaj6mtvJHub5VYLjH3eP8KomLyxKygqNxPJ6iub8SXL/YTHG7I7uBv77e+PwFeDBXaPXbsjzzxdqpvtZutSmbe8kp2jHYADHHpWj8KvD8lxqD394hWNV3FjnH1I9qw7S2/tDVSixl1D7VXH3cn/P5V6ybv7Bosun6fDuvXjBkCqSkMZ/jcjp7Dqe1ekoyqyUI/PyRx3UFzP8ApmtpVsupauZ5X8lbj5I1HzYhjIPQ92P5ZrtL69+0XI8vOQOM9M1xWjywfbtLtJoSZootyOsYALgcsccL9P8A9Z3bRjJeIoPU4OO1YS0jyp7lrWV30NHWtQbT7FN/AfgHnGfeuLkvC0xhxvkI6DgZ7/8A666fxLIZyIGxhV+XHUHtWDo8CSX0slwdzJ8pPAwf8azla+nQuN7Fm00bMDzXQWUEZX0GeRXHeKrLDxRqAqAZYFsdOxH49q9Oaxea2DW74UAgADqPeuU1TSJNRu0hw7d3BHuP8KasmG6PC9Xe5i1CaK3dpUbHyg4Ucdq7H4e+FINemn+0WwCKvJdASTnjB/HP4VsfEfwWbbwxdXlnHIZjKiNk5OP4gPyHHoK634JeE7vS9Cv53WcW0pR4RMMHpycdhk8V2cy5NGc1nzao838beBJPC2p2epQ5lsXbDAnmM9ev0r6r+B9+l98NdK8tQv2bfbMAf7rHB/EEH8a4/X9Ki1nRZbSXDh1/HPrVX9nm5n0rUdR0S5ysMqiWIMTkOnykAH1XGf8Adp05a2ZNRaXPd+2aKQdKUVsZBRQaKACoL6UQWVxMx2rHGzk+mBmp65X4kXMq+GpdPs2K3uon7LFjkgN95sey5/SjYDynR/Da6j4Nk1m5CB55jIrkckElv614/wCMtS05Lia2aGCW8Q7N7c+vQfjX0X8Q72Hwx4Fh06Bgsltb5wB/Fjjj86+JNUnmudSdzIPPlkbDtztA5wB6kn9K40uad9jpTtE3bYJqFyPJKb87SF+6Pwr0ax0W80nTlumR7goNjoudzR7eqnqGUD8V44IGa3w/8JsJLTzo2E7ojlCOY89j75/SvpO08NQ2c9szwgb1AAAwV96VOvao2tY7Pz/r8HqXOHuJPfdeR5tbIbyxtzZYkjdVcGM8YPINT2Flev53m7ogCeQeAPQ+tbFxZp4D1t5XjA8LXsu2QjgafMx4b0ETk8jorHsDg9fdrEJtqBduOAKKuFUGmneL2f6eq6/5ChiOZWa1W55N4n0iU2jR48yQBJFiI4JU5x+ldLp0rz20exSAyDYCOnb8an8SFnkjMLAqr5OB19h+dZ+j3VpDO9g58tY9jRu7schyRtBPoU6e4rH2N24o09popMd48sjJ4LkaRQ+1trKD/F1r5+8LXM9h4tiXzVQTKyfO5CFscbuDxn2719GeJJY7jwjfWdxiF2ZXQL1BHH8v5V81azb/AGLVY3lyWRuT90U7qM0/IavKLRreP47ie4hluLP7PdCIeapHUf31xkOvB+YEjjnFN8JzMkiq7OFYY2gY/I16GukS6j4c8owoZApmSMt5ijvkH3HdSCM4rzjTJo0vR8hadXIKr8zEg4yOgbkezc/xV0uFOvH93o+z2+T/AEf3syUp0n7+q7/5r9V9yPefDDFrFAMDp8o/lXcwfDnwhr9tFf6lodtJeOP3kiM0ZY56tsIBPuea848C3dvNAJIZopow43MG7g9weVPscH869w0O9tV0yENcQqQOhcA0YZ1aNWyvF29DOvyTh0aMHT/hX4L06/tr2z0SOK6tpVmicTyna6kEHBbHUCpPHPhSbxHMNlvozfuDFFdXEL/abRyTl45FYHH3TtBXlc7ueOqW9tXYKtzCzE4AEgyTWFrHiG5h1e50/TYbLNnbx3N1c31yYYoxIzLGowpyTsbPQAY65xXZOc5/G2/U5oxjH4UYXiDwtqEOmeJ2t5TeteQxXNqVXNyt7BHGsTDPyn5olbPHPtzTbn4eTT2WlxC/jS4trG5jmmMZbzrqa4trhpSMjKmSBsjIyHxW3L430yyfyNTZo7mOxXULk2sclzBDCfM+czKmNv7l8ZwTxgc1IPGWneWweG+S9EyW62L27Cd3dWdQF6EFVZs5wArZIwQIKKFh4Tvh4gt9Zvrq2+0nUHvpooVbYAbT7MqqTyTgBiTj0xwKzl8B6nBpOlW9lqyW9zY6X9gMse9DIfOhkYBlIZVZYmQkHcN+RyK6BfG+htaXVwbiVUtrY3citC4faJHjKhcZLh42QoOQcDHIzJYeMNJvta/syCWTzmeWKN2TEcskRIkRT3K4b67WxnBoA49vh1qaWlwbS9tbbUJrmeaO7imuFktRLHCuFbfmQAwglHyrkKflxitmfwlqYvLye3vbUk6pHq1uZUbmQQrE0cgBxtIViGHQkcHbzLqnjX7B4uvNNmtpFsbKGBpZhC8jTSzsyxxptGASwUc9Sx6bSau/8JtpPmWkO2+N3cySwrbLZyPKjx7d4dVB243qcngg5BIxQBz1x8PLyVY5TqNuLpTLcn903lmd7+K8C7c58vdHsPOSCT3xXU+FNJu9LOry6hLBJPqF8bzEAIVAY40288nGzr39B0qDxt4rh8N6ddskE13fx2c14lvEhbCRryzn+FclR688A4OI08ZWqzy280TyXQljhit7UNJJIzQLMeCoAwpJzkjAHIJ20AYP/CAahFoMOnW2oWmZtG/sW7aWJmAT5v3kYyOfnb5Twfl5GMHSn8I30dhrMenagIJr7U470sHeMyRKkSGJ5EIcZ8s/Mp79xkG3ceO9Gt7HS7+U3K6fqKxtFcmLagDkKobODnJ5ABwOTgc1BqXj2xttH1TUbSyv7uCxcxl1hISVlmETqrc8qxPBAzgkZHNAGXpHw/u7JAJLy3J+yarbkIrkA3k0MikbiThfKIOSScijVPh7c3k0U6agI5be006GII0ke57U3O7cyMrBWFxwQcgrnnodjVfHWnWSX6JFdG6s7YXMyTW0yRxKVLKJJAjBCQDxgn2rV0/xBa6hqU9paQ3ciQyPA1yIG8jzE4dA/qDkE9MgjOQRQBx83w9uJdI1u1Se1t31LR7vT8K0soWSdnYyM8jFn5fJJ6nPAr0iiigAooooAKKKKACiiigAooooAKKKKACis/VtZ0/SBF/aF0kTzEiKPBZ5MddqDLNjvgcVY0+9ttRs4ruwnjuLaQEpJG25Tg4P4gggjsRQBYooooAKKKo3GrWcGqQadJKxvZlLrGkbPtXpuYqCEGeAWwCeBzQBeooooAKKKimuIYJII5pFR53McSk8u21mwPfarH8DQBLRUVzcQ2sayXEixoXSMMxwCzsFUfUswH40WtzBdw+bazRTxFmXfGwYZUlWGR3BBB9CDQBLRVaG+tptQubKOUNdW6JJLHg5VX3bT+O1vyqzQAVk+KsnQLzHXaP5itasfxfC1x4Y1OJGKu0DYYdjjrUVFeLRUXaSZ4JqjN5EmCSxPPvXA+LMrpzOTsba2DjAJPH512V9NdWsxilAkgXarvt6HkHHr0yfqK5nxLNE8bxRL5jQnLu3SNuoXb0Z8HoeF43c8DzsLQlUlbot30S8/wCvQ9CtVjFebOe8EaZcOQ8ChbiUBzI65WFW6OwPUkcqnfqcL19C1e3ttI8MtaxSnfPL5zSOdzynH3nPfv8A0rn/AA9dSWunny0jM2S6gk856knux9T/APWqDU7y5+ySXN6Y1EaZLHhcdh9K6q1Zfw6Xw/i/N/ounrqYU6b+Oe/5en6s6bwzeY1i3hl3FZo/JDL3PGBjqOh56V1NkBBqRyd0YJ9q8/8ACMzXV/p+o2aSG6UB4RE2FdeAc+q4POeOlehQPGdVlCgAF2IxjoT1rndrRXU06t9DE1i5jkuJHJDYzlQ2Dx6VHozblErBfnPzHPH1FVbqJRquSxVhuVeRzkjOf89q0IYo4RHEofnI5GfxNYPRmvQ3NPkbcyp909j2rWS2XeCEVDjO4dzWfpEe0bsnJI/CuhSFJCoz92tFpG5nLcUNYyWjQX0STxk5w3cinXt+osTbWsIS3iGxgvByfSqxTy5Qyjdg4xirjKo52YTIx7ev61CnLYbgnqZyx7rORtjyFB8yqpG49MDPXpXNa/Y3VjrEWs6SjrdKRKfl+VGXHU/7XcfWu7tZFllngOcDaRx2qzaW0TzF1dQQAGRxkSA9c11U7P1MJO3odD4R8Q2fiTSUu7Ntrj5ZoW+9E/dT/Q9xW3Xm914Sl0y9Oq+Grt7W5CkNGRkEehHRh7H9DWrY+NHjfydZsJIZVHMkGGQ/gTkfr9a6+e3xHPy3+E7OiucHjLSc/euemf8AUMf6Vj6x46kSJv7MsWyT8stzwCPXaOfzIodWCV2wUJN2sddq2qWekWb3V/MsUS/iWPoo6k+wrhbfUY7vWpNZv13ybTHZwHjyYupLe56nHsK5HUdQuryb7brFwJXXhWfCqo9FHQfhyfeue1XxVJDbslmrPk4LlSB7YzXHPFcztFaHTHD2V3uZfxj8TNfSSwRfvZrhiB/sL6n+eK8y8GaA8+sRzC2eedOUJXAB75rvNK0G61S9FxdW4FzJku0jZVRn7ox9P1r13wtoX2NW8qNfMxjI/p+VRrNaM00gWPAfhOTTRHqWqnc5+fBGOfSu5vbyOaeEhGJGfwHrWdaSJFbTxyOCGQnJPp3rAi119ULm3UJag7VZDgtg+vpVRioxstEzKTcpXZvaxHHeWtzDeLFLaOhRlYbgynggj05xXnOl3kvhq/Tw9eStPYy/LpV4/Ugf8u7n+8v8J/iX0IxXXTlYky7fIBub3rI1bSrLVtMmt78MIJACGU4dGHKup/hYHBB/A5BIPXRmlenL4X9681/WqMZx+0t0F9bvJHFPtYwhvmIB6f41yeuEQ3MsavGYZQWJKhsYGRxVzw3rOqWl9NpOoziS6iXcynAjuoicCZB2bPDDoG+uK5vxndxWVzfT2pCDAjXPPzNwT+GDXPXg6UvS3zXdeTN6UudGr4m1OO4t3isCrbBmNwMCTBwSAe319q8w8Z6T5v8ApEaEBhhcDIB7iukgupl8O2c0+wPLIWjIyd6YAySfp9DUd9q8S+RaRCGed3DTR8blBHBxWVW7k2a09IpGt4Z1BrPwOks8xWWOErmTAzjpXlOm7p74MUGWkzyepJyTXd+KlWTSAGjRQcDYOMfjXN+GrVhfrGIzlCDjAzgZOP0qG9C1vc9S0jRdJvLQzX2nWtzOoAZpIQzE9Bk4yR/QV6X4Y+HPhS50xZL3w9pskrHJYRDHQcVwvh+FbiUXCLtjZVXBHXHr+de3eGo/K0a3XBHB4I967MPiaqkoKT0XdnHXpQa5rL7jIsvh34RsryC7tPD9hDcwSLLFIsfKOpyCPcEVc1bw2t5qkmo2l9cWN1NAtvP5aRukyKzMm5XVhlSzYI/vHOa368y+IOrapD4j1Kx0u81FLyPSI7nTra1hLpJdmWUL5hCn5TtUEMQu3ce2R1ynKfxO5zqKjsjesvAOlWum3un+bdSWl3pMGjursAwiiMxDAgDDnz256cDAFObwVHJN9tn1a+l1hbiO4jvysQdCkbxqoUIE27JZQeMnzG5HGOfN/wCIDq8ypc6rFe/a79LlGs2kt4LRUm+zSxgJh2yLc4UlmLSA524XG02XVbu98Py6jJraQWWqMkl3EZZUl3WjYYB4VdVL4UgqVDNgNngSM7d/AOmP/Ypee6dtOuJblmLKDdNJL57+bgAEGYJJgADKDtxU2ieDLPRdYkvbGd1iaaWfyDBCcNISzDzNnmbdzMQN3GcZ2gAcDFqnjEaXrU8t1eRaqtjcl7QWsr7Jww8sxkx+WABkAKzbwc/MQTWvrEesaV4jvIludTuLH7Lpq3epJbI1yYzNfGTDRxjO3MQIUfIrFhgksQDrdW8J2mpXmoXT3FzFPdfZGV4yuYXtpGkjdcgjO5uQcggYxgmo9K8LWdhrNvem+nuNSj+0SytIUDTNN5YZiqgYAESKMAcDnJ5rn/Dj+IdR1vSIru/1W302OO8n3NAqNcol0gtxNujypaI8gbWI5ODmq/xGN7b+KLi6099VivBojrZGygaQSXQkJjRiFI5OOGIBGc8DIAOq8V+FIdeeaU6hdWLzWUthO0AQiSF+oO9Tgg9CMdT+GNqXhfF2NT8N3LTan9ojm3C5jQIn2YQ8ZjcEMqqcED1B42nHW78Tz+KL2LUZprfE80f2VYJpIpbbym2bCI9g5KtvL53AqeoWsrR7jVfC2hnW1troRWNtpRurXy9rXMX2bypEXd/ErMrYHOU298UAdHZfC6H+x9Pt73U5xcx6fbWVy0UcTCTyWLjaXQsoLMc4xnA6GtG6+HVhd32q3lxeXP2i/ge3aSKGCJgDIsgLFYx5jKUUKX3YGRzuYnpPDUOoQaDYprUwm1Mxh7lhjaJG5ZVx/CCcD2ArToA5i78IQXljrkF3e3Mj6xBHDcS4RSNqbdygDAJzTJfDN9Y2eqx+HtYuLU3bXE0MMqxtFBPMzM0gOwsQHZnC5xk+nA6qigBqLtRVyWwMZbqfrTqKKACiiigAooooAKKKKACiiigAooooA5HX7HUrfxR/a1ha3N3FPp5sT9keFZ7ZhJvDoJiEIbPOe6Jwe2DD4a8RarPHc6y88d9Hpk6W87TqoiuTM5hZ0iIRnVChJAIznFb3jzxpH4SiaZrZLtIbeS7uI45HMyQp95lRY2468uUXj71Z/iDxvqdudQXSdFEiWWqWmmtcXE6hJHmnt0KqoO4HbP8AeIwCAfm6UAY0PhnVvslx9m0SeysCLAXOlG5iLXzRyOZ2BEhX5lZMlyDJtIfA6um8MeJI9NgOkRyWZvJbqxltWuFzY2Uz7lkBBKl4tpKqpIHmFRkKK6C18di48SjSl0ydkW5+xyzR738ubYGJwE2+WCdpYsDn+HHNVrH4kRNomn6vquk3Gm6fqFg9/avJMkhkCxLKEwpPzMpcqOpCHIB4oAoaP4W1Oy8c/a7mK/aOO8d4LuF4DEbYxlUhkZm87aoIGwKV3KGz1IteMvCl7qXiTVNTsbUGVtLt4IJRKEZ2WaRpYgc5UtG23dwPm68Gu9s5JJrOCWeEwTPGrPEWDGNiMlcjrjpU1AHl9v4RvL2+tEm0y40/w+2qSXH9mi5WP7PD9j2YIikI2tMC2xSRzk9TjoPHOl3F9qWmTtpUms6ZDDcJNYRyoh85vL8qX52UfKFkGc5BkBHIrsKKAPLbfw1r0StHqlpJqesHT7aCz1gTRlbKZIQsjEMwcZly5KBtwIB6Cnw6LeW9nobWPh+50f7JcNLqLNcxN5wFjdR+YSjkv+8eP5m+YkgkcEj0+igDxjwromsXvh7Sb7TNPubGKaDRHmElxHuvHjuopZpztc/8sg2SxDuDgjgA2I/COoQaLBpR8OFrYahdyXMkQtZXcNI7QyRiZigXa2CWXeOML1I9fooA4H4d6Pr2mwtPrEP+nvoem27vNMH33MUcglDMpJ4Zhlu+eM1a874if8+PhL/wMuP/AI1XaUVcJ8vRP1JlG/U4vzviJ/z4+Ev/AAMuP/jVRXI+IVxbyQy2PhFo5FKMDd3PIIwf+WddzRV+2X8q/r5k8j7s+ZdUs9eV7i1vJdOgO7a8ls8ryqAf+WZZAoY4xuOcdQMgVxGuRPaSLELdo7eONEjjibCKc5wO5J6k9fr1r3L4had9m1+4mjAxKPMIx1yP8c/nXlPiADyXUphcfeK5OK8yrWk37NJJdl37noUoK3Ne7OZ0u4Eih8BS7HPOcCq3iOAajpt1aSzMkbgAuP4Qp3dM89BxWem6zkZYRIAjnykHTns3tyc9+laLG41G8htBCls0hbEruGQAAnBxzk9utSk07oq91ZnV+B4YLO40m3tdyRQQlz5QGc4P3snO05z7nArtdNBa+3cnHXPc1yHhLyraCe3tS5hBVfmbP3RjIHuSTXU6RP8AvJHY/cUkZ4HAzxWcmrryGlZM57VWZNSlcFSI4mY7m25JdRwf/rVoQ3SfICrAOwXONxJPuAePesCe+tkv5pL1S8DRGNmAycE549+B/hWzDcIwT7FvjiyCIpSAy8dGx7VEoqyLTZ12lybowxPXAwfpzW5bTfKT2rj9Ml2pJtdH2sRwScfX1xW/bzAQA9Tj8qT0QLU0Vbc4ycHNWHZi4CsCgHfrmsqOUBVYkkjnr0q3E4d0jDYLHn6DrStYC7a7Y4ZLgtneoVQO4HeubvfErwTkRYPJBz3HpWvrUypYuqMR/BxxiuOi026N3NNeyRfZiVFvEqnc3GWZj068AU5S5dQUbnaWHiaUxrulw2BxWl9phvpBK8UeXwcjrmuJijAIQKMdOa0oJ2hIDY2nqR2qFib6SG6FtYmxqkDBQ0eApPJUdq4bxD4hjtZvKSRyy9QOeD0xXalpZLWRkHO0jcTXkGvxGfVlG3essgXpjaoHX37VrNKyIp3uPvZ77UmRwQFyDsbOf0PpWppGkGeQAuSOpJ9f8Km02x27VcZOep/xroooBDbyeUo3ldo7e39TWSkjVoueGYLdoZZIsHDABh3x7V0clwbUJJbqBIvRvUHtWfpUC21jBGqBQR07irWoMI4DlgGA9envWybijFq7H6hdJd6cs2zy2kBRl/Q1z2izm2t/LcbpIsqQe2K0LaQyWccb4yQz4z1+brUFxZGEvLAwLL821+jVLcnZhFJXRfu7xUsixVfMY7fYZ4rHNwYppYZdzqkTTEFsAbR39jVGWSbVLuG3iQKpOWk6ADPJzVbxVqXmalqFtYOPIZFiLAcnHUCr9q/i6IPZr4TJ1pW1W1huIi1tcwzM9vcdTHJ3I7lD91h3HYkCuA8Wak895Ba3MUsFxHuN1ET0fjgHuCMEEcEHPrXqOl2htrJ9Qvs7LdMwh/u57D6V5Brt9JcarPM6ByCdjEKeDyR8wIxkkjjgk10QkqlLkrO3Z9u/yf4PXuZuLhPmpq/fz/4KNm/1S0udKgi08SK0EYV43U/KdxHy+3THtWn4O8JWtm9/4k1O48yeQsyLg5bJzk56Y6YrkrGUs5xtQSDbvEUOMcEA/u/WurSwvZtMlOp30htFKiERGLbJJyTkGIYCjHrnParVKEldVF56P/IlzlHTkf4f5mTrtzLqNxstwfJDEqo53f4VNoNlFO6TEO0hG9WJK4YHGD69OnNWktFjLqlzcKT8nEcGcY5z+6rUsdKnupY91/dLgfKRHBwOOn7us1SpLX2iv6P/ACLdSb05Hb1X+Z3nhuNZEUptUdNo7H+tez2KeXZwp6IB+leF6X4bv5Z4oYNf1RC52jasA/8AadehL4J1cKAPHXiEAcdIP/jda4WjT5m1UT+T/wAjGvUlZLl/L/M7msLVdX0XSNXL3KyNqcluC32a0luJRCrHBYRqxVNxbBOBnOO9Zdh4Q1S2vreeXxnrtzHFIrtDIIdkgByVbCA4PTip7yy1XTfFd/q+mWUOoRX9nBbtG04ieJ4mlKnJBBQiU5xyCDgNnjqnFR2dzni291Y6K0vrW7tba5tbmGW3ukEkEiOCsqkZBU9wRzxSzXkEONz5PmLEQilyGY4GQM469TwK870LwXeaNeWH27TtP1uNbG3t1eRgospUlkkkZFZThSXUgr837tQegIZpXg/ULfRNIsZNIsI9QsbqzkutTSVS975c6vJIfl3EthnO453HHPWoKPR7m7ht45HlckR4LhFLsMnA+UZNMt9Rs7iCaaG5iaGGV4ZH3YCurbWUk9wRivGtE8Hanqnh2CSz0u209ltriB3LBZLxnuo3UsAOirG3Lc5bjjJO5L4N1C3iv7e00fT/ACp9YlvZ5olg825hcysgUyIwVkLgEkZ2ltpFAHo6albPq8mmq5N3HAlyy7Tjy2ZlBz06o1WhIhkMYdfMAyVzyB64rg/hz4Y1PQZ7ZtSEYWLSYbH5JN+GSaZto4HAV0A4HpgYqjeeD9QntNbtDpenTXt1dz3KarLIN00Ty71gf5S4Hl4hI6bFB5+7QB6T50Rh80SJ5WM79w249c1neI7vS7PSzca15bWkckcgDrv+dXUoQO5DBT7Yz2ribPwVNcavZ3N7pVhBpf8Aasl6dNOyRIENn5I+XG3cZBvIHAznOc1jyeAtZOh21ncWFlfTDS7KzikllH+hPBIzPtyDwwKYK9SgBwADQB6zqd7BpunXV9eMUtrWJ55WAJIRQSTgdeAakhuIphGY3Ul0Eirnkqe+K8t1Dwre6nrXiywtdraXbwXM1hEwKqt/dwESDJ4woZ2z0/0pv7vFnTPBWpW3i9dQvPNuFF2lzFPHLCgjURBDGxMRlOPmAUPtIIzjmgD06iiigAooooAKKKKACiiigAooooAKKKKACiiigDC8ReE9G8RNKdWtpZDNbNaS+Vcyw+bC2co/lsu4cnGc4ycYyamuvDmlXVpf201qTFfXC3c+2V1YzLs2uGBypBjQgqRgqCOa16KAMWDwxpdvqP26BLqOcsrvtvZgkrqoUPIm/a7YC/MwJOBk8Cqmo+D9PutL8O6VEiRaVo08EsVuymQlYUKxKGY5GDtJJySFIP3ia6WigAooooAKKKKACiiigAooooAKKKKACiiigDjPiNY77SK7UZIBib1I6j+teG+IbYiGYBNxAOM9q+mtVtFvtPngYcuvH17V4d4n05UaVCjZwRt9CK4cRC0lI68PPTlPD5/3c+8HJ6MCO9K9/LbLFLbDdMjCPBbaCG+XGe3OK19asDGSDgN0Lg9D2LVhXaZsDJMNkSuquWAbADDoP5URsy3odL4dvWgIEhjD42kLyN/pmut0u6RB5h3lMMSSMjGOR7V5tpm+yX5XyyksGGRkHtz/AI10cN5JJZFeVcghlB7Dt+IrOS966KWsbMytVuHtrneWIidgSwbPH5V0nh69cW95fX74WHLxrnO/0x/Lt0rm7qIzR4f5UTnjjmktpVjikgmJeCVAGUtz3xx+lU7PcSuj0Dw/P9q3S8eXEgJIXG3PAH58fhW7bzPuwSwUcDiuP0fWw1t9nZVtgHVsR/x46bs/y7ZrpUnHlhQQz45wP5Vi4pLfUtN3NOJ1yxV+BwferFvjzBKSd2eCCe9YYuDGGYjLlchR3P8AnFW7O+U542ng47UWuh8yuamoublFiJYY59PXH61SikDqnnEHC7SPfvThcxzFcEkg5yaQxxXAYPgjGDnjNZVIvoaQaHxBANsYCqOFAPQDtViedLezmlnJESLkkKWOB7Dk0Wtl5m1UDjHBNaWnaaRd+beNiJWBjXHJGO/41lClLmuxymraFjUbIJ4We1cPH55YPtkYNyOoIOR+FeU3VjqNnMHtLgagi5Cx3jbZfoJQMMSe7gf71epavrcL3HkIweNG+ck8A+lY9zpa312wtCsbEHg8ZP1r0o1JQXKkpJ9Hr/wV8mji5U9Xp/X9bnPaTrNiZ0t7syWN6eVhvF8svzjKH7rj02k10loz3l+sUcBEKdXY45HtU7+EL7UYTbXFjDcQddkgDoT688dKrXHgjV/DscEnh3UY4srzYXbmeBDjhVYnzEHU8E/SksPTqu8bwfZ6r5PdfNPzZTrSho7S9N/u/r0OlE8KOQSvHy0a9ZWSWcU7zu2QBIkQyWx0xnoa4m/8Ryackdn4isJdKmMu57ksJreTjCgSr93PJw4XAp15q0dxCoWZ5k25Voz8r+hBHB+op1Kc6H8SO/XdffsTGUausH/mbNtepJK85QIc8Rg/dXoBUep38YgaRphGSPu55+lcxLdmO3AHylht5OCPf61k6je7wSXZc9W9f8K5lPqb+zNOCeW/c7JMRIThskce1WYpbe1VlhRS3VpG65rkzeNbwEq25cZXYOPrz7Vk3WqXDSHzsmMfKFYHkfT1/ShO43FnQeNfEcs8CWETk8bioHX8P61xBj3XLmTYUU4GB6/5FWpnMrNNudmkGDg5z/8AWp8NsQUR2Ge+4fqKpzfUSilsO0q2JljkYAMrFgjcbj7/AKYrsJgW0TcGRUikViQ3XeMAAf8AATz6YrEsoFaUAMgLfMQO49vat98S6LJFHtR4rglRjkjYuD9Adwz65q4ap+hM9GvUzrRN8gZvmccb89feup0WI53A4ABwO2K5+yQIiKMgEZKg5GPTPauv0qFRHCWwoYhQG9ew59ay2Kbud/4FtPNm88j5YxkcdzXcVmeHbT7HpcKsMSMNzVp16GHhywV+pw1Zc0gooorczCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDI8U64nh7Sft8tnd3kYljhMdt5e8GRwin52UY3Mo696P8AhJNIGrDS2v4F1EuIjb7ssjlBIEbHAYodwBPI6ZqHxrpF3ruhGxsZ4LeUzwzF5kLriORZMYBHUoB+dZ0nhKWTULy6a8QG41qDV9ojPAjtoYSnXuYic++KAItE+ImialYPfTXMNpZtK6QtJICzqhw0jKB8ijgkngBhkjpWrd+LdFt7m4tUv7a4vbdkEtrFPH5kYd0QFgzAAZkXqec8ZOBXLzfDd/s2mCO9glltbaa0kS4jk8qVJJN+cJIpBHTBJBHpwa0k8FFNE1TT0uoU+2ahb3oZISqoIvI+TGT18g4543d8cgG1/wAJToXmXyHVbQNZRyS3BMgARIziRs9CEPDY+6eDg1Yi13SpdIl1WLUbV9MiDF7pZQYgFOGO7pgYPNcXqHw7ur3Rr3SpNVhFn9i1C0siLciRDdAjdI2/D7ASMADPU4rr/FmjnXfDGpaTHKsBu4GhEhXITIxnFADtP8Q6RqJRbO/glZ5mgVc4YyBN5UA852fN9OelRzeKNEhWzZ9StsXaebCVbcHTIG/jouSBuPHI5rFv/CF43iOXWtP1C3iujfrdxpPAZEC/ZPs7KQGUk/xA5Hp7iLw94O1Lw+bB9O1S1aVNNg0258+1ZlcQvIyugDgqf3rggk5+X05ANLw7410fWrF547lIZIopJ5YXPKIjFWbPQgYGcZxkA1N/wlmnS3OkxWTm5+33zWBK5UwSLbyz/OrAEfLF0I/iU9KwT4Du00+xgtdYNtcWumX1gs8aMG3XE0MgcEMCAPJIOCD82QQRRofgKbT9Wt76S7tQY9V/tIxW8LquPsUltsyzsScybixPODwM0AdBqPia3sNbk06aFyyR2r+YHRQftFwYFHzEdGGeuT0AJwDJb+KtCuJ7iGLVbRnt45JZTvwqLGcSEt0+UkBueMjOM1meI/CT6xrT3y3axBv7O+Qx5/49bwXJ5z/EPl9uvPSsq/8Ahx9v0mCwm1EokcWoRl44+c3Myyqev8O3BHf2oA7TSNWsdXhkl064SdI38twAQyNgHDKcEHBB57EHvV6ua8L+GzpVvfpefZGe8wJGtllQsAu3lnkdu/GCMe/Ws4/C7wmetlen/uKXX/x2rgoP4216K/6omTl0R21eeeP9JKXJu0X91LjPoG7/AJ1d/wCFW+Ev+fG9/wDBndf/AB2obv4V+F3tpFgsrsS4Owtqd0Rn/v5TnToyVuZ/cv8A5IIzqRd7L7/+AeN61YI0zpxhuNnHzDrzXHeILWOHTJ3BBj+XKnBZQOuRXoereE9PtZWQWcykH+K7uOo6j/WVh3OiWaICsDLnP/L1cfn/AKyuPloR+0//AAFf/JHVzVH0X3/8A89DLF5OW3KcoS7dcng5FWYrpUVG3DafmHGMVoahZywXZiW3VUcN5eLmY7RxjOXqiCyuRImAOoE82QR/20ocaH87/wDAV/8AJFXq/wAq+9/5EquJDIFwcDkZ5GfX8qqyNsYLHINxABIHWtKIRuBug2juRPOSP/IlTLAhMf8Ao57bi084xx/10qHHD/zv/wABX/yRSdX+Vfe/8jGFyTnymRGYksrcg49+3Fa1hr00BEUrsyBfvmpLyG3Rd0UBGRwBcTk57/8ALSqiMgJUwEsTlQbifjrx/rKXJh9+d/8AgK/+SHzVduVfe/8AI2I9cZkbMoL8Ddnnt+dT2upuRkMG2qQ+G9M/5xXPuyxBGaLcT94faJuD/wB/KiW8gDbTBlsYAFzP/wDHKfLh+kn/AOAr/wCSC9X+Vff/AMA7Gx1maaLcUQEkgfN1xWlHrAiK72GxRubBHHpXnn2kyx4zkBdqqrs2Oc9SSTye5/lU3nTEeWSTjrjqBXNKEb6bGsZO2p6lH4ojgTIdM4GeelY+t+NJblXhtpTvz1JwvHWvPL+/LZQqvl4+Vt2f89KpmeWJwSSc8nqaFoDS3O2S9uoEEn2lpScMdwxjmrVr4nuLOQOJCS2Cc9APb9K5ppX/ALOllYdAFPGM8GsDzbqV2iXdI23IRRkkZ9PTiqWjFo0e0WHjqUDAuSnYkNgH2qb/AITCFgN1x8x4Ubsn6V4hDJMqMwlUlRkhfmI5744H/AiKfFceSQGkLE5Ut9/HuACB/wCPt9K3+qVErz91een4bv5Iy9rTekdX5f1Y9hvNdivFzJKMt8uCSWIxyMDmuPubmxt55P7Fmlhum+d4tOXzUPGMtFgpxz12n3rlo7hpiROnmx5GA7fKCD12ABfzBrViuHZsRSBYlJZYQAqr67QOB+AFXTqU8P8ADJy8tov1ve/zSJlTlV3SX4v8LW+9l06veuNt7bAMcjMLiUEepUFmXA5OC/0FIsv2tDcLNG8IYYkjfgex9PoefaqpRXuATnaedrfy+lMvl5+0EkT4274yVkH/AAMcnjjByPas5ToVX70eR+Wq+5/o/kaqNWmtHzLz3+//AIHzJLm5Zg0KL1+U5/8ArdqrCFpGBVd6gYZieM+1VjI7vg4JzklAsbe/H3GAA/2Cc1ftH37oYTmXq8W0rIvflDz07jI96znhpxjzQ96Pdfr1XzSKjWjJ8stH5/1Z/Id5bblADFcH5VxwPSrcMQKlkIKoA5Gegz6/pT7SFsgghQTuxnt6g1ohAbeMR7kROhIwTz15rm3RrsVrNChDlBuGABkmug06286MxhDGzLvL5wpP9096zrSLMhIDBBxgGujtkCbGhx5vZiehPqTx2Na4da2Maz0KcUCwzxG7ljQucDe4XJ9Bnqfaug+Gei6hrPiO9utYnZre3uAI7VHPlJsAGdrLznhgwPVu2KxfEHh6a+v7SSDPn58l45fnj8pvvYX+/kAhhznHbivcvCOjjRtIjhKhZCMsAOF9q1p07uxlUnZXNzFFFFd5yBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw3xC0MzJ9ugUHGPMH9a82mtcRscAqedvX8a+gJY1ljZHGVYYIrxT4j6LLbztaWu9A53I4cxn22sPxHOc9K5a1PW6N6U7aM87uLB5pru4kRRG+I4sHJZAc8845PIxWHqGl5LFAyljtwucgjnPt9K9FtdMkbQrNp4zHIqDevoRxise5tMllDOMjGR2J7+tcspWeh0x2OCtUMd1ILjhhwy84+ta1ujum1gSnQhPXjBIqxfaKv73y95mwMsSTuH9aS3XzIyC2JAuAScYHv70pMtIbMpEZ4AY8fLjJPf8ACseaF4yQTzyuRx2rdliUxMrozbuGPTHpg1ROmSeTtgPmEDhX6j6DpUpjaMyaCSRdqYBJGNxPIx0pEg6YiAJYdh04rehtNzJ9rXyiCV4I70s1gASMfIfl+ZeR7fy5qk+gNHOi1ETlo4wDg9Dhcn2qYysAGZRhcg5/l71uPpqmQMCudpUEdCR/+qq81km1GUEMMkbuxPp61V0RZnPtE5mT5QUfJbceQe3FJPEYmy/AUBgO5Fbo05rZUHzyNnAduSPX+v51RuIcoojA+b5cluo9c+mQRSWpT0LMaO3h6SQeXjf8xdSxXjjAyOee+fpXOXMjsjqMYyCAcbM+u0AL/wCO5ruptOl/4R60gYfMxzlhjPHWuKurGWISF0fG7O/0rWOKqU1ywdvTf79zN0YTd5K/5fdsUoQrwF7luIuRuJOAOTgdhxVuEOArMNoYblBHIz2NRtGVG0HIbqDyTVmKMu20kkISAf73rWEpX1ZqlbRFmMjaFdV2nB44xVqDf5YVVLKSPmA5471Hax7oyDj6scZq1NbFlRVzvDDHYDB5/rSRViZGDFYmYnHU57+9VrjlC0QG1QAEAx+NaDWwSBt7n5sfKvLfU1DiRHAYqSCSQp5Ht70hlCJVwz/dJPHFWoLKOcKsqLMgyQp9+p9R0HIwalFsWk+cEN6Y/U1qWEBj2vgjJ47cevv/APXpRnKEuaDs/IUoxkrSV0Qx2l7DJ5kMi3aKQSlwx3H1xKBn0ADBgKsNq9pCojvzJp8ufuXC5XP+y65VgPXI+laoIjjUK+B/ez2qSwjZpjKu5RnAAPX3P+FdX1iM/wCNG77rR/k1+F/M5vZyj/Dlbyeq/wA/xMq28QaKjK39p269Ou7j9K3bbxb4biVQdagCr2UPuPsPlxW5p0MhkG55d2eTk13vhvT2uZUXLiJeW5IIFaU3h76Rl/4Ev/kTOo6iWsl9z/zOO8I+PPBVpKLzVPEFt5qfLBCsUpEY7knbya6//hcPgP8A6GGH/vxL/wDEV3qqFUKowAMAUteinRX2X96/+RON+0fVfd/wTgP+FxeAv+hhi/78Tf8AxFH/AAuPwF/0MMX/AIDzf/EV39FPmo/yv71/8iK0+6+7/gnD6d8VvBWo6hbWVlrsct1cyrDFGIJRudiAoyVxySOtHiXxHrFr4wbSdNES26WEd0W/syW8cs0ki4OyVAowg65713GecVian4bs7/VjqTT31veGBbdntrl4tyKzMAQDzgs351nNwfwJr1d/0RUb9TI1jxuLO91TS7fTLt9XsreW68tlAjMKoWSYvnGxmGwD724NxhSazbj4mw2FnZHUdNlW8ewj1G5gjkUskTlgpQAkux2OQo5+XGckA9LJ4R0aTUpNQktma+leRpJzI251dAjRtzzHtC/J0BUHGeagXwVpKR2yxNqMTwQi2EsV/MkjwgkiNnDZZRk4ycjJwRk5gop3PjnypL0RaJfyxW1+mmrNviVZp2kVAqgvnHzgkkAfU1T1T4kW+m6N9unsD5kTXS3NqLhTKn2d9khRerjuDwOm4rmunbw5prRPGYW2vfLqLDef9erBg3XplRx0rNvvAmh3ouBJFdR/aBOsxgu5IjKsz75FbawyCxJx2yR0JBAJ/DetSajfeJ/tDp9lsL9IYDtxiI2dtMc+p3Sv+GKyY/iFB9hjubnS7yE3VvDdWEW+NmuklkSKNeuEcvLECCcDeOeuOp0zSbPTHvns4ypvJVmmyxbcyxRxA89PkiQfhnvWRB4F0CGzmtBazPbvEkCJJcyt5EaMGRIiWzGFYAjbjBVf7owANbxLfjUU01dCmfUVi+0TxLcx7Ui3bVYMSNxYhsAgfdbJHGcgfEExWM039nT3ht4Lm8uHiCRBIIZ3jbCs5JfCZAzg4/hzit5/CGmvNFO0mo/akUxm4F/MJZEJBKMwbJXIyB25xjJzmXHw90yfVN7vONNNrLbSWaTyKJfMmaVw5DDcpLEFT2OOmRQBAvjS8l8UW2m2Vmt5by309s7gCIxqkEUgPLnd/rCc4HAxjuaOp/EcSWuqQ6fEiXkEIuIJkkE8UiCZI2+YcZG8cAkc9eK6yTwrpTXovFjmjuRdm9EkU7ofMKLG3Q/dKqoK9OPWqEHw/wBAhhEKxXTQrbfY443u5XWKEOjiNAWwqgxpjHYYoA09e1t9Ou7CxtLJ73UL3zDFEJFjUIgBdmY9ANyjgEksO2SMHUPiDFYNqv2nR76OLTp4bSWZ5IQhuJUhdIh8+f8AluuWxtGCcmuk1rRLPWGtpLoTJPbMWhngmaKSPcMMAykHBHBHTp3AxWbwrpL2WoWskErxX00dzMWncv5sccSI4fO5WAhjIYHOVznPNAHNN8TbRY7MtZGJp5pIWee5jhg3IUG1JXwrs3mKVHGcNnBGK3/CeuXms3Wtx3diLeKxvpbWKVXBEqqeuMkg9+3WkvfBumX1i1pezapcW8gdZkk1GcrOjYDI43YKkADHpn+8c6Wm6Paade39zaCVGvZPOlQysyb8AFlUnCk4GcdfzoA0aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqjqum2+oxYmjRpFHyMwztq9RSaTVmCdjzHVNOkjneOeMgAnjH6iuY1DTyQ23Kj3r2bVbBLyLkfOOhrgdVsTC7pIh6Y+ntXk1oOm7M7aU+Y83uLfchBB3jJwO4rCu7Uyv5gHlsM5A6n6V6BdaflOA3XIOf0rn7my3PuwN468cVK7m1zDSMtn5SwPTJ6U6KII65Rtv3g22tD7OQ2BnGMCmGNosbTuxxnpn8KENsRoUcZZSSfYZ+tJFG0YwzeZxw3Q/j69KPP8tsk/J/e65pG1S1UqHdO+TmmtBCCBfMJwBzge1SNaqyASbAN3BHOKa+q2O1ssuOmQ35VFHrNkuV3Jndg5PT8KpN9UL0JvsqSOBGRgZBHc0lnoEN1cwQxWyhFXy1VRhUXOaZH4ksFd9wUgcbk9R1rN8Q+OxaWZi0YiF3UgyNy4H+z6VpGF9iJStuN8ea5ZxavDaBwttZpsaQHALdDWjDbWesWKTwNGyFcgY+97143Peie9aa6h3wZxhiPbnkEfpW5pWoyQyY09bhbHjb5U8asAevHl/yrX6tCcbynZ+jJ9rKLtFXOqn8N3B8xRCqydAT0x7VDHocwkMbsi8YJzxirFtfRTxqZbzV0OOd1zF8vX/pjUubeVD/AKdqHqN1zDz/AOQfeoeGpr/l5+DKVaf8n4oclikTYVwIwMnjjP8Ak1OkEXEkYyv3jkc/r34qFok6vc6njj/l6h4J65/c082cW357vUue3nxf/Gfan7Gl1qL7mP2s/wCT8UO8jfK5kO1WGdqg5FNMMUTBUO1uvTr7VGYYGZt82q7cZLefEc/+QagmtUCg79RLnAx50R5/78/rQ6VJ/wDLz8H/AJCVSp/J+KLhAwoBCr/E3UZqzbgmPcF6cnHWs1LCFioMuo7u376I8/8AfqtCHSY2wftOq9uk0XH/AJCpKhSX/LxfcwdWf8n4ovww+ZjbuCEcketdBpVm2UJ5wax7Lw3G7A/2hrCD1E0II/8AIVdDYeFGnZVi1vxCGJAAW5h6/wDfqqVCk3/E/BkSqzS+H8UdBp1g8kqLGmSTgY55r0zS7JbK2WMAbzyx964qw+HMsMSt/wAJb4phlI5CXUPH/kKrf/CBXH/Q7eL/APwLh/8AjVd1LDU46uf4M5J1py05TtqK4n/hArj/AKHXxf8A+BcP/wAapP8AhArj/odvF/8A4Fw//Gq29nT/AJ/wZlzS/lO3oriP+EBuP+h28X/+BcP/AMao/wCEBuP+h28X/wDgXF/8ao9nT/n/AAYc0v5Tt6yNT8R6Xpl8LO8uWW6MYm8pIXkYISQGO0HAyCPwrEtPA89tdwznxj4rmEbq5jluoij4OdrDyhkHvVXxJo9zJ44k1NtM1i9s306K3VtM1EWrK6yysQ376MkYdcde/SonGK+F3Ki291Y7meWOCGSaZ1SKNS7uxwFAGSTRBLHPDHNC6vFIodHU5DAjIIrzTVfCOp3/AIm1WdrJDol4lxDHZyTgrHO8Ow3hTphxuQoMkZ34y7gY174Ev7m101TpV5a2sWmR2cdpYNZJJZ3Ss5edWkVgu/KEPGQ48sEgnpBR7PRXmt14HluRqM01jFLc3euxzu0kgbfZCaNmXk4C4Vjs7+nNYXiLwNrVxos+mWulwNao2pHT/IW232zSzFofmlB8uPbj/VgOCB0wMAHrlnqFre3N/BbS75bGYW9wu0jZIY0kA5HPySIcjI5x1BFW65nwppV/Y3PiaS8/dvf3sc8Mm4OSBZW0RY+++J+D6e9cPaeCtaXRWtrfToLGVLK2t79FnUDV5UmjeViy84eNJU3vhj5xyOM0AevVFa3EV1D5sDbk3MucEcgkHr7g153J4bDavb3R8GwPpIt2ig0wm3X7HPv3GYpu8sbhgFkLMNgwDuNc1qPhrUp7ubR59J+2382mXv2eV5E2Wcsl5I0U24nKlQynKZcdhQB7Eup2Zuxa/aEFwztGsZOGZlUMwGeuAwPHrTtU1C10qwlvb+XyraLG99pbGSAOACepFeev4SvT4qttT1DTYtUhg1aaZN/ls6pJbwoJQGOBh4ySAd3QgGsG28E+InF+76dHbT3dh5d0kX2aKGW5FxE+6MRgMUwJNrSkvyc4J5APaqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArO1XTI75OeJByD2rRoqZQU1ZjTa1R5fqunyW0rRSxMFHt1rCu7VXIcHBA717Je2cN2m2ZAcdD3FcLr+gvZt5iElCeD2FcFWg4arY6YVb6M4C6tiDuGBx90VTkiCoAR249q6aeAj76BT15rPngGTkYboOea5GmjpTTOZuI8N3IH4Vz99A88rBkUDhVI5IPtXbz22QQAD6nvVOWwjMjZGSvfvkUX7FLTc4GW1uFbeFOQSFyecc1UkgJ3Ng5HBYkkN2rvpdNG0hEBB7HvVOewlbcCE29fStI1BNI8+ntXM/Q85IbHXHr+JrMm02Y4BjJAb5mPv6fjXo8lpu+WQbhnGM9KqppgaQscbmI68/nWqqWJcLnCSaQ86KsxkUED5VOMj0rXtrCOHAghKknbhVwPxroxZIZkI+mPQ+tTTWw8zI2/L8xHqcGk6jYKCMeyty7brgSK5B5z/Or4sWQIyEMR93sMdv6Vft0AiiUr8mMdK0baACQkpxntxWbmWkZdpa5XzgW3g4Ibkfl+NWZbdVQ8ZBO09zWoYAQQhUN1AbpUsdrvcE/K2MHHrU8yCxjfZtyuUwMAAhTg/561Yisi7hn653ccZPatlLJQckAnoQDVyO0Jf5SQPpTTEzItrHLAIvAwvTGRWxa2mwgfLnHb/Cr0FkQBhfmKgcV0GjaHNfSYjQcYyTwB9TWkYtvQzlJJamfo+nS3EiJGjMx6DHWvTNC0WPT498gDTnnP8Ad+lWNJ0qDTo/kUNMfvORz+FaFd1Kjy6vc46lTmCiiitzMKKKKACiiigArj/FvjCfQbzUUi01Lq303Tl1S7ka58thDucMEXYdzARsQCVB6ZFdhXOan4QsNU8Svq2ol51a1jtfsxdljISR3y4DAOCX+6wI+XNAGZL41vTeXMFtoqMo1E6XbSS3mwTTgbiThGKJtDHPJyMAHINUZPHOptqtksGm2gt1stTlvonuWDJJaTwxN5bbMMPnYjIGdwztK4PXz+H9LntLi2ktB5Vxcfan2uyt52QfMVgcq2QMFSMdqiHhfRlSxVLIILLzBDtkdTiQhpAxB+cOwDMGyGIycmgDmfEfjO6/su6Gkw+ReRWulXqO7Ahlu7lozGcqcYETDdg/e4GRTb34iXFrevpf9imTW4554pIIZJpogsccEhcPHAznIuoesYAJYE8DO9D4I8Pw2d1apYN5VzHBDLuuJWYpCxaJdxbICFjjBGOB0AFTP4R0VrSOD7LIvlytMs6XEqz72GGbzg3mEkYBJbkAA9KAML/hPLhxcyJoptbe2traaV9QuDA6SToDHCY1R337iEIAJyQACeKZp3j291M29rZaLH/acl1PatFc3EkEaNFGsmdzQh8FXXrGDn25rpZPDOjyWlzbPZKYbhYlkG9snyseWQc5DLgEMCCCAc55o03wxpGmzxzWdptmSV5xI0ruxd1VHYliSSVVQSfTPWgDA0Tx3Jrlouoadpqf2XFZ295eSz3JSSISwibaiBG3lUZScsvJwM4NW/BHi648SyP5+jXdjC1ulzDM8cwR1b+EtJEg3gYOFLrzwxq/a+EtEtHsja2RhFpDFbxLHNIqmOIYjV1DYk2jpvBxVnRvD+m6KxOmwPCu3y1QzSOkaddqIzFUX2UAUAatFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTZI1kQpIoZT1BFOooA5PV/C6yFntfunnZnn8K5C/wBJeNWDA4969bqC4tYbhcSxq3v3rmq0ObWJrCq47niFxA0UmGTYQO/IzUPkkg7uGycZr1TVPC0dwpMJXPbI5ri9R8N3lmWaSBjHnO4cgVwzoSj0OmNZM5vytgIK8qOMiqk1uWB79sAV0Js3PAByOmaimsWCcAYHGPSs+Ro057nKy2zAHHUjv7VV8raoyCOe36V1RsQy85z6jrUEmnMDj7w+madmPmRzptRu9CO9V2t8l2CjJHPPXmuoOnt2QnHHWmLp2x9u080KLDmOegtwu1QML2wec1qwWmRwSWOMVf8AsIViwAzzxWjb2hPQNn1A/lQ4BzmWsH7vYVJOeuKtx2ZwrMuVGc1tR6ZKwyFJ469K07HRppDsCM2RxtHamqb6CdRHNw2RYkKDjG3OO9atnpjMRuDEHjAGa7Gy8NP5iPIUjTHIHJroLLT7ezH7mMbv7x5NdVPDN6s551+xzekeGdwD3WY0/ufxH/CuqtreK2iEcCBEHYVLRXZCChsc7k5bhRRRVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBAIweRRRQBRuNKsp23PAobOcrxWfceGbSQ5iZ0Pvg1vUVEoRluhqTWxyJ8JMG4liKY5+UgmoJ/CcoPybG9+ldrRU+xiV7SRwv/AAilyeNiZ/vZqRfCM2/OYwPrXbUUexiHPI5GLwjx87xgZ6YzxV638M28ZG58gdguK6CiqVOK6CcmyjbaVaQfdj3H/a5q6qqowoAHoKWiqSSJCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inferior view of the external aspect of the skull.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, PhD, FRSM, FIAC &amp; Dalley AF II, PhD. Clinical Oriented Anatomy (4th ed.). Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31416=[""].join("\n");
var outline_f30_43_31416=null;
var title_f30_43_31417="Components of cardiac rehabilitation and exercise prescription";
var content_f30_43_31417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Components of cardiac rehabilitation and exercise prescription",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Lynne T Braun, PhD, RN, CNP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Nanette K Wenger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31417/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/43/31417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of cardiac rehabilitation in men and women with coronary heart disease was illustrated in a 2004 systematic review and meta-analysis of 48 trials of 8940 patients with coronary disease who were assigned to exercise-based cardiac rehabilitation or usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/1\">",
"     1",
"    </a>",
"    ]. Cardiac rehabilitation was associated with a significant reduction in all-cause mortality (odds ratio [OR] = 0.80; 95% confidence interval [CI] 0.68 to 0.93) and cardiac mortality (OR = 0.74; 95% CI 0.61 to 0.96). There were no significant differences in the rates of nonfatal myocardial infarction (MI) and revascularization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac rehabilitation following a cardiac event was traditionally divided into three phases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phase I or inpatient phase was introduced in the 1960s and consists of the early graded mobilization of the stable cardiac patient to the level of activity required to perform simple household tasks.",
"     </li>",
"     <li>",
"      Phase II consists of outpatient monitored exercise and risk factor reduction. This multidimensional approach gained popularity in the 1970s and became well structured in the 1980s [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phase III or maintenance phase consists of home- or gymnasium-based exercise with the goal of continuing the risk factor modification and exercise program learned during phase II.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to economic pressures and the movement toward evidence-based practice, cardiac rehabilitation programs were remodeled and the structure of phases streamlined with the integration of coronary risk factor reduction programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multifactorial rehabilitation program consists of baseline patient assessment, nutritional counseling and weight management, aggressive coronary risk-factor management, psychosocial management, physical activity counseling, and exercise training (",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"mobipreview.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performance measures for referral to and delivery of cardiac",
"    <span class=\"nowrap\">",
"     rehabilitation/secondary",
"    </span>",
"    prevention services were published in 2007 for hospital settings, office practices, and cardiac rehabilitation programs. They were designed to translate the strongest clinical evidence into practice and to provide incentives for rehabilitation referral and better standardization of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2007 American Heart Association and American Association of Cardiovascular and Pulmonary Rehabilitation scientific statement outlined the essential components of a cardiac rehabilitation program in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/9\">",
"     9",
"    </a>",
"    ]. Most outpatient programs consist of three times weekly ECG-monitored exercise sessions for 8 to 12 weeks, and sometimes longer. The goals of these sessions are to develop and teach an individualized exercise prescription that is both safe and effective, to initiate interventions aimed at reducing coronary risk factors, and to identify and manage the psychosocial problems that commonly affect the cardiac patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. Testing procedures to assess exercise capacity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3687?source=see_link\">",
"     \"Exercise assessment and measurement of exercise capacity in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been wide acceptance of the benefits of supervised exercise programs for patients with stable angina, recent myocardial infarction and recent coronary artery bypass surgery (CABG) for decades. In the United States, health care insurers have recognized these benefits and approved payment for them. In early 2006, the Centers for Medicare and Medicaid Services expanded coverage for outpatient cardiac rehabilitation. The following indications are now covered by Medicare and many third party payers in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute myocardial infarction within the preceding 12 months",
"     </li>",
"     <li>",
"      CABG",
"     </li>",
"     <li>",
"      Stable angina pectoris",
"     </li>",
"     <li>",
"      Heart valve",
"      <span class=\"nowrap\">",
"       repair/replacement",
"      </span>",
"     </li>",
"     <li>",
"      Percutaneous coronary intervention (PCI) with or without stenting",
"     </li>",
"     <li>",
"      Heart or heart-lung transplant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Heart failure is not currently a covered benefit of most insurers, although it is recommended in the current",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    Heart Failure Guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other candidates for cardiac",
"    <span class=\"nowrap\">",
"     rehabilitation/secondary",
"    </span>",
"    prevention programs include those with diabetes, peripheral arterial disease, pulmonary artery hypertension, and congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H870866319\">",
"    <span class=\"h1\">",
"     TIMING OF FIRST VISIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the proven ability of cardiac rehabilitation programs to lower the rate of adverse cardiovascular outcomes (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    ), participation in such programs is suboptimal. There are likely many reasons for low rates of participation. The best information available is that among eligible coronary heart disease patients, fewer than 20 to 30 percent are referred to cardiac rehabilitation programs and, of those referred, about 40 percent participate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the knowledge that the average time from discharge to first visit is around 35 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] and the knowledge that early exercise after MI or PCI is safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/23\">",
"     23",
"    </a>",
"    ], it has been hypothesized that an early first visit would improve participation. In a single-blind trial, 148 patients with a nonsurgical qualifying diagnosis for cardiac rehabilitation were randomly assigned to receive an orientation appointment either within 10 days or at 35 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/24\">",
"     24",
"    </a>",
"    ]. The median time to orientation was 8.5 and 42 days, with attendance rates of 77 and 59 percent (relative risk 1.56, 95% CI 1.03-2.37), respectively.",
"   </p>",
"   <p>",
"    While the evidence to support early enrollment is not robust, in part because there has not been demonstration of improved patient important outcomes, we suggest that health care providers attempt to make early appointments at cardiac rehabilitation programs for qualifying patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION FOR EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cardiovascular complications from exercise training should be evaluated before starting an exercise program. The risk stratification guidelines published by the American Heart Association use four categories of risk according to clinical characteristics and included contraindications for exercise (",
"    <a class=\"graphic graphic_table graphicRef50753 graphicRef60012 graphicRef72809 graphicRef52847 graphicRef80110 \" href=\"mobipreview.htm?11/11/11455\">",
"     table 2A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar guidelines have been published by the Health and Public Policy Committee of the American College of Physicians.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class A are individuals who are apparently healthy and in whom there is no clinical evidence of increased cardiovascular risk of exercise.",
"     </li>",
"     <li>",
"      Class B individuals have established CHD that is clinically stable. These individuals are at low risk of cardiovascular complications of vigorous exercise.",
"     </li>",
"     <li>",
"      Class C individuals are at moderate or high risk of cardiac complications during exercise by virtue of a history of multiple myocardial infarctions or cardiac arrest, NYHA class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 3",
"      </a>",
"      ), exercise capacity of less than six METs, and significant ischemia on the exercise test. One metabolic equivalent (MET) is defined as 3.5 mL O2",
"      <span class=\"nowrap\">",
"       uptake/kg",
"      </span>",
"      per min, which is the resting oxygen uptake in a sitting position. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3687?source=see_link\">",
"       \"Exercise assessment and measurement of exercise capacity in patients with coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Class D patients are those with unstable disease who require restriction of activity and for whom exercise is contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients referred for outpatient cardiac rehabilitation typically belong to class B or C. They require different degrees of monitoring or supervision during exercise. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Supervision'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cardiac rehabilitation programs have observed increases in patients who are older, have multiple comorbidities, have heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral artery disease, and who have undergone PCI or cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/5,25,26\">",
"     5,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although generally beneficial in class B and C patients, supervised exercise rehabilitation is associated with a small risk of adverse events. The 2007 American Heart Association scientific statement on exercise and acute cardiovascular events estimated that the risk of any major cardiovascular complication (cardiac arrest, death or MI) is one event in 60,000 to 80,000 hours of supervised exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link&amp;anchor=H13#H13\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXERCISE PRESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of an exercise prescription include the mode, frequency, duration, and intensity of exercise (",
"    <a class=\"graphic graphic_table graphicRef75107 \" href=\"mobipreview.htm?33/13/34012\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"mobipreview.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    ). Exercise progression and provision of appropriate supervision are also important elements of a cardiac rehabilitation program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/28\">",
"     28",
"    </a>",
"    ]. The American Heart Association has published recommendations for exercise prescription for endurance and resistance training and for classification of exercise risk, which are used to determine the need for supervision and the level of monitoring required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of exercise should be one that requires the use of large muscle groups and aerobic exercise such as walking, jogging, cycling, rowing, machine stair climbing, and other endurance activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/11,29,30\">",
"     11,29,30",
"    </a>",
"    ]. Low impact activities are recommended because of a lesser risk of physical injury. The mode or modes of exercise chosen should be enjoyable for the individual and simple to carry out to maximize compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended frequency of exercise is three to five times a week, which is necessary to achieve a significant improvement in functional capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/10,29,30\">",
"     10,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Content and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each exercise session includes three phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Warm-up for 5 to 10 minutes. Warm-up exercises consist of stretching, flexibility movements, and aerobic activity that gradually increases the heart rate into the target range. This gradual increment in oxygen demand minimizes the risk of exercise-related cardiovascular complications.",
"     </li>",
"     <li>",
"      Conditioning or training phase, which consists of at least 20 minutes and preferably 30 to 45 minutes of continuous or discontinuous aerobic activity.",
"     </li>",
"     <li>",
"      Cool-down for 5 to 10 minutes. The cool-down period involves low-intensity exercise and permits a gradual recovery from the conditioning phase. Omission of cool-down can result in a transient decrease in venous return, reducing coronary blood flow when heart rate and myocardial oxygen consumption remain high. Adverse consequences can include hypotension, angina, ischemic ST-T changes, and ventricular arrhythmias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity of exercise may range from 40 to 85 percent of functional capacity (VO2max), which corresponds to 55 to 90 percent of maximal heart rate (estimated as 220 minus the age in years, or more accurately measured at the highest exercise intensity on the maximal exercise test). Estimated heart rate is inappropriate for patients using HR-limiting cardiac drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The target heart rate range may be determined by several methods. Selection of a fixed percentage of maximal heart rate, which is the method most commonly used to guide exercise intensity. A percentage range is calculated from the maximal heart rate (percent HRmax) reached at peak exercise during a symptom-limited exercise tolerance test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/29\">",
"     29",
"    </a>",
"    ]. Exercise intensity has been categorized using the percent HRmax as light (&lt;60 percent), moderate (60 to 79 percent), and heavy (80 percent).",
"   </p>",
"   <p>",
"    Energy expenditure is related to both intensity and duration. In general, lower intensity exercise should be performed for a longer duration. Symptom-limited patients may begin with discontinuous exercise and progress to 20 to 30 minutes of continuous exercise. The duration is increased before increasing the intensity. It is common for cardiac rehabilitation patients to rotate among a variety of dynamic exercise modalities: treadmill, bicycle, Schwinn Aerodyne, arm ergometer, rowing machine, etc. Energy expenditure and heart rate response are related to the intensity of the activity and the amount of muscle mass used to perform the activity.",
"   </p>",
"   <p>",
"    Beta blockers, which are administered to most patients after myocardial infarction, reduce the cardiac output response to exercise predominantly by limiting heart rate. Although resting heart rate, submaximal and maximal exercise heart rates are reduced by beta blockers, traditional heart rate methods may be used to prescribe exercise intensity based on the patient's maximal heart rate measured during an exercise test performed on medication.",
"   </p>",
"   <p>",
"    Symptom-limited exercise refers to a submaximal testing modality in which a patient's test is terminated at the onset of symptoms related to CHD, usually chest pain or shortness of breath (or leg fatigue if it is severe and occurs before the patient reaches age-predicted functional capacity). This heart rate level becomes the maximal heart rate, and the exercise training heart rate is a given.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of the heart rate maximum reserve (a percent of the difference between the maximal and resting heart rates). Table 6 shows an example of an exercise prescription using the HRmax reserve method in a 40 year-old individual (HRmax of 180), with a resting heart rate of 60 and a desired exercise intensity of 60 to 80 percent capacity (",
"      <a class=\"graphic graphic_table graphicRef50179 \" href=\"mobipreview.htm?31/25/32155\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Observation of the relationship between exercise heart rate and VO2 or metabolic equivalents (METs) (",
"      <a class=\"graphic graphic_figure graphicRef63482 \" href=\"mobipreview.htm?0/37/605\">",
"       figure 1",
"      </a>",
"      ). One MET is defined as 3.5 mL O2",
"      <span class=\"nowrap\">",
"       uptake/kg",
"      </span>",
"      per min, which is the resting oxygen uptake in a sitting position. These methods require the monitoring of heart rate or pulse-taking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rating of perceived exertion (Borg scale)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise intensity can also be prescribed using the rating of perceived exertion (RPE or Borg scale) (",
"    <a class=\"graphic graphic_table graphicRef70470 \" href=\"mobipreview.htm?20/13/20699\">",
"     table 6",
"    </a>",
"    ). This is a validated method that most patients can learn and apply easily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. On the category scale (6 to 20), an RPE of 12 to 13 (somewhat hard) corresponds to 60 percent VO2max and an RPE of 16 (hard-very hard) corresponds to 85 percent VO2max. An individual's subjective response during graded exercise testing is employed in specifying the RPE level for exercise training.",
"   </p>",
"   <p>",
"    The exercise intensity for healthy adults is usually 60 to 70 percent of functional capacity (using VO2max, maximal METs, or heart rate maximum reserve) or a 12 to 13 level of the RPE scale (",
"    <a class=\"graphic graphic_table graphicRef70470 \" href=\"mobipreview.htm?20/13/20699\">",
"     table 6",
"    </a>",
"    ). The incremental benefit of very high intensity exercise (&gt;90 percent of HRmax) is small and is not recommended because it leads to lactate accumulation and fatigue, and increases the risk of physical injury and cardiovascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/10,29\">",
"     10,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with a low-baseline fitness level, which is often the case with cardiac patients, should begin at a lower percentage of capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with stable angina may have an exercise prescription based upon 60 to 70 percent of the heart rate at which ischemic ST segment changes or anginal symptoms appear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exercise progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important element of the exercise prescription is the progression of exercise through stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise programs should begin at the light intensity level, then gradually progress over a four to six week period to a moderate intensity level. This period is referred to as the conditioning or training stage.",
"     </li>",
"     <li>",
"      During the subsequent four to five months or improvement stage, exercise intensity can be further increased to the upper range of moderate intensity as training effects occur. These include a reduction in resting or submaximal exercise heart rate and increased ease with which a submaximal work load is performed",
"     </li>",
"     <li>",
"      Finally, during the long-term maintenance stage, the objective is to maintain compliance with the exercise regimen without any further significant changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Supervision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The last important consideration when prescribing an exercise regimen in a cardiac rehabilitation program is the level of supervision required:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients at moderate or high risk of cardiac complications from exercise (Class C) should participate in a medically supervised program with ECG monitoring and personnel and equipment suitable for advanced cardiac life support. This level of medical supervision should be continued for 8 to 12 weeks until the safety of the prescribed exercise regimen has been established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low-risk patients (class B) may initially benefit from medically supervised ECG monitored exercise (6 to 12 sessions), which helps to reassure the patient about the safety of the program. Self-monitored, home-based exercise programs also have been shown to be effective and safe in these patients, and result in better rates of adherence when compared to group-based programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. Patients may exercise without supervision when they understand how to monitor activity levels. They are taught to guide exercise intensity by heart rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RPE. Low level isometric (resistance) activities may be prescribed for low-risk patients to increase muscular strength.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Resistance training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cardiac rehabilitation programs incorporate resistance training along with aerobic exercise training. The primary goals are to increase muscle strength, endurance, and mass, thereby enhancing a patient's ability to perform household and vocational tasks.",
"   </p>",
"   <p>",
"    Resistance exercises are referenced to the individual's measured or estimated maximal strength or the \"1-repetition maximum,\" the maximal weight a patient can lift once. A general recommendation for resistance training in cardiac patients includes 30 to 40 percent of the 1-repetition maximum for upper body exercises and 40 to 50 percent of the 1-repetition maximum for lower body exercises; there are 12 to 15 repetitions per set, performed two to three times weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lifestyle activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A changing paradigm in the exercise prescription seeks to assist patients in achieving significant health benefits from regular activity which are related to the degree of both exercise and fitness (",
"    <a class=\"graphic graphic_figure graphicRef60770 \" href=\"mobipreview.htm?8/13/8414\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"mobipreview.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have shown that only moderate-intensity exercise is required for cardiovascular health benefits, not the higher intensities that might be necessary for substantial gains in aerobic fitness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Exercise may also be performed for short periods several times a day and integrated into the course of one's daily life.",
"   </p>",
"   <p>",
"    When lifestyle activity was compared with structured exercise in a randomized trial of 235 healthy, but sedentary, men and women, both groups had a similar increase in energy expenditure over baseline at six months (1.53 versus 1.34",
"    <span class=\"nowrap\">",
"     kcal/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/40\">",
"     40",
"    </a>",
"    ]. Although both groups had an increase in fitness compared to baseline, the increase was significantly greater in the structured exercise group (3.64 versus 1.58",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min in the lifestyle group). Both groups had significant reductions in total cholesterol, total",
"    <span class=\"nowrap\">",
"     cholesterol/HDL",
"    </span>",
"    cholesterol ratio, diastolic blood pressure, and percentage of body fat, and there were no significant differences in outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/41\">",
"     41",
"    </a>",
"    ]. These results were maintained for up to 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since lifestyle activity is as effective as a structured exercise program for increasing energy expenditure and reducing cardiovascular risk, patients may be advised to accumulate at least 30 minutes of moderately intense physical activity on most, preferably all, days of the week. Examples of lifestyle activity are brisk walking at a speed of 3 to 4 miles (4.8 to 6.4 km) per hour (equivalent to 3 to 6 METs), active yard work, walking up stairs, dancing, and active play with children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/30,43,44\">",
"     30,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SPECIAL GROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heart failure patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the available data, cardiac rehabilitation should be offered to patients with stable class II to class III HF who do not have advanced arrhythmias and who do not have other limitations to exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations are in general agreement with those published in 2009 focused update of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines, which gave exercise training a class I recommendation to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced left ventricular ejection fraction (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The beneficial effects of exercise may be seen with high or low levels of training, and are apparent as early as three weeks after training. There are insufficient data at present to recommend cardiac rehabilitation for patients with class IV HF.",
"   </p>",
"   <p>",
"    Recommendations for the intensity and duration of exercise in patients with HF differ slightly from those discussed above (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Exercise prescription'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A longer warm-up period may be necessary in patients with HF to increase skeletal muscle vasodilation prior to reaching the desired training intensity.",
"     </li>",
"     <li>",
"      Exercise training should begin at 40 to 60 percent VO2max for intervals of two to six minutes separated by one to two minutes of rest.",
"     </li>",
"     <li>",
"      The length of the exercise interval is gradually increased by one to two minutes until the patient tolerates 30 minutes of continuous exercise.",
"     </li>",
"     <li>",
"      Patients should exercise in 15 to 30 minute sessions three to five times per week. They should be instructed to notify their physicians immediately if they develop worsening HF with exercise.",
"     </li>",
"     <li>",
"      Repetitive lifting of greater than a few pounds should be avoided in patients with HF due to the potential deleterious effects of isometric exercise on ventricular size and function.",
"     </li>",
"     <li>",
"      The rating of perceived exertion (RPE, Borg scale) should be maintained at 10 to 13 (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 3",
"      </a>",
"      ). Use of the RPE as a measure of intensity is important since the heart rate response is often impaired in heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If guided by the large randomized HF-ACTION trial, a goal exercise intensity of 70 percent of heart rate reserve, for 30 minutes three days a week for six to eight weeks is a reasonable prescription [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, one small randomized trial found that a high-intensity aerobic interval approach provided greater hemodynamic benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/47\">",
"       47",
"      </a>",
"      ]. The exercise program consisted of a 10-minute warm-up period at 50 to 60 percent of VO2max followed by four 4-minute intervals at 90 to 95 percent peak heart rate (RPE 17&plusmn;1), with intervals separated by three minute periods of walking at 50 to 70 percent of peak heart rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercise may consist of walking on a treadmill or track, stationary bicycle, or arm ergometry. The intensity of exercise should be increased every one to two weeks to achieve the same RPE. This can be accomplished by an increase in exercise duration or speed of",
"    <span class=\"nowrap\">",
"     walking/ergometer",
"    </span>",
"    resistance.",
"   </p>",
"   <p>",
"    For patients who do not have access to cardiac rehabilitation programs, walking at a moderate pace should be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiac transplantation patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular response to exercise is influenced by the loss of autonomic control of heart rate after cardiac transplantation. As a result, the rating of perceived exertion (RPE) must be used to regulate intensity, which is initially set at 60 to 70 percent of VO2max. A longer warm-up and cool-down period is important because the physiologic responses to exercise and recovery take longer than in patients with intact cardiac innervation. Intensity and duration are increased as tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CORONARY RISK FACTOR MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to regular exercise training, cardiac rehabilitation programs typically address the traditional modifiable risk factors or smoking, hypertension, diabetes and lipid abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term success of any of the risk-factor reducing interventions depends largely upon patient compliance. As an example, compliance with exercise, diet, and smoking cessation should be assessed regularly by the rehabilitation nurses and physical therapists. When poor compliance is suspected, the cause should be identified and alternatives should be provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nutritional counseling and weight management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional counseling is aimed at achieving weight loss or weight control and an improved lipid profile (",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"mobipreview.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    ). It is best offered by a registered dietitian who can spend enough time with the patient to discuss dietary habits, food choices, and how to implement an individualized dietary plan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .) Sodium restriction and diabetic control may also be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cessation of smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective smoking cessation is difficult to achieve because of the strong psychologic and physiologic dependence that occurs (",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"mobipreview.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    ). Some approaches that may be helpful for the smoker to quit and avoid relapse include patient education about the risks of continued smoking, referral to smoking cessation group programs, nicotine patch therapy or Nicorette gum or other pharmacotherapy, self-help literature, and encouragement by the primary care providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/11,48\">",
"     11,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diabetes management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac rehabilitation program and the long term maintenance of interventions learned and reinforced in these programs can have a major beneficial impact on the long term control of blood sugar and HbA1c levels in patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Management of hypertension and hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic management of hypertension and dyslipidemia are usually instituted in parallel by the physician. In the absence of a contraindication, all patients are treated with a statin both for lipid-lowering and the likely pleiotropic effects of these drugs (",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"mobipreview.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Comprehensive risk factor intervention programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recent years there has been an increasing effort within cardiac rehabilitation programs to formally manage the traditional risk factors of hypertension, smoking, diabetes and lipid abnormalities using interventions such as those described above in addition to exercise. The EUROACTION trial evaluated one such program and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link&amp;anchor=H8#H8\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\", section on 'Comprehensive risk factor intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third major component of a cardiac rehabilitation program is the identification and management of the variety of psychosocial and vocational problems that arise as a consequence of a cardiac event (",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"mobipreview.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/48\">",
"     48",
"    </a>",
"    ]. Depression, anxiety, and denial are common in patients following myocardial infarction, occurring in up to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/49\">",
"     49",
"    </a>",
"    ]. Depression is associated with lower exercise capacity, less energy, more fatigue, and a reduced quality of life and sense of well being. Women, and in particular younger women, are at increased risk for depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These symptoms often translate into problems within the family, marriage, and the workplace and may lead to low rates of return to work, job loss, or disability. Individual or group psychotherapy and sometimes pharmacotherapy can be beneficial. Trained personnel including psychologists, psychiatrists and social workers should be available within the rehabilitation program or on a referral basis to best manage these issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115151381\">",
"    <span class=\"h1\">",
"     MEDICAL DIRECTOR RESPONSIBILITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An update of the responsibilities of medical director of cardiac",
"    <span class=\"nowrap\">",
"     rehabilitation/secondary",
"    </span>",
"    prevention programs, issued in a 2012 joint statement from the American Association for Cardiovascular and Pulmonary Rehabilitation and the American Heart Association, reflects changes in federal legislation and regulations and changes in health care delivery and medical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ALTERNATIVE APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate approaches to the delivery of cardiac rehabilitation, other than traditional supervised group interventions, appear safe and effective for stable coronary patients, including those after MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/52\">",
"     52",
"    </a>",
"    ]. Transtelephonic and other means of monitoring and surveillance can extend cardiac rehabilitation beyond the setting of supervised, structured, and group-based rehabilitation.",
"   </p>",
"   <p>",
"    In a Cochrane systematic review and meta-analysis of 12 trials with 1938 participants, home based and traditional group cardiac rehabilitation were equally effective in improving outcomes of mortality, cardiac events, exercise capacity, or modification of risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 American Heart Association statement on exercise, cardiac rehabilitation, and prevention presents models that include home-based programs for which a nurse serves as a case manager to supervise and monitor patient care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/6\">",
"     6",
"    </a>",
"    ]. The following two studies have evaluated this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The participation rate in one study of medically directed home exercise was 72 percent at six months and 41 percent at four years, a rate comparable to that of supervised exercise regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Over 500 low- to moderate-risk patients in the United Kingdom, following either myocardial infarction or revascularization with either CABG or PCI, were randomly assigned to either home or center based (predominantly hospital) comprehensive rehabilitation programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/16\">",
"       16",
"      </a>",
"      ]. After one year there were no significant differences between the programs in outcomes of blood pressure, smoking cessation rates, total or high-density lipoprotein cholesterol levels, psychological status (using measures of depression and anxiety) or exercise capacity.",
"     </li>",
"     <li>",
"      In as study of self-reported outcomes in 280 patients referred to a three-month, home-based cardiac rehabilitation, physical activity increased from 89 to 191 minutes per week following cardiac rehabilitation. The increase was significantly larger for males, patients without the metabolic syndrome, and patients who did not meet the baseline physical activity guideline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other alternatives include community-based group programs with guidance by nurses or other nonphysician healthcare providers, and electronic media programs for home-based comprehensive risk modification, education, and instruction, as well as for guidance of a structured exercise regimen.",
"   </p>",
"   <p>",
"    A Presidential Advisory from the American Heart Association addresses the referral, enrollment, and delivery of",
"    <span class=\"nowrap\">",
"     rehabilitation/secondary",
"    </span>",
"    prevention programs at clinical centers and beyond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31417/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term assessment of the effectiveness of these approaches and the optimal mode of their delivery remain unknown. The attractiveness of these models is the potential to provide cardiac rehabilitation to low- and moderate-risk coronary patients, who comprise the majority of contemporary postinfarction patients, most of whom do not participate in structured, supervised cardiac rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/6/37987?source=see_link\">",
"       \"Patient information: Heart attack recovery (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21156?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=see_link\">",
"       \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27508593\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac rehabilitation&nbsp;improves outcomes, including a significant reduction in all-cause and&nbsp;cardiac mortality, in many patients with cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link\">",
"       \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multifactorial rehabilitation programs consist of a baseline patient assessment, nutritional counseling and weight management, aggressive coronary risk-factor management, psychosocial management, physical activity counseling, and exercise training. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Comprehensive risk factor intervention programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current indications for cardiac rehabilitation include: Acute myocardial infarction within the preceding 12 months; CABG;&nbsp;stable angina pectoris;&nbsp;heart valve",
"      <span class=\"nowrap\">",
"       repair/replacement;",
"      </span>",
"      percutaneous coronary intervention (PCI) with or without stenting; and heart or heart-lung transplant. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternate approaches to traditional supervised group interventions appear safe and effective for stable coronary patients. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Alternative approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/1\">",
"      Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/2\">",
"      Squires RW, Gau GT, Miller TD, et al. Cardiovascular rehabilitation: status, 1990. Mayo Clin Proc 1990; 65:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/3\">",
"      Fletcher BJ, Thiel J, Fletcher GF. Phase II intensive monitored cardiac rehabilitation for coronary artery disease and coronary risk factors--a six-session protocol. Am J Cardiol 1986; 57:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/4\">",
"      Fletcher BJ, Lloyd A, Fletcher GF. Outpatient rehabilitative training in patients with cardiovascular disease: emphasis on training method. Heart Lung 1988; 17:199.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of Cardiovascular and Pulmonary Rehabilitation. Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs, 4th ed, Human Kinetics, Champaign 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/6\">",
"      Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005; 111:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/7\">",
"      Wenger NK. Current status of cardiac rehabilitation. J Am Coll Cardiol 2008; 51:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/8\">",
"      Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists, Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/9\">",
"      Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2007; 115:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/10\">",
"      Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/11\">",
"      Cardiac rehabilitation programs. A statement for healthcare professionals from the American Heart Association. Circulation 1994; 90:1602.",
"     </a>",
"    </li>",
"    <li>",
"     www.cms.hhs.gov/mcd/viewdecisionmemo (Accessed on August 21, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/13\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Medicare and Medicaid Services. Decision memo for cardiac rehabilitation programs (CAG-08889R). Available at file://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=164 (Accessed October 8, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/15\">",
"      Kwan G, Balady GJ. Cardiac rehabilitation 2012: advancing the field through emerging science. Circulation 2012; 125:e369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/16\">",
"      Jolly K, Lip GY, Taylor RS, et al. The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. Heart 2009; 95:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/17\">",
"      Blackburn GG, Foody JM, Sprecher DL, et al. Cardiac rehabilitation participation patterns in a large, tertiary care center: evidence for selection bias. J Cardiopulm Rehabil 2000; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/18\">",
"      Mazzini MJ, Stevens GR, Whalen D, et al. Effect of an American Heart Association Get With the Guidelines program-based clinical pathway on referral and enrollment into cardiac rehabilitation after acute myocardial infarction. Am J Cardiol 2008; 101:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/19\">",
"      Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001; 345:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/20\">",
"      Arena R, Williams M, Forman DE, et al. Increasing referral and participation rates to outpatient cardiac rehabilitation: the valuable role of healthcare professionals in the inpatient and home health settings: a science advisory from the American Heart Association. Circulation 2012; 125:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/21\">",
"      Zullo MD, Jackson LW, Whalen CC, Dolansky MA. Evaluation of the recommended core components of cardiac rehabilitation practice: an opportunity for quality improvement. J Cardiopulm Rehabil Prev 2012; 32:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/22\">",
"      Russell KL, Holloway TM, Brum M, et al. Cardiac rehabilitation wait times: effect on enrollment. J Cardiopulm Rehabil Prev 2011; 31:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/23\">",
"      Soga Y, Yokoi H, Ando K, et al. Safety of early exercise training after elective coronary stenting in patients with stable coronary artery disease. Eur J Cardiovasc Prev Rehabil 2010; 17:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/24\">",
"      Pack QR, Mansour M, Barboza JS, et al. An early appointment to outpatient cardiac rehabilitation at hospital discharge improves attendance at orientation: a randomized, single-blind, controlled trial. Circulation 2013; 127:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/25\">",
"      Richardson LA, Buckenmeyer PJ, Bauman BD, et al. Contemporary cardiac rehabilitation: patient characteristics and temporal trends over the past decade. J Cardiopulm Rehabil 2000; 20:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/26\">",
"      Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/27\">",
"      Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007; 115:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/28\">",
"      Thompson PD. Exercise prescription and proscription for patients with coronary artery disease. Circulation 2005; 112:2354.",
"     </a>",
"    </li>",
"    <li>",
"     Kenney WL, Humphrey RH, Bryant CX, et al. American College of Sports Medicine Guidelines for Exercise Testing and Prescription, 5th ed, Williams &amp; Wilkins, Baltimore 1995.",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/31\">",
"      Dimsdale JE, Hartley LH, Guiney T, et al. Postexercise peril. Plasma catecholamines and exercise. JAMA 1984; 251:630.",
"     </a>",
"    </li>",
"    <li>",
"     Borg, G. Physical performance and perceived exertion. Gleerup, Lund, Sweden 1962.",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Perceived exertion (Borg rating of perceived exertion scale). file://www.cdc.gov/nccdphp/dnpa/physical/measuring/perceived_exertion.htm (accessed November 19, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/34\">",
"      Miller NH, Haskell WL, Berra K, DeBusk RF. Home versus group exercise training for increasing functional capacity after myocardial infarction. Circulation 1984; 70:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/35\">",
"      DeBusk RF, Haskell WL, Miller NH, et al. Medically directed at-home rehabilitation soon after clinically uncomplicated acute myocardial infarction: a new model for patient care. Am J Cardiol 1985; 55:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/36\">",
"      Ades PA, Pashkow FJ, Fletcher G, et al. A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitoring. Am Heart J 2000; 139:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/37\">",
"      Applegate WB, Miller ST, Elam JT, et al. Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension. Arch Intern Med 1992; 152:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/38\">",
"      Hagberg JM, Montain SJ, Martin WH 3rd, Ehsani AA. Effect of exercise training in 60- to 69-year-old persons with essential hypertension. Am J Cardiol 1989; 64:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/39\">",
"      King AC, Haskell WL, Young DR, et al. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995; 91:2596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/40\">",
"      Dunn AL, Garcia ME, Marcus BH, et al. Six-month physical activity and fitness changes in Project Active, a randomized trial. Med Sci Sports Exerc 1998; 30:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/41\">",
"      Dunn AL, Marcus BH, Kampert JB, et al. Reduction in cardiovascular disease risk factors: 6-month results from Project Active. Prev Med 1997; 26:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/42\">",
"      Dunn AL, Marcus BH, Kampert JB, et al. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA 1999; 281:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/43\">",
"      Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/44\">",
"      AHA, ACC, National Heart, Lung, and Blood Institute, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/45\">",
"      Georgiou D, Chen Y, Appadoo S, et al. Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. Am J Cardiol 2001; 87:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/46\">",
"      O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/47\">",
"      Wisl&oslash;ff U, St&oslash;ylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 2007; 115:3086.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger NK, Hellerstein HK. Rehabilitation of the Coronary Patient, 3rd ed, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/49\">",
"      Milani RV, Lavie CJ, Cassidy MM. Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events. Am Heart J 1996; 132:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/50\">",
"      Mallik S, Spertus JA, Reid KJ, et al. Depressive symptoms after acute myocardial infarction: evidence for highest rates in younger women. Arch Intern Med 2006; 166:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/51\">",
"      King M, Bittner V, Josephson R, et al. Medical director responsibilities for outpatient cardiac rehabilitation/secondary prevention programs: 2012 update: a statement for health care professionals from the American Association of Cardiovascular and Pulmonary Rehabilitation and the American Heart Association. Circulation 2012; 126:2535.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger, NK, Froelicher, ES, Smith, LK, et al. Cardiac Rehabilitation. Clinical Practice Guideline No. 17, Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, and the National Heart, Lung, and Blood Institute, AHCPR Publication No. 96-0672, October 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/53\">",
"      Dalal HM, Zawada A, Jolly K, et al. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ 2010; 340:b5631.",
"     </a>",
"    </li>",
"    <li>",
"     Burke LE. Adherence to a heart-healthy lifestyle &ndash; what makes the difference?. In: Cardiac Rehabilitation. A Guide to Practice in the 21st Century, Wenger NK, Smith LK, Froelicher ES, et al (Eds), Marcel Dekker, New York 1999. p.385.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/55\">",
"      Blanchard CM, Reid RD, Morrin LI, et al. Demographic and clinical determinants of moderate to vigorous physical activity during home-based cardiac rehabilitation: the home-based determinants of exercise (HOME) study. J Cardiopulm Rehabil Prev 2010; 30:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31417/abstract/56\">",
"      Balady GJ, Ades PA, Bittner VA, et al. Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation 2011; 124:2951.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1477 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31417=[""].join("\n");
var outline_f30_43_31417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27508593\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H870866319\">",
"      TIMING OF FIRST VISIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK STRATIFICATION FOR EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXERCISE PRESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Content and duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intensity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rating of perceived exertion (Borg scale)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exercise progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Supervision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Resistance training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lifestyle activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SPECIAL GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiac transplantation patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CORONARY RISK FACTOR MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nutritional counseling and weight management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cessation of smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diabetes management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Management of hypertension and hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Comprehensive risk factor intervention programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PSYCHOSOCIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115151381\">",
"      MEDICAL DIRECTOR RESPONSIBILITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ALTERNATIVE APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27508593\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1477|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/37/605\" title=\"figure 1\">",
"      Heart rate and VO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/13/8414\" title=\"figure 2\">",
"      Graded benefit of fitness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/21/9566\" title=\"table 1A\">",
"      Core components rehab A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/3/57\" title=\"table 1B\">",
"      Core components rehab B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/22/30059\" title=\"table 2A\">",
"      Risk classific exercise class A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/34/40492\" title=\"table 2B\">",
"      Risk classific exercise class B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/38/38508\" title=\"table 2C\">",
"      Risk classific exercise class C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/41/31387\" title=\"table 2D\">",
"      Risk classific exercise class D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/11/16572\" title=\"table 2E\">",
"      Contraindications to exercise treadmill testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 3\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/13/34012\" title=\"table 4\">",
"      Exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/25/32155\" title=\"table 5\">",
"      Heart rate maximum reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/13/20699\" title=\"table 6\">",
"      Rating of perceived exertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/1/40989\" title=\"table 7\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=related_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3687?source=related_link\">",
"      Exercise assessment and measurement of exercise capacity in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=related_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/6/37987?source=related_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21156?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_43_31418="Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma";
var content_f30_43_31418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31418/contributors\">",
"     Christopher W Ryan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31418/contributors\">",
"     Janelle Meyer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31418/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31418/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/43/31418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/43/31418/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/43/31418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12227065\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas are a rare and heterogeneous group of malignant tumors of mesenchymal origin that comprise approximately 1 percent of all adult malignancies and 12 percent of pediatric cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Approximately 80 percent of sarcomas originate from soft tissue and the rest from bone. There are about 11,410 new cases of soft tissue sarcoma diagnosed each year in the United States, with 4400 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathologic spectrum of sarcomas is broad, presumably because the embryonic mesenchymal cells from which they arise have the capacity to mature into striated skeletal and smooth muscle, adipose and fibrous tissue, bone, and cartilage. Although ectodermal in origin, malignant tumors affecting peripheral nerves are included because of similarities in their clinical behavior, management, and outcome.",
"   </p>",
"   <p>",
"    This topic review will cover the clinical presentation, diagnostic evaluation, and staging of soft tissue sarcoma other than gastrointestinal stromal tumor (GIST), the most common sarcoma, discussed in detail elsewhere. Issues specific to soft tissue sarcomas arising in the head and neck, retroperitoneum, and in the breast are discussed elsewhere, as are bone sarcomas and Kaposi&rsquo;s sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"     \"Head and neck sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=see_link\">",
"     \"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227072\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As classified by the World Health Organization (WHO), the group of soft tissue sarcomas includes more than 50 different histologic subtypes (",
"    <a class=\"graphic graphic_table graphicRef78933 graphicRef59405 graphicRef68105 \" href=\"mobipreview.htm?9/38/9839\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2\">",
"     2",
"    </a>",
"    ]. The most common subtypes that arise in adults are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef60983 \" href=\"mobipreview.htm?14/7/14459\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The WHO classifies most soft tissue sarcomas according to the presumptive tissue of origin (ie, the normal tissues the tumor most closely resembles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2\">",
"     2",
"    </a>",
"    ]. Examples include liposarcoma, synovial sarcoma, leiomyosarcoma (LMS), rhabdomyosarcoma (RMS), fibrosarcoma, and angiosarcoma. In some cases, histogenesis is uncertain and the designation reflects the morphologic appearance of the cells or the architectural pattern (eg, alveolar sarcoma of soft parts, epithelioid sarcoma, clear cell sarcoma, Ewing sarcoma).",
"   </p>",
"   <p>",
"    Histologically, the diagnosis of a soft tissue sarcoma is made on the basis of morphologic pattern. Immunohistochemical staining (IHC) often aids in the identification of the presumptive tissue of origin. Some of immunohistochemical markers are more characteristic than others, and it is the spectrum of markers examined that determines the histological subtype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desmin is particularly valuable in the identification of myogenic differentiation: rhabdomyosarcoma and, to a lesser degree, leiomyosarcoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link&amp;anchor=H6#H6\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\", section on 'Tissue diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of S100 antigen and neurofilaments suggest cells arising from neural sheath.",
"     </li>",
"     <li>",
"      Cytokeratin can help distinguish between synovial sarcoma or epithelioid sarcoma (which both contain cytokeratin) and fibrosarcomas (which do not).",
"     </li>",
"     <li>",
"      Factor VIII related antigen identifies tumors of endothelial origin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of histologic subtypes are associated with specific chromosomal translocations (",
"    <a class=\"graphic graphic_table graphicRef64666 \" href=\"mobipreview.htm?23/27/23997\">",
"     table 3",
"    </a>",
"    ), and molecular techniques such as fluorescence in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR) to detect the protein products of these fusion genes can aid in the diagnosis of these tumors. In general, the decision of whether to do genetic testing on a specimen is usually made by the pathologist and largely based upon the morphology and clinical picture. &nbsp;Routine cytogenetics on fresh sarcoma specimens have largely been supplanted by FISH probes that can be performed on paraffin-embedded material. FISH testing can be definitive in ruling-in a specific sarcoma subtype in certain cases when the differential diagnosis has been narrowed but histology and IHC staining remain equivocal (eg, synovial sarcoma). However, when a translocation-associated tumor is highly suspected based upon the clinical presentation (eg, Ewing sarcoma), it is reasonable to send fresh tissue for cytogenetic analysis at the time of biopsy in consultation with the pathologist. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Chromosomal translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After GIST, the most common soft tissue sarcoma subtypes in adults are pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor (MPNST) (",
"    <a class=\"graphic graphic_table graphicRef60983 \" href=\"mobipreview.htm?14/7/14459\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Undifferentiated pleomorphic sarcoma",
"      </strong>",
"      <strong>",
"       (UPS)",
"      </strong>",
"      &ndash; This subgroup was formerly included in a broad category of malignant fibrous histiocytoma (MFH), which was the most common subtype of soft tissue sarcoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. However, many sarcomas that were previously identified as MFH are reclassified by many pathologists as other subtypes when reanalyzed using histology and IHC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/7\">",
"       7",
"      </a>",
"      ]. The term UPS is now reserved specifically for sarcomas that lack specific lines of differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2\">",
"       2",
"      </a>",
"      ], although some pathologists use the term sarcoma, not otherwise specified (NOS) for at least a portion of these sarcomas. One version of what was formerly termed myxoid MFH is now classified as a distinct sarcoma subtype, myxofibrosarcoma. In comparison with UPS, myxofibrosarcomas may be associated with a greater local recurrence risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Liposarcoma",
"      </strong>",
"      &ndash; Liposarcomas appear to arise from precursors of adipocytes (fat cells) and are most commonly found in the extremities and retroperitoneum. The three main morphologic subgroups are",
"      <span class=\"nowrap\">",
"       well-differentiated/dedifferentiated,",
"      </span>",
"      <span class=\"nowrap\">",
"       myxoid/round",
"      </span>",
"      cell, and pleomorphic liposarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2,11\">",
"       2,11",
"      </a>",
"      ]. There is a great range of biologic behavior amongst these subtypes, spanning from well-differentiated liposarcomas with low metastatic potential to the high-risk round cell or pleomorphic types, which are associated with a high rate of distant metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some well differentiated liposarcomas are referred to as &ldquo;atypical lipomas&rdquo; by some pathologists, a confusing name that underestimates the risk of local recurrence of such tumors. The metastatic pattern of the various subtypes of liposarcomas is also unique, with metastases to other sites of fat",
"      <span class=\"nowrap\">",
"       (myxoid/round",
"      </span>",
"      cell liposarcoma, dedifferentiated liposarcoma) more common than metastases to liver or lung (as may occur for pleomorphic liposarcomas or UPS) (see",
"      <a class=\"local\" href=\"#H12227114\">",
"       'Pattern of recurrence'",
"      </a>",
"      below).",
"      <br/>",
"      <br/>",
"      Myxoid and round cell liposarcomas share the same reciprocal translocation t(12;16)(q13;p11), in which the CHOP gene (also called DNA damage inducible transcript 3 [DDIT3] gene, or GADD153) is inserted adjacent to a novel gene called FUS or TLS (Translocated in LipoSarcoma). While no specific chromosomal translocations have been identified in well",
"      <span class=\"nowrap\">",
"       differentiated/dedifferentiated",
"      </span>",
"      liposarcomas, amplification of MDM2 and CDK4 is very frequent in these subtypes, and their identification may be useful diagnostically. Furthermore, overexpression of MDM2 and CDK4 is also being exploited for therapeutic gain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/11,13\">",
"       11,13",
"      </a>",
"      ]. Pleomorphic liposarcomas genetically most closely resemble UPS.(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link&amp;anchor=H18#H18\">",
"       \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Myxoid and round cell liposarcomas'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Somatic gene mutations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Leiomyosarcoma",
"      </strong>",
"      &ndash; Leiomyosarcomas, which are characterized by smooth muscle differentiation, can be found throughout the body including the retroperitoneum, any location where there is a vein, and the uterus. Leiomyosarcomas that originate in the uterus may be a distinct subgroup of tumors as they have different gene expression patterns when compared to non-uterine leiomyosarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/14\">",
"       14",
"      </a>",
"      ]. Uterine leiomyosarcomas are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2408?source=see_link&amp;anchor=H8#H8\">",
"       \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Leiomyosarcoma'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Unlike superficial and deep tumors, cutaneous leiomyosarcomas typically have a more indolent course and are less likely to metastasize [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Synovial sarcoma",
"      </strong>",
"      &ndash; Synovial sarcoma initially derived its name from a histologic resemblance to synovial cells, but its cell of origin is unknown. There are two morphologic subtypes, monophasic and biphasic. The most common presentation is a soft tissue tumor of the extremities in young adults.",
"      <br/>",
"      <br/>",
"      The majority of synovial sarcomas are characterized by the chromosomal translocation t(X;18)(p11;q11). The breakpoint of this translocation fuses the SYT gene from chromosome 18 to one of three homologous genes, SSX1, SSX2, and SSX4 on the X chromosome. SYT-SSX1 is associated with biphasic tumors (glandular epithelial differentiation on a background of spindle tumor cells), while SYT-SSX2 is associated with monophasic tumors that lack glandular epithelial differentiation.",
"      <br/>",
"      <br/>",
"      Cytogenetic analysis, FISH, or RT-PCR can be used to detect the translocation or the protein product of the fusion gene, thus aiding in the diagnosis of synovial sarcoma. The specific SYT-SSX fusion type may have prognostic importance, with better outcomes reported for patients with the SYT-SSX2 fusion in many, but not all reports. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link&amp;anchor=H19#H19\">",
"       \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Synovial sarcoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Malignant peripheral nerve sheath tumor (MPNST)",
"      </strong>",
"      &ndash; MPNSTs are of ectodermal origin and originate from peripheral nerves. Approximately 50 percent of these tumors occur in patients with neurofibromatosis type I and result from degeneration of plexiform neurofibromas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23946?source=see_link&amp;anchor=H30353503#H30353503\">",
"       \"Peripheral nerve tumors\", section on 'Malignant peripheral nerve sheath tumors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Neurofibromatosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      MPNSTs are commonly found in the trunk, extremities, and head and neck. The diagnosis of an MPNST can be difficult due to variable histomorphology. There are no characteristic chromosomal translocations. The presence of S-100 protein can aid in the diagnosis, but it is not uniformly expressed in these tumors, since the line of differentiation appears to be lost to some degree in many.",
"     </li>",
"     <li>",
"      <strong>",
"       Desmoplastic small round cell tumor (DSRCT) &ndash;",
"      </strong>",
"      DSRCT is an uncommon tumor that most typically presents with multifocal abdominal masses in a male aged 15 to 35 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/16\">",
"       16",
"      </a>",
"      ]. The small round blue tumor cells represent a minority of the tumor with a prominent background of vigorous reactive fibrosis. The tumors cells contain a characteristic translocation t(11;22) EWSR1-WT1, which differentiates them from Ewing sarcoma and other small round blue cell tumors (",
"      <a class=\"graphic graphic_table graphicRef64666 \" href=\"mobipreview.htm?23/27/23997\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link&amp;anchor=H16#H16\">",
"       \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Chromosomal translocations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      These tumors are generally treated similarly to the Ewing sarcoma family of tumors. Debulking surgery is usually undertaken, although the multiple masses that are typical for patients at initial diagnosis are associated with a very poor survival. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"       \"Treatment of the Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Angiosarcoma",
"      </strong>",
"      &ndash; Angiosarcomas are uncommon tumors that arise in subcutaneous tissue of many sites of the body, typically head and neck, or breast. It is one of the most common tumors caused by therapeutic radiation, often after treatment of breast cancer of Hodgkin lymphoma, with a median time of development of 8 to 10 years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=see_link&amp;anchor=H30564621#H30564621\">",
"       \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Ionizing radiation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link&amp;anchor=H24#H24\">",
"       \"Head and neck sarcomas\", section on 'Angiosarcoma'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In immunohistochemistry, the tumor cells stain positive for vascular markers such as CD31 and factor VIII. Mutations in the vascular endothelial growth factor receptor-2 (VEGFR2, also called",
"      <span class=\"nowrap\">",
"       Flk1/KDR)",
"      </span>",
"      are seen in a subset of these patients, with unclear clinical implications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of angiogenesis inhibitors\", section on 'VEGF receptors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Solitary fibrous tumor (SFT)",
"      </strong>",
"      &ndash; SFTs are slow growing tumors that arise most commonly in the pleura, pelvis or dura, where they can reach a very large size before detection due to their slow change over time. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\", section on 'Solitary fibrous tumors'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      While many SFTs are classified as benign tumors with a very low risk of metastasis, others are classified as malignant because of the finding of hypercellularity, at least focal cytologic atypia, tumor necrosis, numerous mitoses,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      infiltrative borders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/17\">",
"       17",
"      </a>",
"      ]. These lesions have a greater ability to metastasize, usually at an interval of several years, most commonly to bone, liver, and lung. Tumors cells stain positive for stem cell marker CD34.",
"      <br/>",
"      <br/>",
"      Rare patients will present with hypoglycemia, on the basis of overexpression of a form of insulin-like growth factor II (IGF-II). This finding resolves with resection of the tumor.",
"     </li>",
"     <li>",
"      <strong>",
"       Desmoid",
"       <span class=\"nowrap\">",
"        tumor/deep",
"       </span>",
"       fibromatosis",
"      </strong>",
"      &ndash; Desmoid tumors, also referred to as aggressive or deep fibromatosis, are not sarcomas but they represent neoplasms of fibroblastic tissue that lack the ability to metastasize. However, desmoid tumors have a propensity for local recurrence, even after complete resection, and they have the capacity to cause local morbidity and death in rare cases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"       \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Desmoid tumors typically arise in the extremity in sporadic cases or in the abdominal wall in association with pregnancy (where they usually improve post-partum) and arise in the mesenteric root in the setting of familial adenomatous polyposis (FAP). FAP is characterized by loss of expression of the gene APC. The development of desmoid tumor in the setting of FAP is a characteristic of Gardner syndrome, a specific version of FAP. Mesenteric desmoids are those with the highest degree of mortality.",
"      <br/>",
"      <br/>",
"      Beta-catenin (CTNNB1) gene mutations are found in most sporadic desmoids, although some instead have loss of the APC gene. The specific type of CTNNB1 mutation may predict for risk of recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among children, who account for 10 to 15 percent of all cases of soft tissue sarcoma, the &ldquo;small round blue cell&rdquo; sarcomas predominate (eg, Ewing sarcoma, embryonal RMS, and peripheral primitive neuroectodermal tumor [PNET]). Central (supratentorial) PNET tumors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to differentiate between the various subtypes of sarcoma for both prognosis and potential differences in treatment. This is especially true for typical pediatric tumors that arise in adults, such as rhabdomyosarcoma (RMS). RMS is generally much more susceptible to chemotherapy and carries a better prognosis than do other typical adult soft tissue sarcomas. Nevertheless, the pleomorphic (anaplastic) subtype of RMS, which has a relatively poor prognosis compared to other RMS subtypes, predominates in adults, and outcomes are worse than in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link&amp;anchor=H9#H9\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\", section on 'Histologic classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7800294\">",
"    <span class=\"h2\">",
"     Histologic grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several grading systems have been developed to increase the prognostic value of histologic assessment, some of which use a three-tier system (ie, grade 1 [well differentiated, low-grade], 2 [moderately differentiated] or 3 [poorly differentiated, high-grade]), and others a four-tier system. The three-tiered system is incorporated into the AJCC TNM staging system for soft tissue sarcomas and is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H351701269\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system is preferred by the College of American Pathologists, which is based on three parameters: differentiation, mitotic activity, and necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Grading should be used only for untreated primary soft tissue sarcomas. The histologic grade does not differentiate between benign and malignant soft tissue tumors and is not a substitute for morphologic diagnosis.",
"   </p>",
"   <p>",
"    Grading is not applicable to all soft tissue sarcomas. It is of little prognostic value for MPNST (the majority of which are considered high grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]), and it is not recommended for angiosarcoma, alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, and epithelioid sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. The impact of histologic grade on prognosis is discussed below (see",
"    <a class=\"local\" href=\"#H12227219\">",
"     'Prognostic factors'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227079\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nearly all instances, sarcomas are thought to arise de novo and not from a preexisting benign lesion. Most cases have no clearly defined etiology, but a number of associated or predisposing factors have been identified. These include genetic predisposition (eg, Li Fraumeni syndrome, neurofibromatosis type I), exposure to radiation therapy or chemotherapy, chemical carcinogens, chronic irritation, and lymphedema. In addition, human immunodeficiency virus and human herpes virus 8 have been implicated in the pathogenesis of Kaposi's sarcoma. These topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link\">",
"     \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227086\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas occur at all anatomic body sites, but the majority are in the extremities. The anatomic distribution of soft tissue sarcomas in 4550 adults reviewed by the American College of Surgery was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thigh, buttock, and groin &ndash; 46 percent",
"     </li>",
"     <li>",
"      Upper extremity &ndash; 13 percent",
"     </li>",
"     <li>",
"      Torso &ndash; 18 percent",
"     </li>",
"     <li>",
"      Retroperitoneum &ndash; 13 percent",
"     </li>",
"     <li>",
"      Head and neck &ndash; 9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some histologic types of soft tissue sarcoma have a predilection for certain anatomic sites. As an example, while only 14 percent of all soft tissue sarcomas present in the upper extremity, 40 to 50 percent of all epithelioid sarcomas arise on the forearm and finger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomic distribution of histologic subtypes is not a simple function of abundance of the tissue type. Liposarcomas are not common in the large fatty deposits of the abdominal wall; while in the thigh, a frequent site, they often arise deep in the muscle mass, rather than in the subcutaneous fat.",
"   </p>",
"   <p>",
"    The most common presenting complaint for a soft tissue sarcoma is a gradually enlarging, painless mass. These tumors can become quite large, especially in the thigh and retroperitoneum. Some patients complain of pain or symptoms associated with compression by the mass, including paresthesias or edema in an extremity. Rarely, a patient may present with constitutional symptoms such as fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss.",
"   </p>",
"   <p>",
"    Clinical presentation of retroperitoneal sarcomas, uterine sarcomas, and sarcomas of the head and neck is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"     \"Head and neck sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227100\">",
"    <span class=\"h2\">",
"     Pattern of growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas grow at various rates depending on the aggressiveness of the tumor. Tumors tend to grow along tissue planes and only rarely traverse or violate major fascial planes or bone. The growing tumor compresses surrounding normal tissue leading to the formation of a so-called pseudocapsule that is comprised of compressed normal tissue with poorly defined margins and fingerlike tumor projections that infiltrate adjacent tissues. Dissection along the pseudocapsule plane will invariably leave residual disease and should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link&amp;anchor=H3#H3\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Resection'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227107\">",
"    <span class=\"h2\">",
"     Pattern of spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common pattern of spread is hematogenous, predominantly to the lung. (See",
"    <a class=\"local\" href=\"#H12227114\">",
"     'Pattern of recurrence'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The presence of distant metastatic disease at the time of initial diagnosis is uncommon but more likely in large, deep, high grade sarcomas, and with specific histologies. In a retrospective review of 1170 patients over a 7.5 year period, the following were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of distant metastatic disease at the time of diagnosis was 10 percent, and 83 percent of metastases were located in the lungs.",
"     </li>",
"     <li>",
"      There was a higher risk of lung metastases in tumors that were deep to the fascia (9 versus 4 percent).",
"     </li>",
"     <li>",
"      The risk of having lung metastases at diagnosis also increased with higher histologic grade of differentiation (12, 7, and 1.2 percent for high-grade, intermediate-grade, and low-grade tumors, respectively).",
"     </li>",
"     <li>",
"      The histologic subtypes most likely to present with lung metastases were soft tissue Ewing sarcoma, MPNST, and extraskeletal chondrosarcoma (25, 16.2, and 13.6 percent respectively). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link\">",
"       \"Chondrosarcoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7798376\">",
"    <span class=\"h3\">",
"     Regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spread to regional nodes is infrequent except for certain histologies. An analysis of 1772 sarcoma patients in a prospective database at Memorial Sloan-Kettering Cancer Center identified 46 (2.6 percent) with lymph node metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/26\">",
"     26",
"    </a>",
"    ]. The histologies with the greatest risk of lymph node metastases are rhabdomyosarcoma, synovial sarcoma, epithelioid sarcoma, clear cell sarcoma, and the vascular sarcomas (including angiosarcomas) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/23,24,26-30\">",
"     23,24,26-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nodal metastases carry a poor prognostic implication, but somewhat less than do overt bloodborne metastases in STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/27\">",
"     27",
"    </a>",
"    ]. Several studies have reported that the prognosis of patients with regional lymph node metastases is similar to those without lymph node involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/27,28,30\">",
"     27,28,30",
"    </a>",
"    ], which prompted a change in the 2010 AJCC staging system to reclassify N1 disease as stage III instead of stage IV (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"mobipreview.htm?23/13/23773\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H351701269\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management of the regional lymph nodes, including the role of sentinel node biopsy, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link&amp;anchor=H8#H8\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Management of the regional nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227114\">",
"    <span class=\"h2\">",
"     Pattern of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent disease after treatment of a soft tissue sarcoma can present as a local recurrence or metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The incidence of local recurrence depends on anatomic location, extent of resection, use of adjuvant radiotherapy, and histology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link&amp;anchor=H4#H4\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Benefit of RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\", section on 'Adjunctive RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\", section on 'Outcomes and prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, about 25 percent of patients will develop distant metastatic disease after successful treatment of their primary tumor; the incidence increases to 40 to 50 percent with tumors that are &gt;5 cm in size, deep to the fascia, and intermediate or high grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 70 to 80 percent of cases, metastatic disease is to the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/25,33,36,37\">",
"     25,33,36,37",
"    </a>",
"    ]. Rare sites of metastatic disease spread include the skin, soft tissues, bone, liver, and brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/32,33,38,39\">",
"     32,33,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some exceptions to the typical pattern of metastatic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In round",
"      <span class=\"nowrap\">",
"       cell/myxoid",
"      </span>",
"      liposarcomas where extrapulmonary metastases to the retroperitoneum, abdomen, bone (particularly the spine), and paraspinal soft tissue are common [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retroperitoneal sarcomas, in particular leiomyosarcomas, also commonly metastasize to the liver as well as lung. Conversely, retroperitoneal liposarcomas, nearly all the well",
"      <span class=\"nowrap\">",
"       differentiated/dedifferentiated",
"      </span>",
"      subtype, recur local-regionally instead of with metastatic disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"       \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227121\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation begins with a history of when the mass was first noticed, how quickly it has been growing, and whether there are symptoms to suggest distal neurovascular compromise. The physical examination should focus on the size and depth of the mass, fixation to adjacent structures, and associated edema or signs of nerve impingement.",
"   </p>",
"   <p>",
"    Delay in diagnosis of soft tissue sarcomas is common. Patients frequently do not seek prompt medical attention due to the painless nature of the tumor, and delays on the part of the physician are likewise common due to assumptions of benignity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227128\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a soft tissue mass includes benign soft tissue tumors, such as a lipoma, as well as malignant tumors including sarcoma, metastatic carcinoma, melanoma, or lymphoma. &nbsp;",
"   </p>",
"   <p>",
"    Given that benign soft tissue masses are at least 100 times more common than malignant soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2\">",
"     2",
"    </a>",
"    ], it can be difficult to determine which soft tissue masses warrant further evaluation. The United Kingdom Department of Health has published criteria for urgent referral of a patient with a soft tissue lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soft tissue mass &gt;5 cm (golf ball size or larger)",
"     </li>",
"     <li>",
"      Painful lump",
"     </li>",
"     <li>",
"      Lump that is increasing in size",
"     </li>",
"     <li>",
"      A lump of any size that is deep to the muscle fascia",
"     </li>",
"     <li>",
"      Recurrence of a lump after previous excision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective review of 365 patients with confirmed soft tissue sarcoma, tumor depth was found to be the most sensitive marker of malignancy, followed by size &gt;5 cm, and a history of rapid growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the diagnosis of soft tissue sarcoma is often unsuspected, unplanned and inappropriate excisions of these tumors frequently occur before a proper pathologic diagnosis has been made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/45\">",
"     45",
"    </a>",
"    ]. Partial excision of the tumor before referral to a tertiary center does not appear to compromise limb preservation, local control, or, in most series, survival. However, a higher incidence of distant metastatic disease has been reported in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/46\">",
"     46",
"    </a>",
"    ], and reresection may entail a larger procedure than a de novo procedure and impact upon the functional result. These data underscore the importance of transferring patients with soft tissue masses of uncertain identify to centers that specialize in treating sarcomas so that they can undergo adequate initial resection. Studies have shown improved outcomes in patients treated at a specialist sarcoma center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=see_link&amp;anchor=H9#H9\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Management of an initially incompletely resected primary tumor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227142\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various imaging techniques are used to assist in defining the etiology of a soft tissue mass, determining the extent of a primary tumor for surgical planning, and establishing the presence or absence of metastatic disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7799658\">",
"    <span class=\"h3\">",
"     Imaging of the primary tumor",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227149\">",
"    <span class=\"h4\">",
"     Plain radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films of the primary site can be useful to rule out soft tissue masses that arise from bone and to detect intratumoral calcifications such as those that appear within soft tissue (extraskeletal) osteosarcomas and synovial sarcomas. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227156\">",
"    <span class=\"h4\">",
"     MRI and CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is the preferred imaging modality for the evaluation of soft tissue masses of the extremities, trunk, and head and neck, while CT is the most commonly used imaging technique for retroperitoneal sarcomas. Several studies report that MRI is superior to CT in evaluating soft tissue sarcomas of the extremity as MRI provides multiplanar images with better spatial orientation. MRI is superior for delineating the extent of the neoplasm and relation to surrounding structures, especially individual muscle involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, a multicenter prospective study that included 133 patients who underwent both CT and MRI within four weeks of surgery for a soft tissue sarcoma of the arm, shoulder, pelvis, hip or lower extremity found no statistically significant difference between the two modalities in determining tumor involvement of muscle, bone, joints, or neurovascular structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/52\">",
"     52",
"    </a>",
"    ]. Combined interpretation of CT and MRI did not improve accuracy of preoperative assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227163\">",
"    <span class=\"h4\">",
"     PET and PET/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies report that PET and integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    using fluorodeoxyglucose (FDG) can distinguish benign soft tissue tumors from sarcomas, with the greatest sensitivity for high grade sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, the ability to differentiate benign soft tissue tumors from low or intermediate grade sarcomas is limited, and PET and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    are not routinely recommended for the initial work-up of a soft tissue mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. One exception may be in the characterization of a suspected peripheral nerve sheath tumor in a patient with neurofibromatosis; in this scenario, PET imaging can be helpful in distinguishing an MPNST from a neurofibroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Gallium scans may also differentiate between neurofibromas and MPNSTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consensus guidelines for workup of a soft tissue sarcoma of the extremity and trunk issued by the National Comprehensive Care Network (NCCN) suggest that PET scan may be useful in the prognostication, grading, and determining response to neoadjuvant chemotherapy in patients with soft tissue sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/63\">",
"     63",
"    </a>",
"    ]. However, this recommendation is based upon a single study from the University of Washington that found that FDG-PET was useful to predict the outcomes of patients with high-grade extremity soft tissue sarcomas who were treated initially with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/64\">",
"     64",
"    </a>",
"    ]. Patients with a baseline tumor SUV max &ge;6 who had a &lt;40 percent decrease in FDG uptake after neoadjuvant chemotherapy were found to be at high risk of systemic disease recurrence.",
"   </p>",
"   <p>",
"    The clinical utility of having this information prior to surgical treatment is unclear. At present, the use of PET for prognostication or assessment of treatment response is not considered routine at most institutions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227170\">",
"    <span class=\"h3\">",
"     Evaluation for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the propensity for lung metastases, chest imaging is recommended for newly diagnosed patients with soft tissue sarcoma of the",
"    <span class=\"nowrap\">",
"     extremity/trunk",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/63\">",
"     63",
"    </a>",
"    ]. While CT scan is often preferred due to its greater sensitivity in detecting small lung nodules, it is unknown whether this provides benefit over chest X-ray (CXR) alone. Both modalities are considered highly appropriate for this purpose by the American College of Radiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/65\">",
"     65",
"    </a>",
"    ]. A retrospective review performed in the United Kingdom found that CXR alone detected two-thirds of pulmonary metastases in patients with soft tissue sarcoma; when compared to CT as the &ldquo;gold standard&rdquo;, the sensitivity, specificity, positive predictive value and negative predictive value of CXR were 60.8, 99.6, 93.3 and 96.7 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/25\">",
"     25",
"    </a>",
"    ]. The use of CXR only to stage the lungs would have missed one-third of all patients with lung metastases, but because of the infrequency of lung metastases overall (96 of 1170 patients), the initial staging would have been inaccurate in only 3.1 percent of cases. A greater proportion (4.9 percent) would have been incorrectly staged if CXR alone had been used in patients with high-grade large deep tumors.",
"   </p>",
"   <p>",
"    The authors recommended that all patients with a suspected soft tissue sarcoma should have a CXR, with chest CT reserved for those with an abnormality on CXR, or who have the highest risk of pulmonary metastases (primary tumor &gt; 5 cm, and deep-seated or",
"    <span class=\"nowrap\">",
"     intermediate/high",
"    </span>",
"    grade). (See",
"    <a class=\"local\" href=\"#H12227107\">",
"     'Pattern of spread'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A CT of the abdomen and pelvis is recommended to evaluate for metastatic disease in round",
"    <span class=\"nowrap\">",
"     cell/myxoid",
"    </span>",
"    liposarcomas due to the common presentation of extrapulmonary metastases to the abdomen and retroperitoneum.",
"   </p>",
"   <p>",
"    Bone scan is usually",
"    <strong>",
"     not",
"    </strong>",
"    helpful for initial staging. Bone metastases are unusual in adults in the absence of multiple metastases in other sites, except possibly in round",
"    <span class=\"nowrap\">",
"     cell/myxoid",
"    </span>",
"    liposarcomas. Bone scan can be insensitive in these patients, so MRI is the recommended imaging modality for symptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12227107\">",
"     'Pattern of spread'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another problem is that a positive bone scan adjacent to a soft tissue tumor is insufficient evidence of bone invasion and instead may represent a reactive process. The diagnosis of bone invasion is best made by demonstration of loss of cortical bone on plain radiographs or CT with bone windows.",
"   </p>",
"   <p>",
"    In addition, guidelines from the National Comprehensive Cancer Network (NCCN) suggest imaging of the central nervous system (CNS) in patients with angiosarcoma due to the propensity of these tumors to metastasize to the CNS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4377878\">",
"    <span class=\"h4\">",
"     PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET scanning can achieve whole body imaging, and it is widely considered to be more sensitive than CT for the detection of occult distant metastases in a variety of solid tumors. However, the utility of PET alone or with integrated CT for staging of distant disease extent in STS is unclear as evidenced by the following reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In several reports, chest CT is more sensitive than PET for detection of thoracic metastases in patients with sarcoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/67,69,71,72\">",
"       67,69,71,72",
"      </a>",
"      ]. In the largest report of 106 patients with bone or soft tissue sarcomas who had PET or integrated",
"      <span class=\"nowrap\">",
"       PET/CT,",
"      </span>",
"      pulmonary metastases were found in 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/69\">",
"       69",
"      </a>",
"      ]. CT identified 17 lesions larger than 1 cm, while PET identified only 13 of them. The authors concluded that subcentimeter CT lesions should not be considered false-positive if inactive on PET and that a negative PET scan in the presence of suspicious CT findings in the chest cannot reliably exclude pulmonary metastases.",
"     </li>",
"     <li>",
"      One purported benefit of PET is its ability to detect additional sites of extrapulmonary metastatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/67,70\">",
"       67,70",
"      </a>",
"      ]. However, the risk of extrapulmonary metastases is so low with most soft tissue sarcomas that the routine use of PET for this purpose is unlikely to change the therapeutic plan. This was illustrated in a report of 75 patients who underwent PET during staging evaluation for a soft tissue sarcoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/71\">",
"       71",
"      </a>",
"      ]. Only one patient was upstaged as a result of PET imaging, and PET did not alter the management of patients already known to have metastatic disease (ie, no new organ sites were identified). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, PET or integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is not routinely recommended as a component of the initial staging workup of soft tissue sarcoma for evaluation of either pulmonary or extrapulmonary metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227177\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of a soft tissue mass is essential for diagnosis and treatment planning. There are several methods for obtaining a biopsy, which are reviewed below. Ideally, the biopsy should be performed after an MRI has been obtained as post-procedural edema may make the MRI difficult to interpret.",
"   </p>",
"   <p>",
"    The diagnostic biopsy must be carefully planned to ensure that adequate tissue is obtained in a manner that does not compromise definitive therapy. A poorly placed initial biopsy may preclude subsequent surgical resection, preparation of flaps,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cosmetic repair, or result in the need for a more extensive surgery to encompass the biopsy site at the time of definitive resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11121521\">",
"    <span class=\"h3\">",
"     Incisional biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although incisional biopsy was the historic gold standard procedure for obtaining diagnostic tissue for a suspicious soft tissue mass, core needle biopsy has become the most common procedure used for diagnosis in recent years (see",
"    <a class=\"local\" href=\"#H12227191\">",
"     'Core needle biopsy'",
"    </a>",
"    below). A biopsy that contains enough material to ascertain the histologic subtype and grade of the tumor is essential prior to commencement of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If definitive diagnosis may require flow cytometry, cytogenetics, or molecular analysis for chromosomal translocations (",
"    <a class=\"graphic graphic_table graphicRef62670 \" href=\"mobipreview.htm?41/10/42155\">",
"     table 5",
"    </a>",
"    ), an incisional biopsy may be preferred. The larger sample provides the pathologist with more tissue and a greater degree of confidence in the diagnosis, in part because of the degree of morphologic heterogeneity throughout the tumor.",
"   </p>",
"   <p>",
"    If needed, incisional biopsy should ideally be performed by the surgeon planning the definitive resection. Errors, complications, and changes in patient outcome occur more frequently when an incisional biopsy is performed in a referring institution instead of a treatment center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Open biopsy incisions should be placed longitudinally along the extremity so that the scar can be resected along with the tumor at the time of definitive surgical resection. Adequate hemostasis is important to prevent dissemination of tumor cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227191\">",
"    <span class=\"h3\">",
"     Core needle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core needle biopsy is considered the preferred method to achieve an initial biopsy in most cases due to its low incidence of complications and high diagnostic accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. In a study of 530 patients with suspected soft tissue tumors, core needle biopsy differentiated malignant soft tissue sarcomas from benign soft tissue tumors in 97.6 percent of patients. Histologic grade was accurately determined in 86.3 percent of patients, and the subtype was accurately identified in 88 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT or ultrasound guidance can assist in the biopsy of deep lesions, and improve the diagnostic accuracy in lesions with cystic areas and necrosis by allowing the operator to select the site to be biopsied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. In cases where core needle biopsy is unsuccessful in obtaining adequate material for diagnosis, a subsequent incisional biopsy is usually considered. The incidence of follow-up biopsy has been reported as high as 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227198\">",
"    <span class=\"h3\">",
"     Fine needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;FNA is not recommended in the initial diagnostic evaluation of a suspicious soft tissue mass as it has a lower diagnostic accuracy than core needle biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In addition, FNA may not provide the histologic subtype or grade of the sarcoma, which are both important for treatment planning. FNA can be useful in confirming disease recurrence, however [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351701269\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used staging system for soft tissue sarcomas is the TNM system developed by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC). The system uses tumor size (T), depth (superficial or deep), lymph node involvement (N), presence or absence of distant metastases (M), and histologic grade (G) in determining the stage grouping for soft tissue sarcomas (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"mobipreview.htm?23/13/23773\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most recent 2010 7",
"    <sup>",
"     th",
"    </sup>",
"    edition of the AJCC Staging Manual contained a number of significant changes relative to the prior 2002 6",
"    <sup>",
"     th",
"    </sup>",
"    edition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      N1 disease was reclassified from stage IV to stage III disease.",
"     </li>",
"     <li>",
"      The histologic grading system was reformatted from a four-tier to a three-tier grading system.",
"     </li>",
"     <li>",
"      Superficial and deep tumors of equal size are now included in the same stage, which eliminates the previous risk stratification for tumor depth. Several studies have reported that patients with superficial soft tissue sarcomas have a better prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. As a result, many clinicians still prefer the 2002 version rather than the 2010 version when the TNM system is used to stage sarcomas of the extremity of trunk (",
"      <a class=\"graphic graphic_table graphicRef69154 \" href=\"mobipreview.htm?10/30/10733\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A problem shared by both the 6",
"    <sup>",
"     th",
"    </sup>",
"    and 7",
"    <sup>",
"     th",
"    </sup>",
"    editions is that tumor size is only stratified as &le;5 or &gt;5 cm but evidence suggests that very large tumors (&gt;10 cm) have an inferior prognosis than those that are 5 to 10 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12227233\">",
"     'Tumor size'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The AJCC staging system is not in widespread use for nonextremity sarcomas. It does not account for disease site or histology, two major prognostic indicators. Because histologic grade, the presence or absence of metastatic disease, and achieving macroscopic total resection are the major determinants of survival for patients with retroperitoneal sarcoma, an alternative staging system has been proposed (",
"    <a class=\"graphic graphic_table graphicRef61503 \" href=\"mobipreview.htm?8/32/8715\">",
"     table 7",
"    </a>",
"    ) but is not in widespread use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227219\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of prognostic factors have been identified in patients with soft tissue sarcoma, the most important of which is the pathologic stage at the time of diagnosis. In a series derived from Memorial Sloan-Kettering Cancer Center (and using the TNM stage groupings from the 2010 7",
"    <sup>",
"     th",
"    </sup>",
"    edition), five-year rates disease-free survival for stage I, II, and III disease were 86, 72, and 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/86\">",
"     86",
"    </a>",
"    ]. The corresponding values for overall survival were 90, 81, and 56 percent.",
"   </p>",
"   <p>",
"    In addition to tumor stage, histologic grade and tumor size have been consistently found to be independent predictors of prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/4,88,90,91\">",
"     4,88,90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227226\">",
"    <span class=\"h2\">",
"     Histologic grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic grading is an independent indicator of the degree of malignancy and the probability of distant metastases and death from sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, histologic grade is a poor predictor of local recurrence, which is mainly a function of surgical margins.",
"   </p>",
"   <p>",
"    The relationship between histologic grade and prognosis can be illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 1225 patients with localized soft tissue sarcoma treated with surgery and radiation therapy at M D Anderson Cancer Center, five-year rates of metastasis-free survival were 98, 85, and 64 percent for grade 1, 2, and 3 tumors respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results are available from the French Federation of Cancer Centers (FNCLCC) Sarcoma Group; five-year metastasis-free survival rates in 1240 patients with locally controlled soft tissue sarcoma were 91, 71, and 44 percent for grade 1, 2, and 3 tumors respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227233\">",
"    <span class=\"h2\">",
"     Tumor size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the AJCC staging system includes 5 cm as the only size cutoff to determine tumor (T) stage, the risk of developing distant metastases increases substantially as tumor size increases, as evidenced by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review from Massachusetts General Hospital, the frequency of distant metastases in high grade tumors as a function of tumor size was [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/89\">",
"       89",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tumors &le;2.5 cm &ndash; 6 percent",
"     </li>",
"     <li>",
"      Tumors 2.6-4.9 cm &ndash; 23 percent",
"     </li>",
"     <li>",
"      Tumors 5-10 cm &ndash; 38 percent",
"     </li>",
"     <li>",
"      Tumors 10.1-15 cm &ndash; 49 percent",
"     </li>",
"     <li>",
"      Tumors 15.1-20 cm - 58 percent",
"     </li>",
"     <li>",
"      Tumors &gt; 20 cm &ndash; 83 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another study grouped 316 patients with soft tissue sarcomas into four subgroups on the basis of tumor size (less than 5 cm, 5 to less than 10 cm, 10 to less than 15 cm, and greater than 15 cm). Each subgroup was found to have a different prognosis with five-year survival rates of 84, 70, 50, and 33 percent respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7800552\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although histologic grade and tumor size are the most important, other factors influence prognosis, including anatomic site (",
"    <a class=\"graphic graphic_figure graphicRef71632 \" href=\"mobipreview.htm?1/6/1135\">",
"     figure 1",
"    </a>",
"    ), patient age, and histologic subtype. The influence of grade according to histologic subtype is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef76085 \" href=\"mobipreview.htm?8/29/8668\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combined use of these factors to estimate prognosis in individual patients is discussed below. (See",
"    <a class=\"local\" href=\"#H12227240\">",
"     'Prognostic tools'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227240\">",
"    <span class=\"h2\">",
"     Prognostic tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimating prognosis in patients with soft tissue sarcoma is important for both individual patient counseling as well as for therapeutic decision making. In addition to stage, grade, and tumor size, factors that are associated with survival include anatomic site, age, and histologic subtype. Prognostic nomograms incorporating such variables are useful tools in patient management.",
"   </p>",
"   <p>",
"    The most widely used nomogram is the postoperative nomogram for 12-year sarcoma-specific death from Memorial Sloan-Kettering Cancer Center (MSKCC) (",
"    <a class=\"graphic graphic_figure graphicRef80175 \" href=\"mobipreview.htm?4/37/4703\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/92\">",
"     92",
"    </a>",
"    ]. This nomogram is also available online [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/93\">",
"     93",
"    </a>",
"    ] and has been validated with an external cohort of patients who were treated at University of California-Los Angeles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/94\">",
"     94",
"    </a>",
"    ]. Histologic grade in the MSKCC nomogram was defined as high or low according to previously published criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/95\">",
"     95",
"    </a>",
"    ]. A subsequent adapted nomogram has been published incorporating the FNCLCC three grade classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/43/31418/abstract/96\">",
"     96",
"    </a>",
"    ]. In our practice, we use the MSKCC nomogram and categorize both grade 2 and 3 tumors as high grade for the purposes of predicting prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12227247\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue sarcomas are a rare and heterogeneous group of tumors of mesenchymal origin, which includes more than 50 different histologic subtypes. Pathologic diagnosis is based on histologic morphology, immunohistochemistry, and sometimes, molecular testing. (See",
"      <a class=\"local\" href=\"#H12227072\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Soft tissue sarcomas most commonly present as an enlarging, painless mass in the extremities or trunk. The presence of distant metastatic disease at the time of initial diagnosis is uncommon but more likely in large, deep, high grade sarcomas. About 80 percent of metastases are located in the lungs. (See",
"      <a class=\"local\" href=\"#H12227086\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of a soft tissue sarcoma is often unsuspected. Partial excision of the tumor before referral may be associated with a higher incidence of distant metastatic disease and the need for an extensive reresection that may impact upon the functional result. In addition, an inappropriately placed diagnostic biopsy may preclude subsequent surgical resection, preparation of flaps,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cosmetic repair, or result in the need for a more extensive surgery to encompass the biopsy site at the time of definitive resection. Because of these issues, early referral of a patient with a suspicious soft tissue mass to a specialized center with a multidisciplinary sarcoma team is recommended. (See",
"      <a class=\"local\" href=\"#H12227121\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our practice for the diagnostic work-up of a soft tissue mass includes (see",
"      <a class=\"local\" href=\"#H12227121\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MRI of a primary extremity lesion and CT of a primary abdominal, visceral, or retroperitoneal lesion. (See",
"      <a class=\"local\" href=\"#H7799658\">",
"       'Imaging of the primary tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our preferred method of obtaining tissue is with a core needle biopsy if technically feasible. If incisional biopsy is required, it should be carefully planned and performed by the surgeon who will be doing the definitive resection. We recommend that all pathology specimens of suspected soft tissue sarcomas be reviewed by a pathologist who specializes in the evaluation of soft tissue tumors. (See",
"      <a class=\"local\" href=\"#H12227177\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of a sarcoma is established, we recommend chest imaging to evaluate for pulmonary metastatic disease in all patients; we use chest CT rather than chest X-ray in patients with a high risk of pulmonary metastases (tumors &gt;5 cm or deep-seated, or intermediate or high grade). We also recommend CT of the abdomen and pelvis in round",
"      <span class=\"nowrap\">",
"       cell/myxoid",
"      </span>",
"      liposarcomas due to the common presentation of extrapulmonary metastases to the abdomen and retroperitoneum. Imaging of the brain is suggested for patients with angiosarcoma due to the high propensity of these tumors for central nervous system metastases. (See",
"      <a class=\"local\" href=\"#H12227170\">",
"       'Evaluation for metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not routinely perform PET or",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      in the initial staging evaluation of a newly diagnosed soft tissue sarcoma. PET or gallium scan may be of value in a patient with neurofibromatosis as an aid to differentiating between a plexiform neurofibroma and a malignant peripheral nerve sheath tumor. (See",
"      <a class=\"local\" href=\"#H12227163\">",
"       'PET and PET/CT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4377878\">",
"       'PET scanning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone scan is not helpful for initial staging of soft tissue sarcomas. (See",
"      <a class=\"local\" href=\"#H12227170\">",
"       'Evaluation for metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue sarcomas of the extremity or trunk are staged according to the TNM system, which is based on tumor size (T), depth (superficial or deep), lymph node involvement (N), distant metastases (M), and histologic grade (G) (",
"      <a class=\"graphic graphic_table graphicRef66617 \" href=\"mobipreview.htm?23/13/23773\">",
"       table 4",
"      </a>",
"      ). Because histologic grade, the presence or absence of metastatic disease and achieving macroscopic total resection are the major determinants of survival for patients with retroperitoneal sarcoma, an alternative staging system has been proposed but is not in widespread use. (See",
"      <a class=\"local\" href=\"#H351701269\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to tumor stage, other prognostic variables include histologic grade, tumor size, anatomic site, patient age, and histologic subtype. A nomogram developed by Memorial Sloan-Kettering Cancer Center is available online to aid in predicting survival and treatment decision making for individual patients. (See",
"      <a class=\"local\" href=\"#H12227219\">",
"       'Prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/1\">",
"      Miller RW, Young JL Jr, Novakovic B. Childhood cancer. Cancer 1995; 75:395.",
"     </a>",
"    </li>",
"    <li>",
"     Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of tumours: Pathology and Genetics of tumours of soft tissue and bone, IARC Press, Lyon 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/4\">",
"      Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003; 97:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/5\">",
"      Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/6\">",
"      Lawrence W Jr, Donegan WL, Natarajan N, et al. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987; 205:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/7\">",
"      Fletcher CD, Gustafson P, Rydholm A, et al. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 2001; 19:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/8\">",
"      Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 2011; 18:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/9\">",
"      Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 2010; 251:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/10\">",
"      Look Hong NJ, Hornicek FJ, Raskin KA, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol 2013; 20:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/11\">",
"      Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011; 2011:483154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/12\">",
"      Ghadimi MP, Liu P, Peng T, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer 2011; 117:5359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/13\">",
"      Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009; 15:5696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/14\">",
"      Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol 1999; 12:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/15\">",
"      Svarvar C, B&ouml;hling T, Berlin O, et al. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer 2007; 109:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/16\">",
"      Arora VC, Price AP, Fleming S, et al. Characteristic imaging features of desmoplastic small round cell tumour. Pediatr Radiol 2013; 43:93.",
"     </a>",
"    </li>",
"    <li>",
"     Extrapleural solitary fibrous tumour and haemangiopericytoma. In: World health organization classification of tumours. Pathology and genetics. Tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F (Eds), 2002. p.86.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/18\">",
"      Deyrup AT, Weiss SW. Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology 2006; 48:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/19\">",
"      Rubin BP, Fletcher CD, Inwards C, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med 2006; 130:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/20\">",
"      Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350.",
"     </a>",
"    </li>",
"    <li>",
"     Woodruff JM, Kourea HP, Louis DN, Schiethauer BW. Malignant peripheral nerve sheath tumour (MPNST). In: World Health Organization Classification of Tumours: Pathology and genetics of Tumours of the nervous system, Kleihues P, Cavenee WK (Eds), IARC Press, Lyon 2000. p.172.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/22\">",
"      Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 2012; 19:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/23\">",
"      Baratti D, Pennacchioli E, Casali PG, et al. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 2007; 14:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/24\">",
"      Sakharpe A, Lahat G, Gulamhusein T, et al. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. Oncologist 2011; 16:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/25\">",
"      Christie-Large M, James SL, Tiessen L, et al. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer 2008; 44:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/26\">",
"      Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/27\">",
"      Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 2004; :129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/28\">",
"      Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987; 60:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/29\">",
"      de Visscher SA, van Ginkel RJ, Wobbes T, et al. Epithelioid sarcoma: Still an only surgically curable disease. Cancer 2006; 107:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/30\">",
"      Blazer DG 3rd, Lazar AJ, Xing Y, et al. Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer 2009; 115:2971.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 7th edition, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/32\">",
"      Vezeridis MP, Moore R, Karakousis CP. Metastatic patterns in soft-tissue sarcomas. Arch Surg 1983; 118:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/33\">",
"      Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985; 3:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/34\">",
"      Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981; 47:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/35\">",
"      Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003; 21:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/36\">",
"      Billingsley KG, Lewis JJ, Leung DH, et al. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 1999; 85:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/37\">",
"      Rydholm A, Berg NO, Gullberg B, et al. Prognosis for soft-tissue sarcoma in the locomotor system. A retrospective population-based follow-up study of 237 patients. Acta Pathol Microbiol Immunol Scand A 1984; 92:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/38\">",
"      Ryzewicz M, McLoughlin HA, Freudenberger C, et al. Unusual metastases from extremity soft tissue sarcomas. Orthopedics 2008; 31:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/39\">",
"      Wang WL, Bones-Valentin RA, Prieto VG, et al. Sarcoma metastases to the skin: a clinicopathologic study of 65 patients. Cancer 2012; 118:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/40\">",
"      Schwab JH, Boland P, Guo T, et al. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann Surg Oncol 2007; 14:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/41\">",
"      Moreau LC, Turcotte R, Ferguson P, et al. Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol 2012; 19:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/42\">",
"      Chotel F, Unnithan A, Chandrasekar CR, et al. Variability in the presentation of synovial sarcoma in children: a plea for greater awareness. J Bone Joint Surg Br 2008; 90:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/43\">",
"      Sinha S, Peach AH. Diagnosis and management of soft tissue sarcoma. BMJ 2010; 341:c7170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/44\">",
"      Hussein R, Smith MA. Soft tissue sarcomas: are current referral guidelines sufficient? Ann R Coll Surg Engl 2005; 87:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/45\">",
"      Noria S, Davis A, Kandel R, et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J Bone Joint Surg Am 1996; 78:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/46\">",
"      Rehders A, Stoecklein NH, Poremba C, et al. Reexcision of soft tissue sarcoma: sufficient local control but increased rate of metastasis. World J Surg 2009; 33:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/47\">",
"      Bhangu AA, Beard JA, Grimer RJ. Should Soft Tissue Sarcomas be Treated at a Specialist Centre? Sarcoma 2004; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/48\">",
"      Gustafson P, Dreinh&ouml;fer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994; 65:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/49\">",
"      Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors. Magn Reson Imaging 1988; 6:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/50\">",
"      Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988; 150:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/51\">",
"      Aisen AM, Martel W, Braunstein EM, et al. MRI and CT evaluation of primary bone and soft-tissue tumors. AJR Am J Roentgenol 1986; 146:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/52\">",
"      Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 1997; 202:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/53\">",
"      Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/54\">",
"      Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000; 231:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/55\">",
"      Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004; 30:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/56\">",
"      Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, et al. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/57\">",
"      Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/58\">",
"      Lucas JD, O'Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999; 86:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/59\">",
"      Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 2010; 116:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/60\">",
"      Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008; 19:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/61\">",
"      Warbey VS, Ferner RE, Dunn JT, et al. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 2009; 36:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/62\">",
"      Levine E, Huntrakoon M, Wetzel LH. Malignant nerve-sheath neoplasms in neurofibromatosis: distinction from benign tumors by using imaging techniques. AJR Am J Roentgenol 1987; 149:1059.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines www.nccn.org (Accessed on May 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/64\">",
"      Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005; 103:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/65\">",
"      Mohammed TL, Chowdhry A, Reddy GP, et al. ACR Appropriateness Criteria&reg; screening for pulmonary metastases. J Thorac Imaging 2011; 26:W1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/66\">",
"      Noble JL, Moskovic E, Fisher C, Judson I. Imaging of skeletal metastases in myxoid liposarcoma. Sarcoma 2010; 2010:262361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/67\">",
"      Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998; 80:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/68\">",
"      Johnson GR, Zhuang H, Khan J, et al. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med 2003; 28:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/69\">",
"      Iagaru A, Chawla S, Menendez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 2006; 27:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/70\">",
"      Pastorino U, Veronesi G, Landoni C, et al. Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis. J Thorac Cardiovasc Surg 2003; 126:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/71\">",
"      Roberge D, Hickeson M, Charest M, Turcotte RE. Initial McGill experience with fluorodeoxyglucose pet/ct staging of soft-tissue sarcoma. Curr Oncol 2010; 17:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/72\">",
"      V&ouml;lker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25:5435.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at www.nccn.org (Accessed on May 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/74\">",
"      Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am 1982; 64:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/75\">",
"      Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996; 78:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/76\">",
"      Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 1997; 4:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/77\">",
"      Strauss DC, Qureshi YA, Hayes AJ, et al. The role of core needle biopsy in the diagnosis of suspected soft tissue tumours. J Surg Oncol 2010; 102:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/78\">",
"      Woon DT, Serpell JW. Preoperative core biopsy of soft tissue tumours facilitates their surgical management: a 10-year update. ANZ J Surg 2008; 78:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/79\">",
"      Serpell JW, Pitcher ME. Pre-operative core biopsy of soft-tissue tumours facilitates their surgical management. Aust N Z J Surg 1998; 68:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/80\">",
"      Hau A, Kim I, Kattapuram S, et al. Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions. Skeletal Radiol 2002; 31:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/81\">",
"      Dupuy DE, Rosenberg AE, Punyaratabandhu T, et al. Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms. AJR Am J Roentgenol 1998; 171:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/82\">",
"      Verheijen P, Witjes H, van Gorp J, et al. Current pathology work-up of extremity soft tissue sarcomas, evaluation of the validity of different techniques. Eur J Surg Oncol 2010; 36:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/83\">",
"      Rougraff BT, Aboulafia A, Biermann JS, Healey J. Biopsy of soft tissue masses: evidence-based medicine for the musculoskeletal tumor society. Clin Orthop Relat Res 2009; 467:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/84\">",
"      Wakely PE Jr, Kneisl JS. Soft tissue aspiration cytopathology. Cancer 2000; 90:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/85\">",
"      Trovik CS, Bauer HC, Brosj&ouml; O, et al. Fine needle aspiration (FNA) cytology in the diagnosis of recurrent soft tissue sarcoma. Cytopathology 1998; 9:320.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/87\">",
"      Salas S, Stoeckle E, Collin F, et al. Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database. Eur J Cancer 2009; 45:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/88\">",
"      Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/89\">",
"      Suit HD, Mankin HJ, Wood WC, et al. Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol 1988; 6:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/90\">",
"      Ramanathan RC, A'Hern R, Fisher C, Thomas JM. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 1999; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/91\">",
"      R&ouml;&ouml;ser B, Attewell R, Berg NO, Rydholm A. Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 1988; 61:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/92\">",
"      Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20:791.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.mskcc.org/mskcc/html/6181.cfm (Accessed on May 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/94\">",
"      Eilber FC, Brennan MF, Eilber FR, et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 2004; 101:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/95\">",
"      Hajdu SI, Shiu MH, Brennan MF. The role of the pathologist in the management of soft tissue sarcomas. World J Surg 1988; 12:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/43/31418/abstract/96\">",
"      Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005; 103:402.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14259 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31418=[""].join("\n");
var outline_f30_43_31418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12227247\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12227065\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12227072\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7800294\">",
"      Histologic grade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12227079\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12227086\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227100\">",
"      Pattern of growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227107\">",
"      Pattern of spread",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7798376\">",
"      - Regional nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227114\">",
"      Pattern of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12227121\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227128\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227142\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7799658\">",
"      - Imaging of the primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12227149\">",
"      Plain radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12227156\">",
"      MRI and CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12227163\">",
"      PET and PET/CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12227170\">",
"      - Evaluation for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4377878\">",
"      PET scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227177\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11121521\">",
"      - Incisional biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12227191\">",
"      - Core needle biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12227198\">",
"      - Fine needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351701269\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12227219\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227226\">",
"      Histologic grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227233\">",
"      Tumor size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7800552\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12227240\">",
"      Prognostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12227247\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14259|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/6/1135\" title=\"figure 1\">",
"      STS survival by primary site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/37/4703\" title=\"figure 2\">",
"      Postop nomogram sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/41/7837\" title=\"table 1A\">",
"      Histolog classification STS I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/30/11757\" title=\"table 1B\">",
"      Histolog classification STS II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/41/11933\" title=\"table 1C\">",
"      Histolog classification STS III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/7/14459\" title=\"table 2\">",
"      Most common histologic subtypes of soft tissue sarcoma in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/27/23997\" title=\"table 3\">",
"      Selected translocations in sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/13/23773\" title=\"table 4\">",
"      2010 TNM staging STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/10/42155\" title=\"table 5\">",
"      Tissue process soft tissue mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/30/10733\" title=\"table 6\">",
"      2002 AJCC staging of STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/32/8715\" title=\"table 7\">",
"      Staging system retroperit sarc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/29/8668\" title=\"table 8\">",
"      Metastasis free survival in STS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=related_link\">",
"      Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=related_link\">",
"      Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23946?source=related_link\">",
"      Peripheral nerve tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18327?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_43_31419="Diet CKD dyslipidemia child";
var content_f30_43_31419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary treatment recommendations for children with dyslipidemia and CKD stages 5, 5D, and kidney transplant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Macronutrient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum LDL-C &gt;100 mg/dL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum TG &gt;150 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Energy",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        If associated with excess weight, energy balance + activity recommendations for weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary fat",
"       </td>",
"       <td>",
"        &lt;30 percent of calories",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary cholesterol",
"       </td>",
"       <td>",
"        &lt;200 mg/d",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Trans",
"        </em>",
"        fatty acids",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saturated fatty acids",
"       </td>",
"       <td>",
"        &lt;7 percent of calories",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Low simple carbohydrate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009; 53:S11. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31419=[""].join("\n");
var outline_f30_43_31419=null;
var title_f30_43_31420="Signs of adrenal insufficiency";
var content_f30_43_31420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of chronic adrenal insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weakness, tiredness, fatigue",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Gastrointestinal symptoms",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nausea",
"       </td>",
"       <td class=\"sublist_other\">",
"        86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vomiting",
"       </td>",
"       <td class=\"sublist_other\">",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Constipation",
"       </td>",
"       <td class=\"sublist_other\">",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abdominal pain",
"       </td>",
"       <td class=\"sublist_other\">",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diarrhea",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salt craving",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postural dizziness",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle or joint pains",
"       </td>",
"       <td>",
"        6-13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Sign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperpigmentation",
"       </td>",
"       <td>",
"        94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension (systolic BP &lt;110 mmHg)",
"       </td>",
"       <td>",
"        88-94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitiligo",
"       </td>",
"       <td>",
"        10-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Auricular calcification",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Laboratory abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Electrolyte disturbances",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyponatremia",
"       </td>",
"       <td class=\"sublist_other\">",
"        88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperkalemia",
"       </td>",
"       <td class=\"sublist_other\">",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypercalcemia",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azotemia",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilia",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31420=[""].join("\n");
var outline_f30_43_31420=null;
var title_f30_43_31421="New Ballard Score 2";
var content_f30_43_31421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    New Ballard score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"15\" rowspan=\"1\">",
"       Physical maturity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       -1",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       0",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       1",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       2",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       3",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       4",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Skin",
"      </td>",
"      <td colspan=\"2\">",
"       Sticky; friable; transparent",
"      </td>",
"      <td colspan=\"2\">",
"       Gelatinous; red; translucent",
"      </td>",
"      <td colspan=\"2\">",
"       Smooth; pink; visible veins",
"      </td>",
"      <td colspan=\"2\">",
"       Superficial peeling and/or rash; few veins",
"      </td>",
"      <td colspan=\"2\">",
"       Cracking pale areas; rare veins",
"      </td>",
"      <td colspan=\"2\">",
"       Parchment deep cracking; no vessels",
"      </td>",
"      <td colspan=\"2\">",
"       Leathery; cracked; wrinkled",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Lanugo",
"      </td>",
"      <td colspan=\"2\">",
"       None",
"      </td>",
"      <td colspan=\"2\">",
"       Sparse",
"      </td>",
"      <td colspan=\"2\">",
"       Abundant",
"      </td>",
"      <td colspan=\"2\">",
"       Thinning",
"      </td>",
"      <td colspan=\"2\">",
"       Bald areas",
"      </td>",
"      <td colspan=\"2\">",
"       Mostly bald",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Plantar creases",
"      </td>",
"      <td colspan=\"2\">",
"       <p>",
"        Heel-toe",
"       </p>",
"       <p>",
"        40-50 mm: -1",
"       </p>",
"       <p>",
"        &lt;40 mm: -2",
"       </p>",
"      </td>",
"      <td colspan=\"2\">",
"       &gt;50 mm; no crease",
"      </td>",
"      <td colspan=\"2\">",
"       Faint red marks",
"      </td>",
"      <td colspan=\"2\">",
"       Anterior transverse crease only",
"      </td>",
"      <td colspan=\"2\">",
"       Crease anterior 2/3",
"      </td>",
"      <td colspan=\"2\">",
"       Creases over entire sole",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Breast",
"      </td>",
"      <td colspan=\"2\">",
"       Imperceptible",
"      </td>",
"      <td colspan=\"2\">",
"       Barely perceptible",
"      </td>",
"      <td colspan=\"2\">",
"       Flat areola; no bud",
"      </td>",
"      <td colspan=\"2\">",
"       Strippled areola; 1-2 mm bud",
"      </td>",
"      <td colspan=\"2\">",
"       Raised areola; 3-4 mm bud",
"      </td>",
"      <td colspan=\"2\">",
"       Full areola; 5-10 mm bud",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Eye/ear",
"      </td>",
"      <td colspan=\"2\">",
"       <p>",
"        Lids fused",
"       </p>",
"       <p>",
"        loosely: -1",
"       </p>",
"       <p>",
"        lightly: -2",
"       </p>",
"      </td>",
"      <td colspan=\"2\">",
"       Lids open; pinna flat, stays folded",
"      </td>",
"      <td colspan=\"2\">",
"       Slightly curved pinna; soft with slow recoil",
"      </td>",
"      <td colspan=\"2\">",
"       Well-curved pinna; soft but ready recoil",
"      </td>",
"      <td colspan=\"2\">",
"       Formed and firm with instant recoil",
"      </td>",
"      <td colspan=\"2\">",
"       Thick cartilage; ear stiff",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Genitals (male)",
"      </td>",
"      <td colspan=\"2\">",
"       Scrotum flat, smooth",
"      </td>",
"      <td colspan=\"2\">",
"       Scrotum empty; faint rugae",
"      </td>",
"      <td colspan=\"2\">",
"       Testes in upper canal; rare rugae",
"      </td>",
"      <td colspan=\"2\">",
"       Testes descending; few rugae",
"      </td>",
"      <td colspan=\"2\">",
"       Testes down; good rugae",
"      </td>",
"      <td colspan=\"2\">",
"       Testes pendulous; deep rugae",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Genitals (female)",
"      </td>",
"      <td colspan=\"2\">",
"       Clitoris prominent; labia flat",
"      </td>",
"      <td colspan=\"2\">",
"       Prominent clitoris; small labia minora",
"      </td>",
"      <td colspan=\"2\">",
"       Prominent clitoris; enlarging minora",
"      </td>",
"      <td colspan=\"2\">",
"       Majora and minora equally prominent",
"      </td>",
"      <td colspan=\"2\">",
"       Majora large; minora small",
"      </td>",
"      <td colspan=\"2\">",
"       Majora cover clitoris and minora",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"15\" rowspan=\"1\">",
"       Maturity rating",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Score",
"      </td>",
"      <td>",
"       -10",
"      </td>",
"      <td>",
"       -5",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       45",
"      </td>",
"      <td>",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Gestational age (Weeks)",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       28",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       32",
"      </td>",
"      <td>",
"       34",
"      </td>",
"      <td>",
"       36",
"      </td>",
"      <td>",
"       38",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       42",
"      </td>",
"      <td>",
"       44",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The New Ballard Score is used to estimate gestational age from neuromuscular and physical features. The scores of each feature are added to calculate a maturity rating which correlates with gestational age (see figure 1a).",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Ballard, JL, Khoury, JC, Wedig, K, et al. New Ballard Score, expanded to include extremely premature infants. J Pediatr 1991; 119:417. Copyright &copy; 1991 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31421=[""].join("\n");
var outline_f30_43_31421=null;
var title_f30_43_31422="Caffeine content";
var content_f30_43_31422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Caffeine content in foods and beverages",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Coffees",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Service size (oz)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Caffeine (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coffee, brewed",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        133 (range: 102 to 200)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coffee, generic instant",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        93 (range: 27 to 173)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coffee, generic decaffeinated",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5 (range: 3 to 12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Espresso",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        40 (range: 30 to 90)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Espresso decaffeinated",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Teas",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Service size (oz)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Caffeine (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tea, brewed",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        53 (range: 40 to 120)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Starbucks Tazo Chai Tea Latte (Grande)",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Snapple, Lemon, Peach, or Raspberry",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arizona Iced Tea, black",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nestea",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Snapple, Just Plain Unsweetened",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arizona Iced Tea, green",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Snapple, Kiwi Teawi",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Soft drinks",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Service size (oz)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Caffeine (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         FDA official limit for cola and pepper soft drinks",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         12",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         71",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jolt Cola",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mountain Dew MDX, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        71 (20 oz = 118)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mountain Dew, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        54 (20 oz = 90)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pepsi, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        36 to 38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mellow Yellow",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coke, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        35 to 47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TAB",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        46.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dr. Pepper, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        42 to 44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Barq's Diet Root Beer",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Barq's Root Beer",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7-Up, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fanta, all flavors",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fresca, all flavors",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mug Root Beer, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sierra Mist, regular or free",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sprite, regular or diet",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Energy drinks",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Service size (oz)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Caffeine (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spike Shooter",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocaine",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        288",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monster Energy",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        160",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Full Throttle",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        144",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rip It, all varieties",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enviga",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tab Energy",
"       </td>",
"       <td>",
"        10.5",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SoBe No Fear",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red Bull",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red Bull Sugarfree",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rockstar Energy Drink",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SoBe Adrenaline Rush",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amp",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glaceau Vitamin Water Energy Citrus",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SoBe Essential Energy, Berry or Orange",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5 Hour Energy",
"       </td>",
"       <td>",
"        2&nbsp;",
"       </td>",
"       <td>",
"        215*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Frozen desserts",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Service size (oz)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Caffeine (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ben &amp; Jerry's Coffee Ice Cream",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        68 to 84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haagen-Dazs Coffee Ice Cream or Yogurt",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Starbucks Coffee Ice Cream",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        50 to 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Chocolates/candies/other",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Service size",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Caffeine (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hershey's Special Dark Chocolate Bar",
"       </td>",
"       <td>",
"        1.45 oz",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hershey's Chocolate Bar",
"       </td>",
"       <td>",
"        1.55 oz",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hershey's Kisses",
"       </td>",
"       <td>",
"        41 g (9 pieces)",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hot Cocoa",
"       </td>",
"       <td>",
"        8 oz",
"       </td>",
"       <td>",
"        3 to 13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * reported by Consumer Reports",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Harland BF. Caffeine and nutrition. Nutrition 2000; 16:522.",
"       </li>",
"       <li>",
"        Juliano LM, Griffiths RR. Caffeine. In: Substance Abuse: A Comprehensive Textbook, Fourth Edition, Lowinson JH, Ruiz P, Millman RB, Langrod JG (Eds), Baltimore: Lippincott Williams, &amp; Wilkins, 2005.",
"       </li>",
"       <li>",
"        Center for Science in the Public Interest. Caffeine Content of Food and Drugs.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31422=[""].join("\n");
var outline_f30_43_31422=null;
var title_f30_43_31423="Intussusception Barium enema";
var content_f30_43_31423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intussusception",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium contrast enema showing intussusception in mid-transverse colon (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_43_31423=[""].join("\n");
var outline_f30_43_31423=null;
